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Pierre-Auguste Renoir (1841-1919) was a famous nineteenth century French artist. 
Renoir battled severe rheumatoid arthritis and fought to overcome the disease so he 
could continue creating his masterpieces. By 1910 he could not even walk using 
crutches and became a prisoner in his wheelchair. His hands were completely deformed 
and Renoir was unable to pick up a paintbrush at this point so it had to be wedged 
between his fingers. He continued to paint everyday unless an attack of arthritis forced 
him to lie on his bed where a wire construction protected his body from being touched 
by his bedclothes 1. 
"One must from time to time attempt things 
that are beyond one’s capacity."                                                                          
~ Pierre-Auguste Renoir 
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Rheumatoid arthritis 
Millions of people nowadays suffer from arthritis or inflammation of the joint. As a 
result of environmental and/or genetic risk factors some individuals can develop 
arthralgia or joint pain. This joint pain can lead to the development of arthritis 
(undifferentiated arthritis; UA or early rheumatoid arthritis), which can ultimately 
develop into rheumatoid arthritis (RA). Other patients having undifferentiated arthritis 
go in remission or develop other conditions 
2
. 
RA is a common autoimmune disease, which is characterized by chronic inflammation 
of the synovial joint. In most cases this is accompanied by the generation of pannus 
tissue, which results from the infiltration of inflammatory cells in the synovial 
membrane, ultimately leading to joint destruction. Although RA is not directly life-
threatening, it affects the quality of life of patients (approximately 1% of the 
population) dramatically 3. The actual cause of RA remains unknown, but several 
factors, including environmental (e.g. smoking), hormonal (women are more affected 
than men) as well as genetic (e.g. certain HLA-DR4 alleles) influences, have been 
demonstrated to be involved in RA pathogenesis 
4
. A common phenomenon of 
autoimmune diseases is the activation of the immune system, leading to the 
proliferation of autoreactive T-cells and the production of antibodies to self 
components. In most cases the immunological targeting of self components displays a 
high degree of disease-specificity. In this Chapter I will focus will be on the B-cell 
response in RA. 
 
Autoantibodies in RA 
In the serum of RA patients several autoantibodies can be present, like the rheumatoid 
factor (RF) and anti-citrullinated protein/peptide antibodies (ACPA). In the last decades 
of the previous century, RF detection was predominantly used as a serological test to 
aid the diagnosis of RA, and represented one of the criteria defined by the American 
College of Rheumatology (ACR) for the classification of RA. RF (either of the IgM or of 
the IgA isotype) is directed against the constant part of IgG. Upon binding of RF to IgG, 
immune complexes can be formed, which can contribute to RA pathogenesis.  
 
 
 
 
Figure 1. Citrullination of proteins. Citrullination is the post-translational conversion of 
peptidylarginine into peptidylcitrulline and is catalyzed by Ca
2+
-dependent  peptidylarginine deiminase 
(PAD) enzymes. R-1 through R1 refer to the side chains of the amino acids flanking the citrullinated 
residue. 
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It is important to note that the production of RF is not very specifically associated with 
RA.  
In 1998, it was reported that peptides or proteins with a citrulline residue are specific 
targets for antibodies in RA patients 5;6. Citrullination is a post-translational 
modification, in which a positively charged peptidylarginine residue is converted into a 
neutral peptidylcitrulline by the peptidylarginine deiminase enzyme family (PAD, EC 
3.5.3.15.) (Figure 1). 
The finding that anti-citrullinated protein/peptide antibodies are very specific for RA 
was confirmed by Sebbag and co-workers who found that citrullinated filaggrin was the 
target antigen in the RA-specific anti-perinuclear factor (APF) and anti-keratin antibody 
(AKA) assays 
7
. The first specific test for these antibodies using a cyclic citrullinated 
peptide, the so-called anti-CCP (cyclic citrullinated peptide) test, was published in 2000 
8. Two years later a more sensitive second generation CCP test (CCP2) became available 
for the medical and scientific community.  
Since then, ACPA became of great interest, because these antibodies are present in the 
majority of RA patients (~75%), can be detected already prior to disease onset 
(sometimes up to 10 years), and are highly specific (94- 99%) for this disease 8;9;10 
(Figure 2). ACPA can also serve as a predictive marker for disease outcome and appear 
to be associated with more erosive RA 9. The diagnostic and prognostic characteristics 
of ACPA have been reviewed extensively the last years 11;12;13. A compilation of the 
results from 188 independent studies obtained with the most widely applied CCP2 test 
for ACPA detection and reported between 2002 and March 2012 is given in Table 1.  
These data show that the specificity of ACPA is about 94% when compared with 
diseased controls and about  99% when compared with healthy controls, and that the 
sensitivity for established RA is about 74% versus 58% for early RA. 
 
 
 
Figure 2. ACPA are already present prior to disease onset. Risk factors can lead to the beginning of 
ACPA production and the beginning of an autoimmune response.  This response can emerge into general 
joint pain or arthralgia. In this phase the patient will visit the general practitioner (GP), because 
symptoms arise. The disease can further develop undifferentiated arthritis (UA). When patients visit the 
clinic for the first time already in 62% of the patients ACPA are present. UA patients can ultimately 
develop RA or remain UA patients. Approximately 75% of the (established) RA patients have ACPA. 
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Table 1. Diagnostic value of the CCP2 test for ACPA detection 
 
Patient group n
a
 anti-CCP2(+) Sensitivity (%) Specificity (%) 
 
RA total 
 
22281 
 
15521 
 
70 
 
       early   5908   3411 58  
       established 16373 12110 74 
 
 
Controls 22432 1034 5 95 
       non-RA 17101 1026 6 94 
       healthy 5331 58 1 99 
 
a 
Combined data from 188 studies published between 2002 and March 2012. 
 
 
In several studies the CCP2 test has been compared with other tests to detect ACPA 
14;15;16
.  
These studies show that the sensitivity of none of the more recently developed ACPA 
tests (e.g. anti-MCV or anti-mutated citrullinated vimentin, anti-CCP3 and anti-
citrullinated filaggrin) is as high as that of the anti-CCP2 test, when evaluated at 
stratified specificity 11.   
 
Figure 3. The hypothesized role of citrullination in RA. An inflammation in the synovial joint can lead 
to infiltration of immune cells, which contain PAD enzymes. After PAD activation, due to a rise in 
intracellular calcium concentration, e.g. during cell death, proteins can be citrullinated. The apoptotic 
cell will normally be removed by neighboring phagocytic cells. However, when the number of dying 
cells is too high or when there is a defect in clearance of apoptotic cell remnants, the cells may become 
necrotic and release their contents in the extracellular space. PAD enzymes will then also citrullinate 
extracellular proteins. In a small percentage of individuals citrullinated proteins may be exposed to the 
immune system eliciting an immune response and ACPA may be formed. ACPA can be generated in the 
synovial joint, but also in other organs, such as the lungs or the gingiva. Ultimately, ACPA generation 
will result in immune complex formation, followed by an up-regulation of pro-inflammatory cytokines, 
which are regarded as the driving force of the chronic inflammation that is typical for RA. 
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The finding that ACPA are present prior to RA onset and that they can serve as very 
suitable markers for the early diagnosis of RA led to the decision that the 1987 ACR 
classification criteria for RA, which included only RF as a serological parameter, needed 
to be altered.  Recently, the 2010 ACR/EULAR (European League Against Rheumatism) 
RA classification criteria were defined and these focus particularly on features present 
early in the disease.  As a consequence, both the presence and the levels of ACPA are 
now included as important parameters to classify and diagnose RA 
17;18
. 
 
From citrullination to RA: what is going (wr)on(g)?   
Citrullinated proteins can be arthritogenic and autoantibodies to citrullinated proteins 
have been associated with disease severity, but the exact role of the synovial 
citrullinome (i.e. all citrullinated proteins in the inflamed synovium) in the 
pathophysiology of RA is not known 19. In 2004, an important role for citrullinated 
antigens in the pathology of RA was proposed 
20;21;22
. It was hypothesized that the 
inflammatory cycle starts with a certain initial trigger (Figure 3).  
This trigger can have an environmental origin, such as an infection (e.g. 
Porphyromonas gingivalis or viral infection) or can be caused by the exposure to toxic 
compounds (e.g. smoking) 23;24;25. As a result of this trigger PAD enzymes can become 
activated, leading to citrullinated proteins and ultimately to ACPA generation. As a 
result of a (secondary) trigger (e.g. infection, trauma, and stress), immune cells will 
infiltrate the synovium. Normally, PAD enzymes are inactive due to the low calcium 
concentration within living cells and not expressed in the synovium, but during cell 
death (many infiltrating cells will die during the inflammation) the intracellular calcium 
concentration rises to a level sufficient (>10-5 M) for PAD activation (step 1) 26. The PAD 
enzymes can then citrullinate intracellular target antigens (such as vimentin and 
histones) (step 2) 27;28;29. Normally these apoptotic cells will be removed by a so-called 
“clearing mechanism”, so that the immune system will not “see” the citrullinated 
antigens. However, when the clearing cells fail to remove the (remnants of the) dying 
cells (for example when one of the factors involved is defective or when too many cells 
are dying) the dead cells will become necrotic and release the citrullinated antigens 
into the extracellular space. Also the activated PAD enzymes will be released into the 
extracellular compartment and may start to citrullinate extracellular synovial proteins, 
such as fibrin 30. These events are not RA specific, since they also occur during 
inflammatory processes in ‘healthy’ individuals and other diseases. More importantly, 
they generally do not elicit an anti-citrullinated protein response and do not lead to 
the production of ACPA 31;32. Only in some individuals (depending on hormonal and 
genetic background) ACPA will be produced and a chronic inflammation (RA) may 
develop.  
Smoking as well as carriage of HLA-DR shared epitope (SE) alleles form an established 
risk for the development of RA 33;34;35. Smoking, for example, may trigger HLA-DR 
restricted immune reactions 36. Several HLA-DRB1 alleles have been found to be 
associated with RA (Table 2). They share a consensus motif (Q/R K/R R A A) which is 
located in the peptide binding pocket  of these HLA class II molecules 37. This binding 
pocket prefers negatively charged or neutral peptides 
35;37;38
.                                                                                            
Individuals having these SE alleles will present citrullinated peptides more efficiently 
(to CD4
+
 T lymphocytes) than the corresponding arginine-containing peptides 
39
.                   
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In a susceptible environment, T cell activation can subsequently activate B-cells to 
produce ACPA (step 3) 
40
. It is noteworthy to mention that Huizinga and co-workers 
found that the SE appears to be associated almost exclusively with the presence of 
ACPA in RA patients 41. The presence of ACPA and citrullinated proteins in the inflamed 
joints may lead to the formation of immune complexes (antibodies bound to 
citrullinated antigens) 
42
, which may result in complement activation 
43
 and 
inflammatory cell activation (via Fc gamma receptor-mediated pathways) (step 4) 
44
. 
This will ultimately lead to cytokine production which constitutes the driving force for 
the perpetuation of the chronic inflammation 45.   
 
Table 2. HLA-DRB1 shared epitope alleles 
 
SE = shared epitope 
 
 
What are the citrullinated antigens in RA?  
In principle, the released PAD enzyme(s) may citrullinate any protein in the synovium. 
It is therefore not surprising that several citrullinated proteins have been found in joint 
tissue from RA patients (Table 3) 28;46;47;48;49;50;51;52;53. Since citrullinated fibrin(ogen) and 
vimentin have been demonstrated to be recognized by ACPA, they may be among the 
genuine citrullinated autoantigens 15;28;52;54.  
It has been described that arthritis can be induced by citrullinated fibrinogen and not 
by unmodified fibrinogen in DRB4-transgenic mice 30. Furthermore, Ho and co-workers 
have shown that mice immunized with citrullinated fibrinogen possess cytokine 
producing T-cells, rheumatoid factor, circulating immune complexes, and ACPA, all of 
which are characteristic of RA 55. Finally, it has been found that citrullinated fibrinogen, 
present in immune complexes can stimulate (mouse as well as human) macrophages to 
produce TNF-alpha, which is an important  mediator of synovitis in RA 44;56.  
In addition, citrullinated vimentin has been found in immune complexes of RA patients 
42 and reactive T-cells towards citrullinated vimentin are present in HLA-DRB1*0401-
positive mice as well as in humans 
57
.  
 
Phage display systems may facilitate the identification of disease markers 
The complexity and diversity of RA has raised the need for new biomarkers, especially 
those that facilitate the differentiation between different subsets of RA. A technique 
that is frequently used in the search of immunological biomarkers is phage display, 
which was developed more than twenty-five years ago by Smith and colleagues 58.  
 
HLA-DRB1 alleles that encode for SE motif SE consensus motif 
 
*0401; *0409; *0413; *0416; *0421; *1419; *1421 
 
QKRAA 
 
*0101; *0102; *0105; *0404; *0405; *0408; *0410; *0419; *1402; *1406; 
*1409; *1413; *1417; *1420 
 
QRRAA 
 
*1001 
 
RRRAA 
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Besides its use in the identification of biomarkers, phage display can be used to 
generate monoclonal antibodies against candidate biomarkers in an easy, fast and less 
time-consuming method than the immunization of animals in combination with the 
hybridoma cell technology 59;60;61. 
 
Table 3. Citrullinated proteins 
 
n.d. = not determined 
 
 
Bacteriophages can infect bacteria leading either to the death of the bacteria (lytic 
phages such as bacteriophage T4) or to replication and assembly of the phage without 
killing the bacterial host (lysogenic phages such as M13) (reviewed in 69. The lysogenic 
filamentous phages are most frequently used in phage display systems. 
Filamentous phages are rod-shaped  phages, which have circular ssDNA genomes, 
enclosed in a tubular capsid composed of five coat proteins (minor proteins pIII, pVI, 
pVII, pIX and major protein pVIII) forming the phage particle or virion (Figure 4A) 58;70. 
Infection of E. coli takes place via pili, which are appendages of certain E. coli strains 
needed for attachment of the N-terminal domain of the pIII minor protein to the 
bacterial cell. Subsequently, coat proteins permeabilize the envelop of the cell and the 
foreign DNA (ssDNA of the phage) is released into the cytoplasm.  
Candidate citrullinated 
autoantigen 
Detected in RA 
synovium 
Autoantibodies 
detected in RA 
Reference 
 
Fibrinogen / fibrin 
 
yes 
 
yes 
 
30;52;54
 
Sa-antigen / vimentin yes yes 
27;28
 
Fibronectin yes n.d. 
50
 
Collagen yes yes 
53;62
 
Alpha-enolase yes yes 
49
 
Nucleophosmin / B23 no n.d. 
63
 
Eukaryotic translation 
initiation factor 4G1 
no yes 
64
 
Epstein-barr virus nuclear 
antigen 1 
no yes 
48;65
 
Capz alpha 1 yes yes 
51
 
Asporin yes n.d. 
51
 
Cathepsin d yes n.d. 
51
 
(Mutant) beta-actin yes n.d. 
51
 
Albumin yes n.d. 
51
 
Histamine receptor yes n.d. 
51
 
Protein disulfide-isomerase yes n.d. 
51
 
ER60 precursor Glucose-
related protein 58 kDa 
yes n.d. 
51
 
Mitochondrial aldehyde 
dehydrogenase 
yes n.d. 
51
 
Aggrecan yes n.d. 
51
 
Far upstream element-
binding protein (FUSE-BP) 
no yes 
66
 
Ribosomal protein s2 (RPS2) no n.d. 
67
 
Binding immunoglobulin 
protein (BiP) 
no yes 
68
 
Citrullination: How subtle molecular changes affect loss of self-tolerance in rheumatoid arthritis 
19 
Chapter 1. General introduction 
In phage display, the phages contain the displayed proteins/peptides of interest 
displayed as fusion protein with one of the phage coat proteins. 
A unique feature of these systems is that the gene encoding the fusion protein and the 
fusion protein itself are combined in a single phage particle, allowing the selection of 
phage particles based upon binding activities of the fusion protein and the 
characterization of its sequence by sequencing the DNA isolated from these phages. 
Phage display systems can be either monovalent or polyvalent. Polyvalent or true 
phage vectors are directly derived from the genome of the filamentous phage used 
and encode all the proteins that are needed for replication and assembly of the phage 
71;72
. With polyvalent display multiple copies of the fusion protein are displayed, the 
number of which depends on the coat protein used for fusion. Polyvalent phage 
display is commonly used for short peptide selection. Monovalent or phagemid vectors 
do not encode the proteins that are needed for replication, assembly and packaging of 
the phage. They only contain the fusion protein gene. 
 
The necessary phage proteins are provided by so-called helper phages. Without these 
helper phages, phage particles will not be released from the phagemid containing 
bacteria 
73
. Since the coat protein encoded by the phagemid vector will also be 
produced, as a non-fusion protein, from the genome of the helper phage, the 
assembled phages will contain both the fusion protein and the corresponding non-
fusion coat protein. Under optimized conditions the assembled phage particles will 
contain no more than a single copy of the fusion protein on its surface. An advantage 
of this approach is that the selections are based on pure affinity rather than avidity. 
Phagemid phage display systems are particularly suited for antibody display.  
Figure 4. Monovalent M13-derived 
filamentous bacteriophages. (A) 
Schematic structure of the M13 
bacteriophage. (B) The sequences 
encoding the variable parts of an 
antibody can be cloned into a phagemid 
fused to the gene that codes for the 
phage coat protein pIII. Subsequently, 
single-chain variable antibody fragments 
(scFvs) are displayed fused to the pIII 
protein at the surface of the phage.   
 
 
A 
B 
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Commonly used antibody libraries are based upon phagemid systems which encode an 
antibody repertoire (e.g. derived from immunoglobulin cDNA from antibody producing 
cells of an autoimmune patient), fused to the minor coat protein pIII of the phage.  
The resulting antibody fragment presented by the coat protein is called a single chain 
variable fragment (scFv). A scFv consists of the variable parts of an antibody; the heavy 
(VH) as well as the light chain (VL) linked together by a linker, which is needed for 
proper folding of the antibody fragment (Figure 4B). 
The selection of antibodies (generally antibody fragments) by phage display starts with 
immobilizing a target molecule (e.g. protein, peptide, nucleic acid). Phages that display 
a protein/peptide (antibody fragment) can bind to the target and, after removal of the 
unbound phages, can be eluted. High titers of the eluted phages are subsequently 
obtained by infecting bacterial cells in the presence of helper phage. The enriched 
phage can be used for further selection rounds (Figure 5). Usually, three to five rounds 
are needed to obtain a sufficiently enriched pool of high affinity phages. Eventually 
individual phage clones can be characterized in detail for target binding features and 
by determination of the sequence of the selected molecule. 
 
Outline of this thesis 
The general aim of the studies described in this thesis was to get more insight into the 
role of citrullination in the pathophysiology of RA. Although it was well established at 
the start of these studies that one of the major immune responses in RA was directed 
to citrullinated proteins, hardly anything was known on the identity of the proteins 
targeted by anti-citrullinated protein antibodies in the inflamed synovial joints of RA 
patients, nor on the peptidylarginine deiminases that are most relevant for the 
development of RA.  
Figure 5. Methodology to select 
scFv antibody fragments from 
phage display libraries. A scFv 
phage display library is produced in 
suitable E. coli strains with the help 
of helper phages (1). A target 
molecule is immobilized and 
incubated with the phage particles 
(2). Phages that do not bind are 
removed (3) and bound phages are 
eluted (4). Subsequently, the 
bacterial host is infected with the 
eluted phages and plated on agar 
plates (5). Phage plaques (clones) 
can be scraped from the plates and 
amplified in liquid cultures (6). The 
resulting phages can be 
concentrated and used for another 
selection round. After a sufficient 
number of such selection cycles, 
individual phage clones can be 
generated and characterized in 
detail (7). 
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Chapter 2 focuses on the enzymes responsible for the citrullination of proteins (the 
conversion of peptidylarginine into peptidylcitrulline), the peptidylarginine deiminases 
(PADs), of which five isoforms are expressed in humans.  
In this study the expression and activity of PAD2 and PAD4, the isoforms that are most 
likely involved in RA, in different tissues of wild-type mice as well as PAD2 and PAD4 
knock-out mice was investigated. PAD expression was studied at the protein level by 
immunoblotting and the activity of these enzymes was monitored by analysing the 
citrullination of proteins in cell and tissue lysates. 
In Chapter 3 a global characterization of citrullinated proteins in synovial fluid samples 
(SF) of RA patients is presented. Proteins isolated from SF samples were analyzed by 
tandem mass spectrometry to determine the molecular identity of citrullinated 
proteins. Three of the identified citrullinated proteins, apolipoprotein E (ApoE), 
myeloid nuclear differentiation antigen (MNDA) and beta actin, which might have 
autoantigenic features, were further investigated. Their recognition by RA sera was 
studied in detail.  
The studies reported in Chapters 4 and 5 address the autoantigenicity of one of the 
best documented citrullinated autoantigens, fibrinogen. Previously, the majority of the 
studies were performed with synthetic citrullinated fibrinogen peptides applied in 
ELISA. In the study described in Chapter 4 a novel methodology was generated to map 
the epitopes of post-translationally modified proteins and this method was applied to 
map the autoepitopes of citrullinated fibrinogen. In Chapter 5 the presence of 
citrullinated fibrinogen peptides in the synovial fluid of RA and arthritic control 
patients was studied by mass spectrometry.  
Another previously identified citrullinated protein that is present in RA synovial tissues 
is fibronectin. Because the autoantigenicity of this protein was still poorly 
characterized, the presence of autoantibodies against citrullinated fibronectin in RA 
sera was investigated and the results are described in Chapter 6.  
DNA microarray datasets were used to identify genes encoding potential targets for 
future therapies of RA. These genes are two members of the signaling lymphocyte 
activation molecule family, SLAMF7 and SLAMF8, and a disintegrin and 
metalloprotease domain family member, ADAM28. As a first approach to validate 
these genes, the expression of which was confirmed to be altered by Q-PCR, their 
cDNAs were cloned and expressed, which is described in Chapter 7. The resulting 
recombinant proteins, which were produced in bacterial expression systems, were 
purified and used to isolate single-chain recombinant antibody fragments from phage 
display libraries.  
Subsequently, these antibody fragments were used to explore their capacity to affect 
the function of the putative therapeutic target molecules, which are all plasma 
membrane associated. Their influence on cytokine production by white blood cells was 
determined.  
Finally, in Chapter 8 the results obtained in the studies presented in this thesis are 
discussed in a more general context.  
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INTRODUCTION 
 
Peptidylarginine deiminases (PAD; EC 3.5.3.15) represent a family of calcium-
dependent enzymes that catalyse the conversion of peptidylarginine into 
peptidylcitrulline, which is generally indicated with (protein) citrullination. This post-
translational modification is associated with the loss of a positive charge of the protein 
involved, which can have important structural and functional consequences 74. Several 
family members have been identified, including PAD1, PAD2, PAD3, PAD4 and PAD6, 
the genes of which are clustered in the human and mouse genomes and share 
sequence similarities. Several studies have addressed PAD expression in different 
tissues on the mRNA 75;76 as well as on the protein 74;77;78 level. Each isotype showed a 
tissue-specific expression pattern. It was observed that PAD1 was mainly expressed in 
epidermis, hair follicles, sweat glands and arrector pili (small muscle that connects hair 
follicle to dermis) 77;79. In some studies PAD1 was detected in uterus, pancreas, colon 
and thymus 
77;80
. PAD2 appeared to be ubiquitously expressed, since it was detected in 
many tissues, including white blood cells 78;81. PAD3 was reported to be expressed in 
(the upper layers of the) epidermis, hair follicles, brain and colon 77;79;82. PAD4 has been 
found in white blood cells (including lymphocytes), brain, colon, kidney, pancreas, 
spleen, as well as in several tumours 77;78;81;83. Finally, PAD6 expression so far has only 
been observed in oocytes, ovary, embryonic stem cells and (peripheral) white blood 
cells 75;77. The different mRNA as well as protein expression patterns of the mammalian 
PAD isotypes are listed in Table 1.  
 
ABSTRACT - Citrullination, the conversion of peptidylarginine to peptidylcitrulline 
is catalyzed by peptidylarginine deiminases (PAD). The expression of PAD isoforms 
displays great variation among different tissues as demonstrated by PAD mRNA 
analyses. Here we have analysed the differential expression of PAD2, PAD4 and 
PAD6 in mouse tissues at the protein level and by enzymatic activity assays using 
PAD2 and PAD4 knock-out strains. As expected, no PAD2 expression was detected 
in the PAD2-/- mice. In contrast, the PAD4 protein was observed in several tissues 
of the PAD4 knock-out mice, albeit at reduced levels in most tissues, and are 
therefore referred to as PAD4-low mice. In material from PAD2-/- mice, except for 
leukocyte lysates, hardly any PAD activity was found and no citrullinated proteins 
were detected after incubation in the presence of calcium. PAD activity in the 
PAD4-low mice was similar to that in wild-type mice. In both PAD knock-out 
strains the expression of PAD6 appeared to be up-regulated in all tissues analyzed, 
with the exception of spleen and testis. Our data demonstrate that the PAD2 
protein is expressed in brain, spinal cord, spleen, skeletal muscle and leukocytes, 
but not detectably in liver, lung, kidney and testis. PAD4 was detected in each of 
these tissues, although the expression levels varied. In all tissues where PAD2 was 
detected, except for blood cells, this PAD isoform appeared to be responsible for 
virtually all peptidylarginine deiminase activity.  
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Table 1. Tissue-specific expression of PAD isotypes  
 
PAD 
isotype 
Gene Tissue mRNA Protein
c
 
   Northern   
blot
a
 
RT-PCR
b
  
 
PAD1 
 
PADI1 
 
Epidermis 
 
n.d. 
 
+ 
 
+ 
  Hair follicles n.d. n.d. + 
  Sweat glands n.d. n.d. + 
  Arrector pili n.d. n.d. + 
  Uterus + + + 
  Placenta n.d. + n.d. 
  Lung n.d. + n.d. 
  Liver n.d. + n.d. 
  Pancreas n.d. + + 
  Colon n.d. + n.d. 
  Prostate n.d. + n.d. 
  Spleen n.d. + n.d. 
  Ovary n.d. n.d. +
 
 
  Olfactory tissue n.d. n.d. +
 
 
  Inner Ear n.d. n.d. + 
  Testis n.d. + n.d. 
  Thymus n.d. + n.d. 
PAD2 PADI2 Brain (astrocytes) + + + 
  Arrector pili n.d. + + 
  Sweat glands n.d. n.d. + 
  (Skeletal) muscle n.d. + + 
  Spinal cord  n.d. + + 
  Schwann cells/myelin + n.d. + 
  Salivary glands n.d. + + 
  Pituitary gland + + + 
  Bone marrow n.d. n.d. + 
  Spleen n.d. + + 
  Macrophages + + + 
  (Synovial fluid) monocytes n.d. + + 
  (Peripheral blood) 
monocytes 
n.d. + -/+ 
  Rheumatoid synovium n.d. + + 
  Epidermis n.d. + +
 
 
  Peripheral blood 
mononuclear cells (PBMCs) 
n.d. + - 
  Lymphocytes n.d. + n.d. 
  Colon n.d. + +
 
 
  Heart n.d. + n.d. 
  Thymus n.d. + +
 
 
  Testis n.d. + n.d. 
  Placenta n.d. + n.d. 
  Pancreas n.d. + n.d. 
  Lung n.d. + + 
  Uterus n.d. + +
 
 
  Prostate n.d. + n.d. 
  Ovary n.d. + n.d. 
  Kidney n.d. + +
 
 
  Liver n.d. n.d. +
 
 
  Eye (retina) n.d. + + 
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[Table 1 continued] 
 
PAD3 PADI3 (Upper layers of) epidermis n.d. + + 
  Hair follicles n.d. + + 
  Brain n.d. -/+ + 
  Prostate n.d. + n.d. 
  Testis n.d. + n.d. 
  Thymus n.d. + +
 
 
  small intestine n.d. + n.d. 
  Colon n.d. n.d. + 
  Lung n.d. + n.d. 
  Kidney n.d. + n.d. 
  Pancreas n.d. + n.d. 
  Liver n.d. + n.d. 
PAD4 PADI4 Granulocytes + n.d. + 
  Eosinophils n.d. n.d. + 
  Neutrophils n.d. n.d. + 
  (Peripheral blood) 
monocytes 
n.d. + + 
  Macrophages + -/+ + 
  Lymphocytes n.d. + + 
  Rheumatoid synovium n.d. + + 
  Brain n.d. + n.d. 
  Prostate n.d. + n.d. 
  Testis n.d. + n.d. 
  Thymus n.d. + +
 d
 
  Small intestine n.d. + n.d. 
  Lung n.d. + n.d. 
  Kidney n.d. + n.d. 
  Pancreas n.d. + n.d. 
  Spleen n.d. + + 
  Liver n.d. + +
 
 
  Skin n.d. n.d. +
 
 
  Aorta/vein n.d. n.d. +
 
 
  Inner ear n.d. n.d. +
 
 
  Various cancers n.d. n.d. + 
PAD6 PADI6 Embryonic stem cells n.d. n.d. + 
  Oocytes n.d. n.d. + 
  Ovary + + + 
  Testis n.d. + n.d. 
  PBMCs n.d. + + 
  Lymphocytes n.d. + n.d. 
  Monocytes n.d. + n.d. 
  Macrophages n.d. + n.d. 
  Spleen n.d. + n.d. 
  Small intestine n.d. + n.d. 
  Thymus n.d. n.d. + 
  Lung n.d. + n.d. 
  Liver n.d. + n.d. 
  (Skeletal) muscle n.d. + n.d. 
  Inflamed rheumatoid 
synovium 
n.d. + - 
 
a 75;76;84;85;86;87;88
, 
b 76;78;79;81;88;89;90;91;92
, 
c
 
25;75;77;78;79;80;81;83;88;90;93;94;95;96;97;98;99
 
 n.d. = not determined 
 
  
Citrullination: How subtle molecular changes affect loss of self-tolerance in rheumatoid arthritis 
28 
Chapter 2. Peptidylarginine deiminase expression and activity in PAD2 and PAD4 knock-out mice 
 
 
For their activity PAD enzymes are dependent on high calcium concentrations.  
Under normal circumstances, the intracellular calcium levels in the cell are too low for 
PAD enzymes to be active. PAD activation especially occurs in dying cells as a result of 
elevated calcium concentrations. PAD (probably PAD4) has recently been found to be 
involved in neutrophil extracellular trap (NET) formation 100.  NETs represent an 
extracellular fibrillar matrix, which is produced as a result of various stimuli by 
neutrophils (through a cell death mechanism other than apoptosis and necrosis called 
NETosis) and which can bind pathogens 101;102. NETs are composed of chromatin and 
granular proteins 102;103. Peptidylarginine deiminase 4 (PAD4)-mediated deimination of 
histone H3 and H4 is required for NET formation 
100
. 
Furthermore, PAD enzymes are involved in cornification of the skin (citrullination of 
filaggrin and keratin), in maintaining the hydration of the stratum corneum and the 
barrier function of the epidermis, in hair follicle differentiation, in hair growth 
(citrullination of trichohyalin), myelin formation (citrullination of myelin basic protein) 
and in the regulation of gene expression (citrullination of histones) 
29;31;79;82
. Alterations 
in citrullination have been reported to occur in several diseases, including multiple 
sclerosis, Alzheimer’s disease, psoriasis and rheumatoid arthritis (RA) 49;104;104;105.  
A 
B 
Figure 1. Generation of PAD knock-out mice. (A) PAD2 knock-out mice were generated by replacing a 
region (~ 164 bp) of the PAD2 gene, which contains the first exon by a LacZ-neo cassette using the 
cre/loxP recombination system. (B) PAD4 knock-out mice were generated by insertional mutagenesis 
which led to the insertion of a cassette (156 bp) in intron 1 of the PAD4 gene. 
LTR = long terminal repeat; SA = splice acceptor sequence; Beta-Geo = antibiotic resistance gene; pA = 
polyadenylation signal; PGK = phosphoglycerate kinase-1 promotor; Btk = Bruton’s tyrosine kinase; SD = 
splice donor sequence 
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Moreover, antibodies against citrullinated proteins are produced in rheumatoid 
arthritis (RA) patients and are employed as a biomarker for early RA 
8;106
. Furthermore, 
in East Asian populations specific PADI4 (the PAD4 gene) genotypes appeared to be 
associated with RA. In addition, autoantibodies against PAD4 have been detected in RA 
patients and can predict disease outcome 54;107. 
To study the potential role of citrullination in pathological conditions, the availability of 
PAD knock-out animals might be very helpful. Indeed, using PAD2 knock-out mice we 
have previously demonstrated that PAD2 and citrullination are not essential to the 
development of experimental autoimmune encephalomyelitis 108.  
The PADs that seem to be most relevant from a pathological point of view are PAD2 
and PAD4. Here, we systematically addressed the expression and activity of PADs in 
murine PAD2 knock-out and PAD4-low strains. 
 
RESULTS 
 
Characterization of the PAD2 and PAD4 genes in the knock-out mice 
The generation of PAD2-/- mice has been described previously by Raijmakers and 
colleagues 108. The PAD4 gene was disrupted via an insertional mutagenesis approach 
(Figure 1). Briefly, this involved the insertion of an omnibank sequence tag in the first 
intron of the PAD4 gene of mouse embryonic stem cells using a retroviral vector.  The 
omnibank sequence tag contains two functional units. Upon integration into the 
mouse PAD4 gene (in intron 1), transcription of the gene with the inserted cassette will 
lead to the formation of two transcripts, one comprising a fusion of the upstream PAD4 
exon 1 and a selectable marker and a second comprising a fusion of another selectable 
marker (gene conferring resistance to a translation inhibiting antibiotic) and the 
downstream exons of the PAD4 gene. The resulting products were used to select and 
characterize the embryonic stem cells containing the cassette inserted in the PAD4 
gene.  
Note that the second transcript will not lead to translation of the downstream exons of 
the PAD4 gene, because all three reading frames contain stop codons at the end of the 
selectable marker gene 109. 
To investigate the disruption of the PAD2 and PAD4 genes in the respective knock-out 
mice, genomic DNA was isolated and the alterations of the genes were determined by 
PCR with selected primers (Figure 2A). For the genotyping of the PAD2-/- mice an 
amplicon was chosen that covers the 3’-region of the first exon of the PAD2 gene and 
the 5’-region of the first intron (Figure 2A).  
In the PAD2-/- mice no PCR product was expected to be formed as a result of the 
replacement of exon 1, whereas in the PAD4 knock-out mice a product of 439 bp 
(indicated with X) should be generated. Indeed, this PCR product was only detected in 
these mice (Figure 2B), confirming the homozygous disruption of the PAD2 gene in the 
PAD2-/- mice. The integrity of the PAD4 gene was checked with two distinct forward 
primers, one matching a sequence element in the first intron and another derived from 
a sequence element of the cassette inserted in the first intron, in combination with a 
reverse primer matching a sequence close to the 3’-end of inserted cassette in the first 
intron (Figure 2A; indicated with Y and Z respectively).  
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Using genomic DNA of the PAD2-/- mice the production of the Y fragment was readily 
detected, in contrast to the PAD4 knock-out mice.  
In the latter the insertion of the large cassette prevents the formation of a PCR product 
using the fragment Y primers. In agreement with the insertion of the mutagenesis 
cassette in intron 1 of the PAD4 gene, the Z PCR product was efficiently formed with 
material from the 
PAD4 knock-out 
mice (Figure 2B). 
Taken together, 
these data confirm 
the homozygous 
disruption of the 
PAD2 and PAD4 
genes in the PAD2-
/- and PAD4-/-, 
respectively.  
Because western 
blotting data 
obtained with 
tissue extracts of 
the PAD4-/- mice 
suggested that 
PAD4 might still be 
expressed in these 
mice, albeit at 
lower levels (see 
below), we next 
analysed the 
presence of PAD4 
transcripts. Using 
an amplicon 
covering the 
complete exons 6 
and 7 of the PAD4 
gene, PAD4 mRNA 
was indeed 
detected by RT-PCR 
in RNA isolated 
from spleen, 
although the 
amount seemed to 
be less than that 
detected in wild-
type mice (Figure 3A). 
 
A 
B 
Figure 2. Genotyping of PAD knock-out mice. (A) Overview of the 
amplicons used for genotyping the PAD knock-out mice. For the PAD2 gene 
a primer set was used that covered the 3’ end of exon 1 and the 5’ end of 
the first intron, yielding product X for the wild-type gene. For the PAD4 
gene two primer sets were used, one that yields a product with the wild-
type gene (Y) and another that allows the detection of the inserted gene 
trap cassette (Z). (B) Genotyping of 5 PAD2-/- and 5 PAD4-low mice (1-5) 
using the approach illustrated in (A). As a negative control milliQ was used 
(6) and as a DNA quality control an amplicon (248 bp) derived from beta-
actin gene was used. Asterisks mark the positions of background products. 
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To investigate whether these 
transcripts exon 2 junction, , i.e. the 
region of transcript containing the 
omnibank sequence tag, a similar 
analysis was performed with a 
primer set for an amplicon covering 
the 3’-end of exon 1, exon 2 and 
the 5’-end of exon 2.  
These data confirmed the presence 
of PAD4 mRNA in the PAD4 knock-
out mice and indicated that the 
inserted sequence tag was 
removed during pre-mRNA splicing 
(Figure 2B). Because the expression 
of PAD4 is not completely 
abrogated in the PAD4 knock-out 
mice, we will refer to these mice as 
PAD4-low below. 
 
PAD expression in various tissues of 
PAD2 and PAD4-low mice  
The data described above indicate 
that the disruption of the PAD2 and 
PAD4 genes have led to a complete 
abrogation of PAD2 and a 
moderate reduction of PAD4 
expression, respectively. To 
investigate the effect of the 
abrogated expression of PAD2 and 
the reduced expression of PAD4 on 
the expression of other PAD 
isotypes in various tissues, all 
available PAD isotype-specific 
antibodies were used to visualize 
the presence of PADs in tissue 
extracts from wild-type and knock-out mice by western blotting. The specificity of the 
anti-PAD2, anti-PAD4 and anti-PAD6 antibodies, which were raised with isotype-
specific synthetic peptides, was demonstrated by their lack of reactivity with other PAD 
isotypes (Figure 4).   
 
 
 
 
 
 
 
Figure 3. PAD4 mRNA expression in the PAD4-low 
mice.  (A) RNA was isolated from spleen homogenates 
and subjected to RT-PCR analyses using PAD4 specific 
primers matching sequences in exon 5 and exon 8 as 
illustrated. PAD4 mRNA was detected in both wild-type 
(WT; B6/129 mice) and PAD4-low mice. (B) To analyze 
the presence of properly spliced exon 1 to exon 2, a 
RT-PCR was performed using primers matching 
sequences in exon 1 and exon 2 as indicated. Products 
obtained after 32 to 38 cycles were analyzed by 
agarose gel electrophoresis and ethidium bromide 
staining. As a negative control (-) milliQ was used and 
and as a DNA quality control beta-actin (248 bp) was 
used. Asterisks mark the positions of background 
products. 
 
 
 
A 
B 
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Tissue extract samples containing 100 μg total protein were fractionated by SDS-PAGE, 
transferred to nitrocellulose membranes and probed with the anti-PAD antibodies 
(Figure 5). 
In wild-type animals PAD2 was detected in brain, spleen, skeletal muscle and spinal 
cord (Figure 5B). PAD4 was observed in all tissues of the wild-type animals (Figure 4C). 
A band stained with anti-PAD6 antibodies and co-migrating with recombinant PAD6 
was not detected in wild-type mice, although a strong ~60.000 band was observed in 
testis (Figure 5D). As expected, in none of the tissues of the PAD2-/- mice PAD2 was 
found (Figure 5B), in contrast to PAD4, which was detected in the same tissues as in 
wild-type mice (Figure 5C). In the PAD4-low mice, the PAD2 protein was found in the 
same tissues as in wild-type mice (Figure 5C) and, although the PAD4 protein levels 
were reduced, PAD4 was still clearly detectable in the tissues that showed the highest 
levels of expression in the wild-type mice (Figure 5C). Interestingly, PAD6 expression 
appeared to be upregulated in several tissues of both the PAD2-/- and the PAD4-low 
mice (brain, liver, lung, kidney, muscle and spinal cord) (Figure 5D). 
To investigate whether the differential expression of PAD proteins is also observed in 
humans, lysates from various human tissues were subject to western blotting and 
probing with the PAD-specific antibodies (Figure 6).  
In agreement with the mouse data, high levels of PAD2 were found in brain and 
skeletal muscle. PAD2 was, however, not detected in spleen. A faster migrating 
polypeptide was observed in the human spleen, but this is probably due to the cross-
reactivity of the anti-PAD2 antibody, because a similar signal was observed in the 
mouse spleen lysates, including the lysates from PAD2-/- mice. 
In contrast to the mice, low levels of PAD2 were detected in human liver. PAD4 was 
found in human liver, spleen and kidney and weakly in placenta, but was not detected 
in brain and muscle, where it was detected in mice. 
Figure 4. Specificity of anti-PAD antibodies. Western blots containing recombinant human PAD 2, 4 
and 6 were incubated with affinity-purified anti-PAD2 (A), -PAD4 (B) and -PAD6 (C). 
 
A B C 
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The PAD6 protein appeared to be detectable in human brain, liver and thymus and in 
ovary a band was observed that migrated somewhat slower than the recombinant 
human PAD6 protein. The combined PAD protein expression data are listed in Table 2.  
 
Detection of PAD activity in tissues of PAD2 knock-out and PAD4-low mice 
To investigate the consequences of knocking-out either PAD2 or PAD4 for PAD activity, 
an antibody-based assay for peptidylarginine deiminase activity (ABAP) 110 was used to 
determine PAD activity in brain, liver, lung, spleen, kidney, muscle, spinal cord and 
testis. In this assay, total PAD activity in tissue extracts is measured by the citrullination 
of an immobilized arginine-containing substrate peptide, which is visualized by anti-
citrullinated protein antibodies.  
In wild-type mice, the highest PAD activity (in mU/μg tissue) was observed in skeletal 
muscle extracts, whereas liver did not show any PAD activity (Figure 7A). No or hardly 
any PAD activity was detected in tissue extracts from the PAD2-/- mice.  
In contrast, PAD activity in tissue extracts from the PAD4-low mice was very similar to 
that of the wild-type mice, although higher levels of activity were observed in spinal 
cord and spleen. 
 
 
 
Figure 5. PAD protein expression in various tissues of wild-type and PAD2-/- and PAD4-low mice. 
Proteins in extracts from various tissues (as indicated above the lanes) of wild-type (WT), PAD2-/- and 
PAD4-low mice were separated by SDS-PAGE, transferred to nitrocellulose membranes and stained 
with Ponceau S (A). The PAD2 (B), PAD4 (C), and PAD6 (D) proteins in these extracts were visualized by 
western blotting with affinity-purified PAD isotype-specific antibodies. As positive controls the 
corresponding recombinant human PAD proteins were used. Arrows indicate the expected positions of 
the PAD proteins; asterisks mark the positions of putative alternative or post-translationally modified 
PAD isoforms. The positions of molecular weight markers are indicated on the left.  
 
A B C D 
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As an alternative method to monitor PAD activity, tissue extracts (from brain, liver, 
muscle and spinal cord) were incubated in the presence of 5 mM calcium and after the 
incubation the presence of citrullinated proteins was visualised by western blotting 
using anti-modified citrulline antibodies.  
Besides the material obtained by these post-lytic incubations, also the non-incubated 
tissue extracts were analysed to detect the presence of citrullinated proteins in the 
lysates. Without post-lytic incubations citrullination was only detected in spinal cord of 
wild-type and PAD4-low mice, although this appeared to occur only at low levels 
(Figure 7B). After post-lytic PAD activation an extensive number of citrullinated 
polypeptides were detected in brain (Figure 7C), muscle (Figure 7D) and spinal cord 
(Figure 7B). 
Citrullination of these polypeptides occurred to virtually equal levels in both wild-type 
and PAD4-low mice. In agreement with the results obtained with the ABAP the lack of 
PAD2 expression appeared to eliminate PAD activity in these tissues completely. Also 
with this approach no PAD activity was detectable in liver tissue extracts (Figure 7E). 
  
A B C D 
Figure 6. PAD expression in human tissues. Proteins in extracts from various human tissues (as 
indicated above the lanes) were separated by SDS-PAGE, transferred to nitrocellulose membranes and 
stained with Ponceau S (A). The PAD2 (B), PAD4 (C), and PAD6 (D) proteins in these extracts were 
visualized by western blotting with affinity-purified PAD isotype-specific antibodies. Asterisks mark the 
positions of putative alternative or post-translationally modified PAD isoforms. 
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Figure 7. Peptidylarginine deiminase activity in various tissues of wild-
type and PAD2-/- and PAD4-low mice.  (A) PAD activity in wild-type, PAD2-
/- and PAD4-low mice was measured in various tissue lysates with an 
antibody-based assay for peptidylarginine deiminase activity (ABAP). See 
Materials and Methods for details. Experiments were performed in 
duplicate and the mean values (as well as the range) are depicted in the 
graph. In addition, lysates from spinal cord (B), brain (C), muscle (D) and 
liver (E) of wild-type, PAD2-/- and PAD4-low mice were incubated, either 
supplemented with CaCl2 (+) or not (-), and analysed for protein 
citrullination by western blotting using anti-modified citrulline antibodies 
(after modification of the citrulline residues on the blot). The positions of 
molecular weight markers are indicated on the left. 
 
A 
B C 
D E 
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Table 2. PAD protein expression in mouse and human tissues  
 
a 
The calculated mass of human PAD2, PAD4 and PAD6 is 76, 74 and 77 kDa, respectively. The numbers in the 
table refer to the relative molecular masses estimated by the migration in SDS-PAGE. 
b 
Putative alternative or 
post-translationally modified PAD isoforms.  
c 
Reduced expression compared to wild-type mice. n.d.: not 
determined. 
 
 
PAD activity in blood cells of PAD2 knock-out and PAD4-low mice 
Because it has been reported that PAD expression can be observed in different types of 
white blood cells, such as monocytes, macrophages and lymphocytes 78, we next 
investigated the presence of PAD activity in peripheral blood mononuclear cells 
(PBMC) and polymorphonuclear (PMN) cells using ABAP.  
 WT mice  PAD2-/- mice 
 PAD2
a
 PAD4
a
 PAD6
a
  PAD2 PAD4 PAD6 
brain 76 74+94
b
 -  - 74+94
b
 77 
liver - 74+94
b
 -  - 74+94
b
 77 
lung - 74+94
b
 -  - 74+94
b
 77 
spleen 76 74 -  - 74 - 
kidney - 74 -  - 74 77 
muscle 76 74+94
b
 -  - 74+94
b
 77 
spinal cord 76 74+94
b
 -  - 74+94
b
 77 
testis - 74+94
b
 60  - 74+94
b
 60 
skin n.d. n.d. n.d.  n.d. n.d. n.d. 
ovary n.d. n.d. n.d.  n.d. n.d. n.d. 
placenta n.d. n.d. n.d.  n.d. n.d. n.d. 
thymus n.d. n.d. n.d.  n.d. n.d. n.d. 
 PAD4-low mice  human 
 PAD2 PAD4 PAD6  PAD2 PAD4 PAD6 
brain 76 - 77  76 - 77 
liver - 74 77  76 74 77 
lung - 74
c
 77  - 74 - 
spleen 76 74 -  60
b
 74 - 
kidney - 74
c
 -  - 74 - 
muscle 76 - 77  76 - - 
spinal 
cord 
76 - 77  n.d. n.d. n.d. 
testis - - 60  n.d. n.d. n.d. 
skin n.d. n.d. n.d.  - - - 
ovary n.d. n.d. n.d.  - - 85
b
 
placenta n.d. n.d. n.d.  - 74 - 
thymus n.d. n.d. n.d.  60
b
 74+77 77 
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PAD activity was observed in both PBMC and PMN cells, although the activity in PMN 
cells appeared to be slightly higher (Figure 8).  
In both PBMC and PMN cells of PAD2-/- mice a slight decrease in PAD activity was 
observed, whereas the activity detected in these cells from PAD4-low mice did not 
significantly differ from that in wild-type mice. These data indicate that the 
contribution of PAD2 to the PAD activity in white blood cells is not as pronounced as 
that observed in the tissues described above and may suggest that another PAD, e.g. 
PAD4, is responsible for most of the activity in these cells.  
 
DISCUSSION 
 
Several studies have addressed the expression of PADs in the past, but to our 
knowledge this is the first study in which PAD expression is systematically analysed in 
PAD knock-out mice. Moreover, most previous studies detected PAD isotype 
expression at the mRNA level, whereas we focused on the proteins and their enzymatic 
activity. 
Although the current study demonstrated that the disruption of the PAD2 gene in the 
PAD2-/- mice completely abrogated its expression, in the case of the PAD4-low mice 
the PAD4 gene appeared to be incompletely inactivated. The most likely explanation is 
that the gene trap cassette, which was inserted in intron 1, can be spliced out together 
with the intron 1 segments, still allowing the production of moderate levels of PAD4 
mRNA. In the tissues analysed the reduction in PAD4 protein levels appeared to vary 
from hardly any reduction to almost undetectable levels. Although PAD4 mRNA levels 
were not measured in these tissues, except for spleen, our data suggest that PAD4 
protein levels do not directly mimic its mRNA levels. The lack of a direct correlation 
between PAD4 mRNA and protein levels has been previously observed in monocytes 
differentiating into macrophages 111. 
In spite of the fact that affinity-purified anti-PAD antibodies were used, which showed 
a high degree of PAD-isotype specificity, the western blots with the tissue samples 
showed multiple bands, especially for the anti-PAD4 antibody. In part, this might be 
the result of alternative splicing of the PAD pre-mRNAs or of post-translational 
modifications. Indeed, some evidence for the expression of alternatively spliced 
isoforms is available (PAD2: BP219556, BQ073003; PAD4: BI027450) 86.  
The expression of PAD isoforms with altered electrophoretic mobilities in certain 
tissues is supported by the observations that some of these bands are absent in the 
PAD2-/- and PAD4-low mice (further discussed below).  
Figure 8. PAD activity in mouse white blood cells. 
PAD activity was measured in lysates from PBMC and 
PMN cells with the antibody-based assay for 
peptidylarginine deiminase activity (ABAP). 
Experiments were performed in duplicate and the 
mean values (as well as the range) are depicted in the 
graph. 
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Moreover, the anti-PAD antibodies do show cross-reactivity with additional proteins in 
the crude tissue lysates, as indicated for example by the reactivity of the anti-PAD2 
antibody with polypeptides in the tissue lysates of PAD2-/- mice. 
The observed expression of PAD2 in brain, spleen, muscle and spinal cord of wild-type 
mice is in agreement with previous reports (Table 1) 95;97.  
The PAD2 protein was not detected in liver, lung, kidney and testis, although some 
PAD2-dependent deiminase activity was found in lung and testis. The overall PAD 
activity in wild-type mice appeared to correlate with the intensity of the PAD2 signals 
on western blots and therefore the PAD2 protein levels in lung and testis may be too 
low to be detectable by western blotting.  
Makrygiannakis and co-workers previously detected the PAD2 protein in human lungs 
by immunohistochemistry 
25
. We have observed PAD2 expression in human brain, liver 
and skeletal muscle, whereas in human spleen and thymus the anti-PAD2 antibody 
stained a band migrating somewhat faster than that in the other tissues (Figure 6A), 
which may indicate that either another isoform of PAD2 is expressed in these tissues or 
that the post-translational modification state differs markedly. In contrast to our 
findings, Nachat and co-workers previously observed PAD2 protein expression in 
human skin 79;112;113 and Coudane and co-workers observed the expression of different 
PAD isotypes, including PAD2 in mouse skin. The reason for these conflicting results 
remains unclear 114. The analysis of additional skin lysates from four individuals 
confirmed the lack of detectable PAD2 expression in these samples (data not shown). 
Table 2 provides an overview off all polypeptides detected with the anti-PAD 
antibodies in the lysates from (knock-out) mice and humans. 
In view of the incomplete elimination of PAD4 expression in the PAD4-low mice, the 
interpretation of the PAD4 expression data is more complicated. Surprisingly, the anti-
PAD4 antibody stained a band comigrating with the recombinant PAD4 protein in all 
mouse tissues analysed, although marked differences in intensities were observed, 
with strong signals in lung, spleen and kidney. The intensity of the PAD4 signals in 
tissue extracts from the PAD4-low mice was strongly reduced or undetectable, except 
for lung and spleen. These data indeed suggest that the consequences of the PAD4 
gene changes may differ between different tissues. Currently, we cannot exclude the 
possibility that the detection of PAD4 in all of these tissues is, at least in part, due to 
the remaining blood cells in these tissues. In addition to the PAD4 signal at the 
expected position, another, slower migrating band was observed in brain, liver, lung, 
muscle, spinal cord and testis extracts. The absence of this band in the corresponding 
extracts from the PAD4-low mice suggests that this represents another isoform of 
PAD4. In human tissue extracts, PAD4 was detected in liver, spleen, kidney, thymus 
and weakly in placenta (Figure 5B). In contrast to the situation with mouse tissue 
extracts, no PAD4 was detectable in human brain and skeletal muscle extracts (Table 
1). The absence of PAD4 in human brain does not agree with observations previously 
reported by Wood and co-workers, who found PAD4 in both mouse and human brain 
96. The reason for these conflicting results is currently unclear.  
Besides the possibility that contaminations with blood affected the detection of PAD4 
in human brain, the results obtained with immunogold electron microscopy of brain 
sections should be interpreted with care.  
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These data were obtained with the same anti-PAD4 antibody as the one used in our 
study and the strong cross-reactivity of this antibody with high molecular weight brain 
proteins (see Figures 4 and 5) may have affected these results. In addition, the 
expression levels of PAD4 may differ between different regions of the brain and 
different parts of the brain may have been used in these studies.  
In human tissues, the anti-PAD6 antibody stained bands of approximately the expected 
molecular weight in brain, liver and thymus. A polypeptide migrating somewhat slower 
than the recombinant PAD6 protein was observed in human ovarian tissue (Figure 6C). 
This might be the result of a post-translational modification of PAD6, but currently no 
information on such modifications is available. Based upon literature data PAD6 was 
expected only in mouse ovary (Table 1, 
75;115
). We also observed PAD6 expression in 
mice ovary, in PAD2-/- as well as in PAD4-low mice (data not shown). Surprisingly, the 
expression of the PAD6 protein appeared to be up-regulated in both the PAD2-/- and 
the PAD4-low mice. In all of the tissues analysed except for spleen and testis PAD6 
signals were clearly detectable, in contrast to the wild-type mice.  
Although the elevated expression of PAD6 may suggest that PAD6 may compensate for 
the loss of either PAD2 or PAD4, this is not a very likely explanation, because it does 
not restore PAD activity in the PAD2-/- mice (Figure 7). This is in agreement with the 
lack of deiminase activity associated with the recombinant human PAD6 protein 116. 
Therefore, it remains puzzling why the down-regulation of PAD2 or PAD4 leads to the 
up-regulation of PAD6 expression. The possibility that PAD6 requires other, yet 
unidentified co-factors to become active and that it is only active under physiological 
conditions, but not in tissue lysates, cannot be excluded.  
The PAD activity analyses with tissue lysates demonstrated that PAD2 is responsible for 
virtually all PAD activity in the central nervous system (CNS), skeletal muscle and 
spleen. Indeed, PAD2 has been previously suggested to be the main PAD in the CNS 
and muscles 88;90;96;117;118. Our data also indicate that neither PAD4 nor PAD6 (in the 
PAD2-/- tissue lysates) displays detectable levels of PAD activity upon post-lytic 
activation in these tissue lysates. However, in both PBMC and PMN cells the disruption 
of the PAD2 gene had only a minor effect on PAD activity, suggesting that PAD4 
significantly contributes to the deiminase activity in these blood cells. This is in 
agreement with the detection of PAD4 mRNA and protein in various blood cells 78;119.  
In conclusion, our data indicate that PAD2 is solely responsible for protein citrullination 
in various mouse tissues. In white blood cells, however, also PAD4 appears to play a 
major role. For yet unknown reasons, the expression level of PAD6 is elevated in 
various tissues upon down-regulation of either PAD2 or PAD4 expression. 
 
MATERIALS AND METHODS 
 
Mice strains 
PAD2-/- mice were generated as described previously by Raijmakers and colleagues 
108
. PAD4-low mice were 
generated via gene trap mutagenesis (Lexicon). Control B6/129 mice (wild-type) were purchased from 
Jackson Laboratories (Bar Harbor, ME). 
 
Genomic DNA isolation from PAD2-/- and PAD4-low mice  
The toes, routinely used for identification of siblings, of PAD2-/- and PAD4-low mice were incubated in 250 ul 
lysis buffer (100 mM Tris-HCl, pH 7.5, 5 mM EDTA, 0.2% SDS, 200 mM NaCl and 100 µg/ml proteinase K) at 
50°C overnight. The next day, insoluble material was removed by centrifugation for 5 min at 7,000g.  
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The supernatant was transferred to a new tube and isopropanol (250 µl) was added. The resulting pellet 
after centrifugation for 10 minutes at 18,000g was air-dried and dissolved in 100 µl TE buffer (10 mM Tris-
HCl, pH 8.0, 1 mM EDTA). 
 
Polymerase chain reaction 
Genomic DNA (150 ng; isolated from the toes) was subjected to PCR using the following primers:  
mPAD2Exon1-fwd, 5’-GCCGCCTATACGGGAAAATATG-3’;  
mPAD2Intron1-rev, 5’-GGTGAAAGGTCAGCCAAGAAG-3’;  
mPAD4LTR-fwd, 5’-GGCGTTACTTAAGCTAGCTTGC-3’;  
mPAD4Intron1-fwd, 5’-CTTTGTTTCATCCGGACCTC-3’;  
mPAD4Intron1-rev, 5’-GAAATGTCAGCTCGGTCCTC-3’.  
To determine the amount of PAD4 mRNA present in the PAD4-low mice the following primers were used:  
mP4-E5-Fo, 5’-ATGGACTTTGAGGATGAC-3’;  
mP4-E8-Re, 5’-TGTCTTGGAACACCAGGG-3’;  
mP4-E1-Fo, 5’-GTGTGTGTGGTGGGCACAG-3’;  
mP4-E2-Re, 5’-TGTAGGGTCACCTCCAGCTC-3’.  
As a DNA quality control beta-actin primers were used: 
Beta-actin-fwd, 5'-ACTCCATCATGAAGTGTGACG-3' and beta-actin-rev, 5'-CATACTCCTGCTTGCTGATCC-3'. 
PCR reactions were performed with Red hot polymerase (ABgene) according to the manufacturer’s protocol. 
Annealing time and elongation time was dependent on primer combinations used and the length of the 
amplicon. A total of 38 cycli were used for amplification. 
 
Tissue isolation and preparation 
Mouse tissue samples were obtained from the animal facility at the Radboud University Nijmegen. Freshly 
dissected tissue samples (pooled material from two mice per group), kept on ice, were homogenized in 
200 μl of ABAP lysis buffer (20 mM Tris–HCl, pH 7.4, 10 mM β-mercaptoethanol, 100 mM NaCl, 10% glycerol, 
supplemented with Complete EDTA-free protease inhibitor mix (Roche Biochemicals)) using a 100 μm cell 
strainer (BD Falcon). After 4 sonication steps (30 sec each) samples were centrifuged for 30 minutes at 
18,000g at 4 °C. Supernatants were used immediately in the ABAP assay. 
Frozen human tissue samples were obtained from the pathology department of the Radboud University 
Medical Center and pulverized using a microdismembrator and the resulting material was solubilised in 
lysisbuffer (20 mM Tris–HCl, pH 7.4, 10 mM β-mercaptoethanol, 100 mM NaCl, 10% glycerol, supplemented 
with Complete EDTA-free protease inhibitor mix (Roche Biochemicals)). After the removal of insoluble 
material by centrifugation, the lysates were fractionated by SDS-PAGE and transferred to nitrocellulose 
membranes. 
Heparinised blood from five mice per group was pooled (total volume 5 ml) and 
and diluted twice with PBS-citrate and added on top of a 5 ml Ficoll Paque (GE Healthcare). After 
centrifugation for 20 min at 500g, PBMCs (peripheral blood mononuclear cells) were collected from the 
interphase (also known as buffy coat) and washed several times with PBS prior to use. PMN 
(polymorphonuclear) leukocytes were collected by resuspending the pellet, after removal of residual Ficoll, 
in RBC lysis buffer (155 mM NH4Cl, 10 mM KCO3, 0.1 mM EDTA, pH 7.3). Red blood cells (RBCs) were lysed for 
10 minutes, after which the PMN cells were washed with PBS. This procedure was repeated, until virtually all 
RBCs were depleted. For PAD activity studies and PAD protein expression, white blood cells were finally 
taken up in ABAP lysis buffer, sonicated briefly (5 times 30 seconds) and centrifuged (30 minutes at 18,000g).  
The resulting supernatant was used in ABAP. 
 
Antibodies 
Isotype-specific antibodies directed against PAD types 2, 4 and 6 were produced by immunization of rabbits 
with PAD isotype-specific peptides (PAD2: amino acids 3–18 and amino acids 517–531; PAD4: amino acids 
181-194; PAD6: amino acids 320-334 (Sigma Genosys). Antibodies were affinity purified as described 
previously 
120
. 
 
Western blotting 
The total protein concentrations of tissue lysates were measured with the Bradford assay (Biorad) and 
samples containing 100 µg of total protein were separated by SDS–PAGE (10% polyacrylamide gels), and 
transferred to Hybond C-extra nitrocellulose membranes (Amersham Biosciences) by electroblotting. 
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After a 2 h blocking step (PBS containing 5% non-fat dried milk and 0.1% Nonidet P-40), the blots were 
incubated for 1 h with the antibody of interest (anti-PAD2, anti-PAD3, anti-PAD4 and anti-PAD6 polyclonal 
rabbit antibodies) 10-fold diluted in blocking buffer. Following extensive washing in blocking buffer, bound 
antibodies were visualized by incubation with HRP-conjugated swine–anti-rabbit IgG antibodies (Dako 
Immunoglobulins), washing (three times with PBS containing 0.1% Nonidet P-40 and one time with PBS), and 
chemiluminescence. 
For the detection of citrullinated proteins, blots were chemically modified overnight as described previously 
and incubated with the anti-modified citrulline antibody (Upstate) for 3 hours 
121
. 
 
Antibody-based assay for peptidylarginine deiminase activity (ABAP) 
The procedure for the ABAP has been extensively described previously 
110
. In short, microtiter plates were 
coated with 500 ng/ml biotinylated arginine-peptide in PBS for 1 hour at 37°C (as a positive control a 
citrulline variant of the same peptide was used). After coating, plates were washed twice with TBS500 (50 mM 
Tris–HCl, pH 7.6, 500 mM NaCl) and once with TBS (50 mM Tris–HCl, pH 7.6, 150 mM NaCl).  
After washing, the immobilized peptides were incubated with PAD-containing samples (supernatant from 
cell/tissue lysates) in citrullination buffer (40 mM Tris–HCl, pH 7.6, 5 mM CaCl2, and 1 mM DTE) or in a 
negative control buffer (40 mM Tris–HCl, pH 7.6, 2 mM EDTA, and 1 mM DTE). Cell/tissue samples were 
normalized based upon total protein content as determined by UV absorbance. Purified rabbit muscle PAD 
enzyme, rPAD (Sigma), was used to generate PAD activity calibration curves. After 1 hour incubation at 37°C, 
plates were washed five times with TBS500 containing 0.5% Tween 20 (TBS500T).  
The plates were then incubated with anti-citrullinated protein antibody (scFv RA3) diluted in PBS containing 
0.5% Tween 20 and 1% BSA, followed by extensive washing in PBST (PBS containing 0.05% Tween 20). 
Subsequently, the plates were incubated for 1 hour at 37°C with rabbit anti-human immunoglobulin 
conjugated to HRP in PBS, 0.5% Tween 20, 1% BSA. After thorough washing with PBST, bound antibodies 
were visualized by the conversion of tetramethylbenzidine (TMB) substrate according to standard 
procedures. After 5 minutes, the reaction was stopped by the addition of an equal volume of 2M H2SO4. The 
absorbance at 450 nm was used to monitor product formation.  
 
Post-lytic activation of mouse tissue 
Cell/tissue lysates (16 µl) were incubated in activation solution (10 mM CaCl2, 5 mM DTE) for 1 hour at 37°C. 
As a negative control, extracts were incubated in the presence of 4 mM EDTA instead of 10 mM CaCl2. 
Samples normalized based upon total protein content were separated by SDS-PAGE, transferred to 
nitrocellulose blots and subsequently stained with the anti-modified citrulline antibody after modification of 
peptidylcitrullines on the blot. 
 
LIST OF ABBREVIATIONS  
 
ABAP, antibody-based assay for peptidylarginine deiminase activity; NET,  neutrophil extracellular trap; PAD,  
peptidylargine deiminase; PBMC,  peripheral blood mononuclear cell; PMN,  polymorphonuclear leukocytes; 
RA, rheumatoid arthritis; RBC, red blood cell. 
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INTRODUCTION 
 
Rheumatoid arthritis (RA) is a common autoimmune disease, which is characterized by 
chronic inflammation of the synovial joints. It is still unknown what causes RA. Several 
factors, however, have been proposed to play a role in the pathogenesis of RA, 
including environmental (e.g. smoking), genetic (e.g. ‘shared epitope’ HLA-DRB1 
alleles) and hormonal factors (women are more often affected than men) 4;33. A 
specific feature of the immune response in RA is the presence of anti-citrullinated 
protein antibodies (ACPA) in patient sera. These antibodies can already occur several 
years prior to disease onset and increasing evidence suggests that they play a role in 
the pathophysiology 5;8;10;122.  
Because the initial studies to detect ACPA in patient sera were performed with 
citrullinated molecules that do not occur in the inflamed joints of patients, such as 
citrullinated filaggrin and citrullinated synthetic peptides from random peptide 
libraries, the identification of inflammation-associated citrullinated proteins severely 
lagged behind ACPA characterization.  
So far, several candidate citrullinated autoantigens have already been described (e.g. 
fibrin(ogen), vimentin, fibronectin, alpha-enolase and others), but their role in the 
pathogenesis of RA remains unclear 30;42;49;50;54. The presence of ACPA reactive with the 
majority of the identified citrullinated antigens in RA sera has been described 123.  
ABSTRACT - This study aimed to generate a catalog of citrullinated proteins 
present in the synovia of rheumatoid arthritis (RA) patients and to elucidate their 
relevance for the anti-citrullinated protein antibody response in RA. The analysis 
of RA synovial fluid samples by anti-modified citrulline antibodies revealed several 
distinct patterns of citrullinated proteins. Using mass spectrometry (fragments of) 
192 proteins were identified in the samples analyzed, including 53 citrullinated 
proteins, some of which contained multiple citrullinated residues. These data 
confirmed the presence of previously reported citrullinated proteins in RA synovia 
(e.g. vimentin and fibrinogen), and also identified a series of novel citrullinated 
proteins, such as apolipoprotein E, myeloid nuclear differentiation antigen, beta-
actin and cyclophilin A. By immunoprecipitation experiments the citrullination of 
apolipoprotein E and myeloid nuclear differentiation antigen was confirmed. ELISA 
analyses demonstrated the presence of autoreactive citrullinated epitopes in 
apolipoprotein E, myeloid nuclear differentiation antigen and beta-actin, although 
strong differences were observed between the frequencies by which these 
epitopes are targeted by RA autoantibodies. In conclusion, synovial fluid samples 
from the inflamed joints of RA patients contain many citrullinated proteins. 
Citrullinated apolipoprotein E, myeloid nuclear differentiation and beta actin are 
novel antigens identified in RA synovial fluid and only a limited number of their 
citrullinated epitopes is targeted by the immune system in RA.  
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Although citrullinated proteins have been reported to occur in most, if not all inflamed 
tissues, the formation of citrullinated protein-specific immune complexes will be 
largely restricted to RA as a result of the disease-specific production of ACPA.  
In view of the putative pathophysiological role of such complexes, it is important to 
obtain a comprehensive view of the citrullinated proteins present in the inflamed 
joints of RA patients and their recognition by ACPA.  
In this study the presence of citrullinated proteins and fragments thereof in synovial 
fluid samples (SF) of RA patients was investigated by western blotting and mass 
spectrometry (MS). This approach yielded an inventory of citrullinated proteins 
(citrullinome) in the inflamed joints of RA patients. The importance for the identified 
citrullinated residues in three proteins that were detected in both patient samples 
analyzed for their recognition by patient sera was assessed by ELISA with synthetic 
peptides. 
 
RESULTS 
 
Citrullinated proteins in RA synovial fluid samples 
RA SF samples were separated into soluble and insoluble fractions by centrifugation. 
The presence of citrullinated proteins in both fractions was analyzed by western 
blotting using anti-modified citrulline (AMC) antibodies, after chemical modification of 
peptidylcitrullines on the blot. As shown in Figure 1, many citrullinated proteins can be 
detected in RA SF samples. Moreover, different RA SF samples often show different 
citrullination patterns. Some SF samples contain a broad range of citrullinated proteins 
(e.g. SFP10 and SFP11), whereas other SFs only contain a limited number of 
citrullinated proteins (e.g. SFP12 and SFP13). In addition, intermediate citrullination 
patterns were observed (e.g. SFS2 and SFS7).  
 
 
Figure 1. Citrullinated proteins in RA SF. SF 
samples from RA patients were 
fractionated by SDS-PAGE and analysed by 
Ponceau S staining (A) and immunoblotting 
using AMC antibodies (B) after citrulline 
modification on the blot. As a positive 
control (H;  200 ng and 1 μg) of 
citrullinated histones were analyzed in 
parallel. SFP = synovial fluid pellet fraction; 
SFS = synovial fluid supernatant fraction. 
The positions of molecular weight markers 
(kDa) are indicated on the left. 
 
 
A 
B 
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As demonstrated in Figure 1, the SFs containing the insoluble SF fractions (SFP) tend to 
show the most extreme citrullination patterns (either a broad range of citrullinated 
proteins or only few low molecular weight citrullinated proteins), while the soluble SF 
fractions (SFS) display more intermediate citrullination patterns.  
Some samples did not show detectable levels of citrullinated proteins (e.g. SFP4), even 
though these SF samples contained similar protein levels (Figure 1A). 
 
Global identification of proteins and citrullinated proteins in RA SF  
After screening SFs of RA patients by western blotting for the presence of citrullinated 
proteins, SF samples of two patients (one soluble, SFS9, and one insoluble, SFP38 
fraction) were selected based upon the presence of multiple citrullinated proteins. 
These samples were depleted for albumin that is abundantly present in SF samples, 
which resulted in two fractions (p1 and p2) per sample 124. The polypeptides in these 
samples were separated by SDS-PAGE, after which each lane was dissected into 18 
slices (Figure 2).  
 
After digestion with trypsin the resulting peptides were eluted and analyzed by LC-
MS/MS to determine the identity of the proteins and the positions of citrullinated 
residues (citrullination was set as one of the variable modifications to detect). The 
fragmentation pattern of each peptide was manually investigated to confirm the 
presence of peptidylcitrulline (1 Dalton difference compared to peptidylarginine) and 
to exclude the possibility that the mass difference was due to deamidation of 
peptidylglutamine or peptidylasparagine in the same tryptic peptide.  
Figure 2. Fractionation of two RA SF samples for citrullinome analysis. Two synovial fluid samples 
(SFS9 and SFP38) from RA patients were selected for (citrullinated) protein identification by LC-MS 
analysis. These samples were depleted for albumin, which leads to two pellet fractions (p1 and p2) and 
a supernatant fraction containing most of the albumin. All 4 samples (pellet fractions of both patients) 
were fractionated by SDS-PAGE and stained with colloidal Coomassie Brilliant Blue (cCBB) or analysed 
with AMC antibody on western blots. The cCBB-stained gel was divided into 18 slices, which were in-gel 
digested with trypsin, after which the resulting peptides were analyzed by LC-MS. The presence of 
citrullinated proteins (or fragments thereof) in the gel slices is indicated on the right of each panel. The 
positions of molecular weight markers (kDa) are indicated on the left of each panel. 
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Table 1. Polypeptides detected in RA SF samples 
Protein  Function
a
 UniProtKB  SFS9 SFP38 
 
14-3-3 protein zeta/delta 
 
 ST P63104 
 
X 
 
26S proteasome non-ATPase regulatory subunit  O O00233  X 
40S ribosomal protein S13  PS P62277  X 
40S ribosomal protein S16  PS P62249  X 
40S ribosomal protein S18  PS P62269  X 
60S ribosomal protein L18  PS Q07020  X 
60S ribosomal protein L22  PS P35268  X 
alpha-enolase   G P06733 X X 
alpha-1-acid glycoprotein 2  IR P19652 X  
actin related protein 2/3 complex subunit 1B  C O15143 X X 
ADP-ribosylation factor 1   VT P84077  X 
afamin  MT P43652 X X 
actin, alpha skeletal muscle  C P68133  X 
collagen alpha-3(VI) chain  C P12111 X  
alpha-actinin-1  C P12814 X X 
alpha-1-acid glycoprotein 1  IR P02763 X X 
alpha-1-antitrypsin (serpin A1)  IR P01009 X X 
alpha-1-B-glycoprotein  O P04217 X X 
alpha-1-antichymotrypsin  PI P01011 X  
alpha-2-antiplasmin  CC P08697  X 
alpha-2-macroglobulin  PI P01023 X X 
angiotensinogen  PI P01019 X X 
annexin A1  IR P04083 X X 
annexin A2  IR P07355 X X 
annexin A3  CC P12429 X  
annexin 4  IR P09525  X 
annexin A5  IR P08758 X X 
annexin A6   VT P08133  X 
antithrombin III, chain A  CC P01008 X X 
apolipoprotein A-I  LT P02647 X X 
apolipoprotein A-IV  LT P06727 X X 
apolipoprotein B-100    LT P04114 X X 
apolipoprotein E  LT P02649 X X 
apolipoprotein L-I  LT O14791 X X 
Actin-related protein 3  C P61158 X X 
ATP synthase subunit alpha, mitochondrial  O P25705  X 
beta-actin  C P60709 X X 
calnexin  PF P27824  X 
carboxypeptidase N, catalytic chain  IR P15169  X 
cartilage acidic protein 1  O Q9NQ79 X X 
cathepsin G, chain A  IR P08311 X X 
ceruloplasmin  MT P00450 X X 
chloride intracellular channel protein 1   O O00299 X  
clathrin heavy chain 1  VT Q00610 X X 
clusterin (apolipoprotein J)  CD P10909 X X 
coagulation factor XIII A chain  CC P00488  X 
cofilin-1  C P23528 X  
complement C1q subcomponent subunit B  IR P02746 X  
complement C1 r subcomponent  IR P00736 X X 
complement C2    IR P06681 X X 
complement C 3  IR P01024 X X 
complement C 4-A  IR P0C0L4 X X 
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[Table 1 continued] 
 
     
complement C4-B  IR P0C0L5 X  
C4b-binding protein alpha chain  IR P04003 X X 
complement C5  IR P01031 X X 
complement C6  IR P13671 X X 
complement C7  IR P10643 X X 
complement C8, beta chain  IR P07358 X X 
complement C9  IR P02748 X X 
complement factor B  IR P00751 X X 
complement factor D  IR P00746 X  
complement factor H  IR P08603 X X 
complement factor H-related protein 1  IR Q03591 X  
coronin-1A  C P31146  X 
corticosteroid-binding globulin  MT P08185 X  
cyclophilin A (peptidylprolyl isomerase A) 
desmoplakin  
 PF 
C 
P62937 
P15924 
X 
 
X 
X 
elongation factor 1-alpha 1  PS P68104  X 
elongation factor 2  PS P13639  X 
endoplasmin  PF P14625 X X 
extracellular matrix protein 1  O Q16610  X 
F-actin capping protein alpha-1 subunit  C P52907 X X 
protein FAM49B  O Q9NUQ9 X  
ferritin, heavy chain  MT P02794  X 
fibrinogen, alpha chain  CC P02671 X X 
fibrinogen, beta chain  CC P02675 X X 
fibrinogen, gamma chain  CC P02679 X X 
fibronectin  C P02751 X X 
ficolin-3  IR O75636 X X 
filamin A   C P21333 X X 
fructose-bisphosphate aldolase A  G P04075 X X 
galectin-2  O P05162 X  
galectin 3 binding protein  IR Q08380 X X 
gamma-actin  C P63261 X  
gelsolin  C P06396 X X 
glia maturation factor gamma  IR O60234 X  
glucosidase 2 subunit beta  O P14314  X 
glucose-6-phosphate isomerase  G P06744 X X 
glyceraldehyde-3-phosphate dehydrogenase  G P04406 X X 
guanine nucleotide-binding protein G(z) subunit alpha  ST P19086 X X 
haptoglobin  MT P00738 X X 
heat shock 70kDa protein 1A/1B  PF P08107  X 
heat shock protein 90kDa alpha   PF P07900 X X 
hemoglobin subunit beta  MT P68871  X 
hemopexin  MT P02790 X X 
heparin cofactor 2  PI P05546  X 
hexokinase 3  O P52790 X  
histidine-rich glycoprotein  CC P04196 X X 
histone H1.3  C P16402  X 
histone H1.5  C P16401 X X 
histone H2A.J  C Q9BTM1 X X 
histone H2B type 2-E  C P0C1H6 X X 
histone H3.3  C P84243 X  
histone H4  C P62805 X X 
HLA class II histocompatibility antigen, DR alpha chain  IR P01903  X 
interferon alpha-inducible protein 6  CD P09912  X 
Ig mu chain C region  IR P01871 X X 
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Ig lambda locus  IR Q6GMW4 X  
Ig kappa locus  IR Q6PJF2  X 
Insulin-like growth factor-binding protein complex acid labile subunit  CA P35858 X X 
inter-alpha-trypsin inhibitor heavy chain H2  MT P19823 X X 
inter-alpha-trypsin inhibitor heavy chain H4  IR Q14624 X X 
ras GTPase-activating-like protein IQGAP1  C P46940 X  
isocitrate dehydrogenase 2 (NADP)  O P48735  X 
keratin  (1 and 9)  O P35527 X X 
kininogen 1 light chain  CC P01042-2 X X 
lactotransferrin  MT P02788 X X 
leucine-rich alpha-2 glycoprotein  CA P02750 X X 
L-lactate dehydrogenase A chain  G P00338 X X 
low molecular weight phosphotyrosine protein phosphatase  O P24666  X 
low density lipoprotein receptor-related protein 2  LT P98164  X 
lumican  C P51884 X X 
macrophage-capping protein  C P40121 X X 
matrix metalloproteinase-9  O P14780 X  
HLA class I histocompatibility antigen, B-7 alpha chain  IR P01889  X 
moesin  C P26038 X X 
monocyte differentiation antigen CD14  IR P08571 X X 
mutant beta-actin  C P60709 X X 
myeloid cell nuclear differentiation antigen  IR P41218 X X 
myeloperoxidase  IR P05164 X X 
myosin 9   C P35579 X X 
n-acetylglucosamine kinase  O Q9UJ70  X 
neuropilin-1  CD O14786 X X 
neutrophil gelatinase-associated lipocalin  MT P80188 X  
nucleoside diphosphate kinase B  O P22392  X 
retinoic acid receptor alpha  O P10276  X 
olfactomedin 4  O Q6UX06  X 
periostin  CA Q15063 X  
phosphoglucomutase-1  G P36871 X  
phopholipid transfer protein  LT P55058 X  
phosphatidylinositol-glycan-specific phospholipase D1  O P80108 X X 
phosphogluconate dehydrogenase  O P52209 X X 
phosphoglycerate kinase 1  G P00558 X X 
pigment epithelial-derived factor  PI P36955  X 
plasma kallikrein  O P03952 X X 
plasma protease C1 inhibitor  CC P05155 X X 
plasminogen  CC P00747 X X 
plastin-2   IR P13796 X X 
pregnancy-zone protein  O P20742 X  
probable E3 ubiquitin-protein ligase MYCBP2  C O75592 X  
procollagen C-endopeptidase enhancer 1  O Q15113 X X 
profilin 1  C P07737 X X 
prohibitin 2  O Q99623  X 
proteasome subunit beta type1   O P20618 X X 
proteoglycan 4  O Q92954 X X 
prothrombin (coagulation factor II)  CC P00734 X  
pyruvate kinase  G P14618 X X 
ras-related protein Rab-7a  VT P51149 X  
receptor expression-enhancing protein 5  ST Q00765 X X 
ras-related protein Rab-8A 
Rho GDP dissociation inhibitor 2 
 VT 
C 
P61006 
P52566 
X 
X 
 
S100 A9  IR P06702 X X 
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a 
G = glycolysis; C = cell mobility/structure/integrity; VT = vesicle formation/protein transport; MT = 
molecular transport; IR = immune response; CC = coagulation cascade; PI = protease inhibitor; PF = protein 
folding; LT = lipid transport; CD = cell death; ST = signal transduction; PS = protein synthesis; CA = cell 
adhesion; O = other 
 
 
The total number of proteins with Mascot scores of 30 or higher that were identified in 
the SF samples, irrespective of their citrullination, was 192; 40 of these were detected 
solely in the material from the soluble fraction (SFS9) and 45 solely in the material 
from the insoluble fraction (SFP38). The identified proteins can be categorized into 14 
groups according to their function.  
These groups include proteins that play a role in the immune response (40 proteins), in 
glycolysis (9 proteins), in signal transduction (4 proteins), in lipid metabolism (8 
proteins), in blood coagulation (14 proteins), in cell mobility/structure/integrity (33 
proteins), in cell death (4 proteins), in protein folding (6 proteins), in protein synthesis 
(7 proteins) in vesicle formation/protein transport (6 proteins), in molecular transport 
(16 proteins), in protease inhibition (6 proteins), cell adhesion (4 proteins) and finally 
proteins that can be categorized according to other functions (34 proteins) (Table 1). 
  
[Table 1 continued] 
 
     
sorting nexin 3  VT O60493  X 
serotransferrin  MT P02787 X X 
serum albumin  MT P02768 X X 
serum amyloid A4  IR P35542 X  
serum amyloid P component  PF P02743 X  
serum paraoxonase/arylesterase 1  O P27169 X X 
sex hormone-binding globulin  MT P04278  X 
spectrin beta chain, brain 2  ST O15020 X  
synaptic vesicle membrane protein VAT-1 homolog-like  O Q9HCJ6 X  
syndecan-2  O P34741 X  
talin 1  C Q9Y490 X X 
tenascin  C P24821 X  
tenascin-X  C P22105 X X 
thioredoxin-dependent peroxide reductase, mitochondrial  O P30048 X X 
thyroxine-binding globulin  MT P05543 X X 
transaldolase  O P37837 X X 
transforming growth factor-beta-induced protein ig-h3  O Q15582  X 
transketolase   O P29401 X X 
transthyretin  MT P02766 X X 
triosephosphate isomerase  G P60174  X 
tropomyosin alpha 3 chain  C P06753 X  
tubulin beta chain  C P07437  X 
ubiquitin modifier-activating enzyme 7  O P41226 X  
vimentin  C P08670 X X 
vinculin  CA P18206 X  
vitamin D-binding protein   MT P02774 X X 
vitamin K-dependent protein S   CC P07225 X X 
vitronectin  PI P04004 X X 
voltage-dependent anion-selective channel protein 1  CD P21796  X 
Zn-alpha-2-glycoprotein  LT P25311 X X 
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Table 2. Citrullinated polypeptides detected in RA synovium 
 
Citrullinated protein UniProtKB SFS9 SFP38 MW *10
-3 a 
 
 
40S ribosomal protein S16  
 
P62249 
 
- 
 
+ 
 
~14 
ADP-ribosylation factor 1  P84077 - + ~14 
alpha-1-antitrypsin (serpin A1) P01009 +  -
 b
 ~43 
alpha-2-macroglobulin P01023 + -
 b
 >94 - 43 
antithrombin, chain A P01008 + -
 b
 ~40 
apolipoprotein A-I P02647 + -
 b
 ~20 
apolipoprotein A-IV  P06727 + -
 b
 ~40 
apolipoprotein B-100 P04114 + -
 b
 >94 
apolipoprotein E P02649 + + 43 - 30 
apolipoprotein L-I O14791 + -
 b
 ~35 
beta-actin P60709 + + 43 - <14 
cathepsin G, chain A P15169 + -
 b
 20 - <14 
clusterin (apolipoprotein J)  P10909 + -
 b
 ~35 
complement C3  P01024 + -
 b
 ~75 
complement component C4-A P0C0L4 -
 b
 + ~30 
complement factor B P00751 + -
 b
 ~43 
complement factor H P08603 + -
 b
 >94 - 43 
complement factor H-related protein 1 Q03591 + - ~20 
coronin P31146 - + ~43 
cyclophilin A (peptidylprolyl isomerase A) P62937 + + ~14 
fibrinogen, alpha chain P02671 + + 67 - <14 
fibrinogen, beta chain P02675 + -
 b
 <14 
fibronectin P02751 + + >94 - 67 
galectin-2 P05162 + - <14 
gamma-actin P63261 + - ~43 
gelsolin P06396 -
 b
 + ~43 
glia maturation factor gamma O60234 + - ~20 
glyceraldehyde-3-phosphate dehydrogenase P04406 + -
 b
 43 - 20 
hexokinase 3 P52790 + - ~80 
histone cluster H1.3 P16402 -
 b
 + <14 
histone H2A.J Q9BTM1 + -
 b
 <14 
histone H2B type 2-E Q16778 + -
 b
 <14 
histone H3.3 P84243 + - <14 
Ig mu chain C region P01871 + -
 b
 67 - 43 
immunoglobulin lambda locus Q6PJF2 + - ~25 
inter-alpha-trypsin inhibitor heavy chain H2  P19823 + -
 b
 >94-50 
inter-alpha-trypsin inhibitor heavy chain H4  Q14624 -
 b
 + >94 - 40 
keratin, type I cytoskeletal 9 P35527 -
 b
 + ~67 
keratin, type II cytoskeletal 1 P04264 -
 b
 + ~80 
kininogen 1 light chain P01042-2 + -
b
 ~67 
myeloid cell nuclear differentiation antigen P41218 + + 43 - 14 
myeloperoxidase P05164 -
 b
 + ~43 
myosin 9 P35579 -
 b
 + ~80 
periostin Q15063 + - ~70 
probable E3 ubiquitin-protein ligase MYCBP2 O75592 + - ~94 
proteoglycan 4 Q92954 + -
b
 ~14 
profilin 1 P07737 + -
 b
 ~14 
prothrombin (coagulation factor II) P00734 + - ~43 
pyruvate kinase P14618 + -
 b
 ~43 
rho GDP dissociation inhibitor 2 P52566 + - ~20 
serum amyloid A4 P35542 + - ~14 
vimentin P08670 -
 b
 + 43 - 30 
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vinculin P18206 + - ~94 
 
a 
The molecular weights (MW) correspond to the positions in the SDS-PAGE gels containing SF material. 
b 
Present in SF sample, but no citrullinated residues detected. 
 
 
Peptide sequences for many of these proteins were not only found in material from 
the gel slice corresponding to known molecular weight for the full-length protein, but 
also in one or more gel slices corresponding to lower molecular weights. This strongly 
suggests that many proteins are subjected to proteolytic cleavage events in the SF. A 
comparison of the proteins detected in both patient samples demonstrated that 107 
proteins (56%) were found in both samples, in spite of the fact that the starting 
material differed with regard to its solubility.  
The majority of the peptides identified with LC-MS/MS did not contain citrullinated 
residues; however citrullinated residues were detected in peptides from 53 proteins 
(28% of all proteins identified), 35 solely in the material from SFS9 and 12 solely in the 
material from SFP38 (Table 2 and Table 3). The citrullinated proteins can be divided 
into 4 major groups, based upon their function (Table 1 and Table 2). The majority of 
the citrullinated proteins are proteins involved in the immune response (14 proteins), 
proteins involved in cell mobility, structure or cell integrity (12 proteins), proteins 
involved in lipid transport (5 proteins), proteins involved in the coagulation cascade (4 
proteins). The remaining citrullinated proteins are divided randomly over the other 
functional groups. 
Six  citrullinated polypeptides were detected in both patients; being alpha-fibrinogen, 
fibronectin, apolipoprotein E (ApoE), myeloid nuclear differentiation antigen (MNDA), 
beta-actin and cyclophilin A (CypA) (Table 2 and Table 4). The majority of the 
citrullinated polypeptides corresponded to fragments of the total protein, based upon 
their position in the gel slices. Some of the citrullinated proteins have previously been 
identified in RA, such as fibrinogen 30;52, vimentin 42 and fibronectin 50.  
The majority, however, have not been described before to occur in a citrullinated form 
in the inflamed synovial of RA patients. There is some overlap between the data 
obtained with material from both patients (Table 2, Table 3 and Table 4).  
Citrullinated fibronectin and fibrinogen were detected in both RA SF samples, while 
citrullinated vimentin and histones were detected in only one of the two samples 
analyzed. For four other proteins, ApoE, MNDA, beta-actin and CypA, citrullinated 
peptides were detected in both patient samples (Table 3 and Figure 3).  
For all the citrullinated peptides derived from ApoE, MNDA and beta-actin also the 
unmodified forms were detected, with the exception of the unmodified counterpart of 
the peptide containing a citrulline at position 204 of MNDA. 
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Table 3. Citrullinated proteins detected in RA SF samples 
 
SFS9       
 
Gel slice 
number 
 
 
Protein 
 
UniProtKB 
 
Mascot  
Score
a
 
 
Citrullinated peptide  
 
Amino acid 
position 
 
Ion 
Score
b
 
 
 
1 
 
alpha-2-macroglobulin 
 
P01023 
 
3923 
 
R.VGFYESDVMGRGHAR.L 
 
705-719 
 
54 
    K.SLNEEAVKKDNSVHWERPQKPK.A 1169-1190 
 
42 
 
1 apolipoprotein B-100 P04114 2987 K.NRNNALDFVTK.S 3211-3221 37 
 
1 complement factor H P08603 497 K.IVSSAMEPDREYHFGQAVR.F 157-175 38 
 
1 fibronectin P02751 4276 R.TSYRIGDTWSK.K 
 
238-247 50 
1 inter-alpha-trypsin inhibitor heavy chain H2 P19823 477 K.TVGRALYAQAR.A 136-146 62 
    R.TWRNDLISATK.T 357-367 37 
 
1 proteoglycan 4 
 
Q92954 374 K.NSAANRELQK.K 187-196 43 
    R.AITTRSGQTLSK.V 1387-1398 42 
 
2 alpha-2-macroglobulin P01023 3472 R.VGFYESDVMGRGHAR.L 705-719 49 
 
2 complement C3  
 
P01024 2288 K.VTIKPAPETEKRPQDAK.N 1365-1381 49 
 
2 fibronectin P02751 3178 K.VFAVSHGRESKPLTAQQTTK.L 977-986 31 
    R.LTVGLTRRGQPR.Q 1029-1040 
 
44 
2 inter-alpha-trypsin inhibitor heavy chain H2 
 
P19823 419 K.TVGRALYAQAR.A 136-146 47 
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[Table 3 continued] 
 
inter-alpha-trypsin inhibitor H4  
 
 
Q14624 
 
 
2114 
 
 
R.NRNVHSAGAAGSR.M 
 
 
615-628 
 
 
79 
    R.NRNVHSAGAAGSRMNFRPGVLSSR.Q 615-638 28 
    K.TGLLLLSDPDKVTIGLLFWDGRGEGLR.L 816-842 57 
 
2 vinculin 
 
P18206 533 K.LLAVAATAPPDAPNREEVFDER.A 608-629 39 
3 alpha-2-macroglobulin  
 
P01023 2936 R.VGFYESDVMGRGHAR.L 705-719 30 
3 complement C3  
 
P01024 1648 K.VTIKPAPETEKRPQDAK.N 1365-1381 
 
35 
3 complement factor H P08603 430 K.IVSSAMEPDREYHFGQAVR.F 157-175 48 
    R.LSSRSHTLR.T 1207-1215 
 
34 
3 hexokinase 3 
 
P52790 431 K.GLRGEASSLR.M 511-520 36 
3 inter-alpha-trypsin inhibitor heavy chain H2  
 
P19823 255 K.TVGRALYAQAR.A 136-146 50 
3 probable E3 ubiquitin-protein ligase MYCBP2 
 
O75592 37 K.ISRKCANR.H 2950-2957 37 
4 complement factor H 
 
P08603 151 R.LSSRSHTLR.T 1207-1215 31 
4 Ig mu chain C region  
 
P01871 634 K.VSVFVPPRDGFFGNPR.K 113-128 43 
4 inter-alpha-trypsin inhibitor heavy chain H2 
 
P19823 96 K.TVGRALYAQAR.A 136-146 40 
4 periostin  
 
Q15063 289 K.LLQEDTPVRK.L 752-761 32 
5 fibrinogen, alpha chain 
 
P02671 225 R.MELERPGGNEITRGGSTSYGTGSETESPR.N 259-287 93 
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5 kininogen 1 light chain 
 
P01042-2 270 K.AGAEPASEREVS- 415-427 42 
6  alpha-1-antitrypsin (serpin A1) P01009 2479 K.FLENEDRR.S 158-165 43 
       
6 fibrinogen, alpha chain 
 
P02671 328 R.MELERPGGNEITRGGSTSYGTGSETESPR.N 259-287 70 
6 inter-alpha-trypsin inhibitor heavy chain H2 
 
P19823 116 K.TVGRALYAQAR.A 136-146 49 
7 alpha-2-macroglobulin precursor  
 
P01023 1523 R.VGFYESDVMGRGHAR.L 705-719 36 
7 apolipoprotein A-IV precursor 
 
P06727 839 R.GNLRGNTEGLQK.S 256-267 41 
7 beta actin P60709 1388 K.AGFAGDDAPRAVFPSIVGRPRHQGVMVGM
GQK.D 
19-50 37 
    R.LDLAGRDLTDYLMK.I 178-191 46 
    K.ILTERGYSFTTTAER.E 192-206 83 
    R.GYSFTTTAEREIVR.D 197-210 76 
    K.DYLANTVLSGGTTMYPGIADDRMQK.E 292-315 71 
 
 
  K.QEYDESGPSIVHRK.C 360-373 50 
 
7 complement factor H P08603 181 K.IVSSAMEPDREYHFGQAVR.F 157-175 38 
 
 
  R.LSSRSHTLR.T 1207-1215 
 
36 
 
7 
 
fibrinogen (alpha chain) 
 
P02671 
 
744 
 
R.GDFSSANNRDNTYNR.V 
 
115-129 
 
65 
    R.MELERPGGNEITRGGSTSYGTGSETESPR.N 259-287 88 
    K.ESSSHHPGIAEFPSRGK.S 559-575 36 
 
 
  K.QFTSSTSYNRGDSTFESK.S 582-599 46 
 
7 Ig mu chain C region  
 
P01871 336 R.QIQVSWLREGK.Q 203-213 37 
7 inter-alpha-trypsin inhibitor heavy chain H2 
precursor  
 
P19823 284 K.TVGRALYAQAR.A 136-146 47 
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7 myeloid cell nuclear differentiation antigen 
 
P41218 74 K.LTSEARGRIPVAQK.R 122-135 50 
7 gamma-actin 
  
P63261 342 K.QEYDESGPSIVHRK.C 360-373 50 
7 pyruvate kinase 
 
P14618 237 K.GPEIRTGLIK.G 116-125 28 
8 alpha-2-macroglobulin precursor  P01023 1426 R.VGFYESDVMGRGHAR.L 705-719 43 
 
 
  K.KDNSVHWERPQKPK.A 1177-1190 27 
 
8 apolipoprotein A-IV  
 
P06727 291 R.GNLRGNTEGLQK.S 256-267 37 
8 apolipoprotein E P02649 787 R.LAVYQAGAREGAERGLSAIR.E 177-196 67 
    R.EGAERGLSAIR.E 186-196 46 
 
 
  R.ERLGPLVEQGR.V 197-207 45 
 
8 apolipoprotein L-I 
 
O14791 255 R.VNEPSILEMSRGVK.L 306-319 42 
8 beta actin P60709 720 K.IWHHTFYNELRVAPEEHPVLLTEAPLNPK.A 85-103 31 
    K.ILTERGYSFTTTAER.E 192-206 78 
 
 
  R.EIVRDIKEK.L  207-215 35 
 
8 clusterin (apolipoprotein J) 
 
P10909 487 K.LFDSDPITVTVPVEVSRK.N 376-393 81 
8 prothrombin (coagulation factor II) 
 
P00734 47 K.GRVTGWGNLK.E 492-501 31 
8 complement factor B 
 
P00751 237 R.GLTLRGSQR.R 194-202 43 
8 fibrinogen, alpha chain P02671 736 R.MELERPGGNEITRGGSTSYGTGSETESPR.N 259-287 88 
 
 
  K.QFTSSTSYNRGDSTFESK.S 582-599 91 
 
8 glyceraldehyde-3-phosphate dehydrogenase P04406 569 R.LVTRAAFNSGK.V 
K.LWRDGR.G 
17-27 
195-200 
54 
30 
 
 
  K.LWRDGRGALQNIIPASTGAAK.A 
 
195-215 44 
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8 inter-alpha-trypsin inhibitor heavy chain H2 
 
P19823 387 K.TVGRALYAQAR.A 136-146 54 
8 gamma-actin  
 
P63261 194 R.EIVRDIKEK.L 207-215 35 
 
 
9 
 
 
apolipoprotein E 
 
 
P02649 
 
 
674 
 
 
R.LAVYQAGAREGAERGLSAIR.E 
 
 
177-196 
 
 
47 
    R.EGAERGLSAIR.E 186-196 43 
 
9 prothrombin (coagulation factor II) P00734 151 R.TRYERNIEK.I 414-424 28 
    R.YNWRENLDRDIALMK.L 
 
90-104 31 
9 complement factor B 
 
P00751 97 R.GLTLRGSQR.R 194-202 26 
9 complement factor H 
 
P08603 94 K.IVSSAMEPDREYHFGQAVR.F 157-175 
 
34 
9 fibrinogen, alpha chain P02671 712 R.GDFSSANNRDNTYNR.V 115-129 71 
    R.MELERPGGNEITRGGSTSYGTGSETESPR.N 259-287 79 
 
9 inter-alpha-trypsin inhibitor heavy chain H2 
 
P19823 375 K.TVGRALYAQARAK.A 136-146 31 
10 fibrinogen, alpha chain 
 
P02671 236 R.MELERPGGNEITRGGSTSYGTGSETESPR.N 259-287 68 
10 Immunoglobulin lambda locus 
 
Q6PJF2 618 K.DNRPSGIPDR.F 70-79 26 
11 apolipoprotein A-I P02647    1173 K.DSGRDDYVSQFEGSALGK.Q 24-40 80 
    K.VERPLRAELQEGARQK.L 119-133 27 
    R.AELQEGARQK.L 123-133 50 
    K.AKPALEDLRQGLLPVLESFK.V 207-226 37 
 
11 fibrinogen, alpha chain P02671 616 T.ADSGEGDFLAEGGGVRGPR.V 19-38 56 
    R.GDFSSANNRDNTYNR.V 115-129 88 
    R.GDFSSANNRDNTYNRVSEDLR.S 115-135 49 
    R.MELERPGGNEITRGGSTSYGTGSETESPR.N 259-287 71 
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12 apolipoprotein A-I 
 
P02647 551 R.AELQEGARQK.L 123-133 62 
12 cathepsin G, chain A P15169 90 R.NRNVNPVALPR.A 99-110 53 
    R.RNRNVNPVALPR.A 100-110 42 
    R.RGTDTLREVQLR.V 134-145 48 
 
 
12 
 
complement factor H-related protein 1 
 
 
Q03591 
 
127 
 
R.LSSRSHTLR.T 
 
306-314 
 
32 
 
12 
 
fibrinogen, alpha chain 
 
P02671 
 
1541 
 
R.GDFSSANNRDNTYNR.V 
 
115-129 
87 
    R.GDFSSANNRDNTYNRVSEDLR.S 115-135 59 
    R.DNTYNRVSEDLR.S 124-135 60 
    K.DLLPSRDR.Q 211-218 39 
    R.MELERPGGNEITRGGSTSYGTGSETESPR.N 259-287 50 
    K.QFTSSTSYNRGDSTFESK.S 582-599 65 
 
12 glyceraldehyde-3-phosphate dehydrogenase 
 
P04406 231 R.LVTRAAFNSGK.V 17-27 48 
12 myeloid cell nuclear differentiation antigen 
 
P41218 162 K.LTSEARGRIPVAQK.R 122-135 55 
13 cathepsin G, chain A P15169 84 R.NRNVNPVALPR.A 99-110 44 
    R.RNRNVNPVALPR.A 100-110 42 
 
 
  R.RGTDTLREVQLR.V 134-145 46 
 
13 complement factor H 
 
P08603 39 R.LSSRSHTLR.T 1207-1215 
 
28 
13 fibrinogen, alpha chain P02671 450 R.GDFSSANNRDNTYNR.V 115-129 64 
 
 
  K.QFTSSTSYNRGDSTFESK.S 582-599 43 
 
13 immunoglobulin lambda locus 
 
Q6PJF2 221 K.DNRPSGIPDR.F 70-79 36 
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13 inter-alpha-trypsin inhibitor heavy chain H2 
 
P19823 57 K.TVGRALYAQAR.A 136-146 40 
14 cyclophilin A  
 
P62937 88 K.TAENFRALSTGEK.G 32-44 54 
14 fibrinogen, alpha chain P02671 220 R.GDFSSANNRDNTYNR.V 115-129 59 
 
 
  K.ESSSHHPGIAEFPSRGK.S 559-575 34 
 
14 glia maturation factor gamma O60234 94 K.NRLVQTAELTK.V 109-119 34 
 
14 Rho GDP dissociation inhibitor 2 
 
P52566 84 K.VNRDIVSGLK.Y 118-124 28 
14 serum amyloid A4 
 
P35542 107 R.YLYARGNYDAAQR.G 53-65 63 
15 cathepsin G, chain A P15169 36 R.RNRNVNPVALPR.A 100-110 28 
 
 
  R.RGTDTLREVQLR.V 134-145 31 
 
15 cyclophilin A  
 
P62937 126 K.TAENFRALSTGEK.G 32-44 79 
15 fibrinogen, alpha chain P02671 433 R.GDFSSANNRDNTYNR.V 115-129 81 
    R.DNTYNRVSEDLR.S 124-135 41 
 
 
  R.GDFSSANNRDNTYNRVSEDLR.S 115-135 54 
 
15 glia maturation factor gamma 
 
O60234 112 K.NRLVQTAELTK.V 109-119 50 
15 histone H2A.J 
 
Q9BTM1 128 R.HLQLAIRNDEELNK.L 83-96 24 
15 histone H3.3 
 
P84243 83 R.YRPGTVALREIR.R 42-53 37 
15 inter-alpha-trypsin inhibitor heavy chain H2 
 
P19823 93 K.TVGRALYAQAR.A 136-146 29 
15 serum Amyloid A4 
 
P35542 71 R.YLYARGNYDAAQR.G 53-65 43 
16 galectin-2 
 
 153 R.VRGEVAPDAK.S 20-29 39 
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16 fibrinogen, alpha chain P02671 639 R.GDFSSANNRDNTYNR.V 115-129 60 
 
 
  R.GDFSSANNRDNTYNRVSEDLR.S 115-135 51 
 
16 fibrinogen, beta chain 
  
P02675 216 K.REEAPSLRPAPPISGGGYR.A 45-64 63 
16 histone H2A.J 
 
Q9BTM1 236 R.SSRAGLQFPVGR.V 18-30 52 
16 profilin I 
 
P07737 506 R.DSLLQDGEFSMDLRTK.S 75-90 61 
17 cathepsin G, chain A 
 
P15169 69 R.RGTDTLREVQLR.V 134-145 42 
17 fibrinogen, alpha chain 
 
P02671 594 R.DNTYNRVSEDLR.S 123-135 66 
17 histone H2A.J Q9BTM1 429 K.TRSSRAGLQFPVGR.V 17-30 69 
 
17 histone H2B type 2-E 
 
Q16778 
 
328 
 
R.IAGEASRLAHTNK.R 
 
74-86 
 
46 
    R.HLQLAIRNDEELNK.L 83-96 85 
    K.RSTITSREIQTAVR.L 87-100 64 
    R.STITSREIQTAVR.L 88-100 70 
       
17 histone H3.3 
 
P84243 101 K.KPHRYRPGTVALREIR.R 
 
38-53 49 
17 proteoglycan 4 
 
Q92954 148 R.AITTRSGQTLSK.V 1387-1398 65 
17 serum amyloid A4 
 
P35542 147 R.YLYARGNYDAAQR.G 53-65 65 
18 proteoglycan 4 
 
Q92954 57 R.AITTRSGQTLSK.V 1387-1398 57 
 
a  
The Mascot Score represents the total of all ion scores from the peptides matching the protein. 
b  
The Ion Score represents how well a measured mass spectrum 
corresponds to the theoretical mass spectrum of that specific peptide. The higher the score, the better the match. Only peptides with an ion score above 20 are listed. 
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SFP38       
 
Gel slice 
number 
 
 
Protein 
 
UniProtKB 
 
Mascot  
Score
a
 
 
Citrullinated peptide 
 
Amino acid  
position 
 
Ion 
Score
b
 
 
 
3 
 
keratin, type II cytoskeletal 1 
 
 
P04264 
 
821 
 
K.SISISVARGGGR.G 
 
75-86 
 
43 
3 fibrinogen, alpha chain P02671 902 K.ESSSHHPGIAEFPSRGK.S 559-575 28 
    K.QFTSSTSYNRGDSTFESK.S 582-600 47 
 
3 inter-alpha-trypsin inhibitor heavy chain H4 
 
Q14624 731 
 
R.DQFNLIVFSTEATQWRPSLVPASAENVNK.
Q 
615-638 98 
3 myosin 9 
 
P35579 1525 R.AGVLAHLEEERDLK.I 765-778 36 
4 fibrinogen, alpha chain 
 
P02671 647 R.MELERPGGNEITRGGSTSYGTGSETESPR.N 259-287 57 
4 fibronectin P02751 1937 R.RPGGEPSPEGTTGQSYNQYSQRYHQR.T 2335-2360 56 
 
4 inter-alpha-trypsin inhibitor heavy chain H4 
 
Q14624 657 
 
 
R.DQFNLIVFSTEATQWRPSLVPASAENVNK.
Q 
615-638 96 
5 fibrinogen, alpha chain P02671 839 R.MELERPGGNEITRGGSTSYGTGSETESPR.N 259-287 44 
 
 
  K.QFTSSTSYNRGDSTFESK.S 582-600 56 
 
5 keratin, type I cytoskeletal 9 
 
P35527 518 K.TLNDMRQEYEQLIAK.N 322-336 25 
6 fibrinogen, alpha chain 
 
P02671 653 R.MELERPGGNEITRGGSTSYGTGSETESPR.N 259-287 67 
7 antithrombin, chain A P01008 245 K.ATEDEGSEQKIPEATNRR.V 30-47 40 
 
 
  K.SKLPGIVAEGRDDLYVSDAFHK.A 350-370 29 
 
7 coronin 
 
P31146 161 L.RVNRGLDTGR.R 406-414 49 
7 myeloperoxidase 
 
P05164 564 R.AVSNEIVRFPTDQLTPDQER.S 229-248 50 
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7 vimentin P08670 629 K.LQEEMLQREEAENTLQSFR.Q 189-207 28 
 
 
  K.TVETRDGQVINETSQMMDDLE.- 445-466 43 
 
8 gelsolin 
 
P06396 418 R.VPEARPNSMVVEHPEFLK.A 44-61 28 
8 fibrinogen, alpha chain P02671 920 R.GDFSSANNRDNTYNR.V 115-129 28 
    R.MELERPGGNEITR.G 259-271 41 
 
 
  R.MELERPGGNEITRGGSTSYGTGSETESPR.N 259-287 72 
 
8 vimentin 
 
P08670 865 K.TVETRDGQVINETSQMMDDLE.- 445-466 24 
9 fibrinogen, alpha chain P02671 939 R.MELERPGGNEITRGGSTSYGTGSETESPR.N 259-287 87 
 
 
  K.QFTSSTSYNRGDSTFESK.S 581-599 27 
 
9 inter-alpha-trypsin  inhibitor heavy chain H4 
 
Q14624 288 R.QGPVNLLSDPEQGVEVTGQYEREK.A 738-761 97 
9 vimentin P08670 918 R.DVRQQYESVAAK.N 271-282 49 
 
 
  K.FADLSEAANRNNDALR.Q 295-310 46 
 
10 apolipoprotein E P02649 418 R.EGAERGLSAIR.E 186-198 29 
 
 
  R.ERLGPLVEQGR.V 197-207 35 
 
10 complement C4-A 
 
P0C0L4 257 R.ALERGLQDEDGYR.M 1601-1613 70 
10 fibrinogen, alpha chain P02671 928 R.GDFSSANNRDNTYNR.V 115-129 54 
 
 
  R.MELERPGGNEITRGGSTSYGTGSETESPR.N 259-287 74 
 
12 myeloid cell nuclear differentiation antigen  
 
P41218 267 R.RNVPQNDPVTVVVLK.A 204-218 47 
13 fibrinogen, alpha chain P02671 1071 R.GDFSSANNRDNTYNR.V 115-129 74 
    R.GDFSSANNRDNTYNRVSEDLR.S 115-135 41 
 
 
  R.DNTYNRVSEDLR.S 124-135 55 
 
16 ADP-Ribosylation factor 1  P84077 351 R.MLAEDELRDAVLLVFANK.Q 109-126 36 
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16 beta actin 
 
P60709 248 K.RGILTLK.Y 63-68 32 
16 cyclophilin A  
 
P62937 311 K.TAENFRALSTGEK.G 32-44 40 
16 fibrinogen, alpha chain 
 
P02671 476 R.GDFSSANNRDNTYNR.V 115-129 50 
16 histone H1.3 
 
P16402 150 K.ERSGVSLAALK.K 54-64 39 
16 myeloid cell nuclear differentiation antigen  
 
P41218 170 K.INQEEVGLAAPAPTARNK.L 104-121 66 
17 40S ribosomal protein S16  
 
P62249 153 K.VNGRPLEMIEPR.T 34-45 27 
17 beta actin  
 
P60709 290 K.RGILTLK.Y 63-68 39 
17 fibrinogen, alpha chain 
 
P02671 272 K.ESSSHHPGIAEFPSRGK.S 559-575 28 
17 histone H1.3 P16402 175 K.ERSGVSLAALK.K 54-64 34 
 
 
  K.ERSGVSLAALKK.A 54-65 21 
 
18 fibrinogen, alpha chain P02671 428 R.GDFSSANNRDNTYNR.V 115-129 28 
    R.DNTYNRVSEDLR.S 124-135 46 
 
a 
The Mascot Score represents the total of all ion scores from the peptides matching the protein. 
b 
The Ion Score represents how well a measured mass spectrum corresponds 
to the theoretical mass spectrum of that specific peptide. The higher the score, the better the match. Only peptides with an ion score above 20 are listed.  
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Citrullinated ApoE, MNDA, and 
beta-actin in multiple RA SF 
samples 
Because only two RA SF samples 
were used to identify 
citrullinated proteins, we next 
studied ApoE, MNDA and beta-
actin in multiple RA samples by 
western blotting with specific 
antibodies. The results showed 
that ApoE, MNDA and beta-
actin were readily detected in 
SF samples of virtually all 
patients (Figure 4). To elucidate 
the citrullination state of these 
proteins, they were 
immunoprecipitated using 
antibodies to each of these 
proteins, followed by western 
blotting with the AMC antibody 
(after chemical modification of 
the citrulline residues on the 
blot). Citrullinated ApoE and 
MNDA were observed in four 
and three out of ten SFs 
samples, respectively (Figure 
4D, E). Control western blots 
demonstrated that ApoE and 
MNDA were precipitated from 
each of the samples used. In 
contrast, the anti-beta-actin 
antibody failed to precipitate 
the protein, which means that 
no conclusions can be drawn for 
the prevalence of citrullinated 
beta-actin in patient SFs.  
 
  
Figure 3. Citrullinated residues in ApoE, MNDA beta-actin 
and cyclophilin A in RA SF. The coverage of the sequences of 
ApoE (A) MNDA (B), beta-actin (C) and cyclophilin A (D) for 
both RA SF samples (SFS9 and SFP38) is indicated by grey 
shading. The citrullinated residues are marked with a black 
boxed R.  
 
A 
B 
C 
D 
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Table 4. Number of citrullinated residues and sequence coverage of citrullinated proteins 
Citrullinated 
protein
a
 
 
SFS9 SFP38 No.   
cit. 
residues 
Sequence coverage (%) 
 
SFS9         SFP38        
No. cit. residues in 
both samples 
 
fibronectin 
 
+ 
 
+ 
 
  5 
 
55  
 
30 
 
3 
alpha-fibrinogen + + 11 49 50 6 
beta-fibrinogen + -
 b
   1 56 47 N/A 
vimentin -
 b
 +   4 46 58 N/A 
ApoE + +   4 76 68 1 
MNDA + +   4 28 41 1 
beta-actin + + 11 57 57 0 
cyclophilin A + +   1 36 43 1 
 
a 
Only previously identified citrullinated proteins in RA SF and citrullinated proteins detected in both patient 
samples are listed. 
b 
Present in SF sample, but no citrullinated residues detected. N/A = not applicable 
 
 
 
 
 
 
 
 
 
 
Figure 4. (Citrullinated) ApoE, MNDA and beta-actin can be detected in multiple SFs of RA patients. 
The presence of ApoE (A), MNDA (B) and beta-actin (C) in RA SF samples was analysed by western 
blotting using specific antibodies to each of these proteins. To analyse their citrullination state, ApoE (D) 
and MNDA (E) were immunoprecipitated from 10 RA SF samples and subjected to western blotting 
analysis with AMC antibodies. As a positive control (+) citrullinated soybean trypsin inhibitor was 
analyzed in parallel. 
 
A 
B 
C 
D 
E 
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Autoreactivity of citrullinated ApoE, MNDA and beta-actin  
Twelve peptide sets, each comprising a citrulline-containing and the corresponding 
arginine-containing peptide, were synthesized based upon the identified citrullination 
sites in ApoE (two peptide sets), MNDA (three peptide sets) and beta-actin (seven 
peptide sets). Some of these peptides contained more than one citrullinated residue 
and all peptides contained a C-terminal biotin group. The reactivity of RA sera with 
these peptides was assessed by ELISA.  
 
First, the reactivity of established RA sera with these peptides was analyzed and the 
results showed that a subset of these peptides was recognized in a citrulline-
dependent manner by a variable number of RA sera (Figure 5).  
The most frequently recognized peptides, one each for ApoE, MNDA and beta-actin 
(the citrullinated peptide of ApoE197-207, MNDA121-135, beta-actin190-216) were 
selected for further studies. Using a larger number of patient sera the citrulline-
dependent reactivity of RA sera with these peptides was confirmed (Figure 6 A-C).  
When cut-off values were determined with sera from healthy individuals, 27%, 16% 
and 27% of the RA sera analyzed were found to be reactive with the citrullinated 
peptide from ApoE197-207, MNDA121-135 and beta-actin190-216, respectively.  
 
 
Figure 5. Autoantibody reactivity to citrullinated peptides derived from ApoE, MNDA and beta-actin in 
RA sera.  All peptide sets derived from ApoE (A: ApoE177-196; B: ApoE197-207), MNDA (C: MNDA113-
125; D: MNDA121-135; E: MNDA198-210) and beta-actin (F: beta-actin22-45; G: beta-actin57-68; H: 
beta-actin85-100; I: beta-actin178-191; J:  beta-actin190-216; K: beta-actin307-317; L: beta-actin366-
375) containing citrullinated epitopes identified in RA SF with tandem MS/MS were used to detect a 
citrulline-dependent autoimmune response in RA patients. R = control (arginine-containing) peptide, X = 
citrullinated peptide 
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To shed more light on the specificity of the autoreactivity with these peptides sera 
from other autoimmune diseases, multiple sclerosis (MS; n=32), primary Sjőgren’s 
syndrome (pSS; n=31), systemic lupus erythematosus (SLE; n=31) and type 1 diabetes 
(T1D; n=32), were analyzed (Figure 6D-F).  
 
 
Figure 6. Recognition of 
citrullinated ApoE, 
MNDA and beta-actin 
epitopes by RA sera.  
The presence of 
autoantibodies against 
different citrullinated 
epitopes of ApoE (A), 
MNDA (B) and beta-actin 
(C) in RA sera and sera 
from healthy individuals 
was determined by ELISA 
using synthetic peptides 
as antigen. In (A) – (C) 
both the citrullinated (X) 
and arginine-containing 
(R) peptides were used. 
Only data for the most 
frequently recognized 
peptides are shown. 
These peptides were 
also used to determine 
the disease-specificity of 
the antibodies 
recognizing them, the 
results of which are 
shown in (D) for ApoE, 
(E) for MNDA, and (F) for 
beta-actin. The ELISAs 
were performed with 
additional RA sera (n = 
32) and sera from 
primary Sjögren’s 
syndrome (pSS), multiple 
sclerosis (MS), systemic 
lupus erythematosus 
(SLE) and type 1 diabetes 
(T1D) patients (32 sera 
each). The broken lines 
indicate the cutoff 
values; * = P < 0.05; ** = 
P < 0.01; *** = P < 0.001; 
OD450 = optical density 
at 450 nm.  
 
F 
E 
D 
B A 
C 
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The results showed that 4% of the control sera (sera from other autoimmune diseases; 
n=126) showed reactivity towards the citrullinated peptide of ApoE197-207 (Figure 
6D), 3% towards the citrullinated peptide of MNDA121-135 (Figure 6E) and 2% towards 
the citrullinated peptide of beta-actin190-216 (Figure 6F) leading to a specificity of 
96%, 97% and 98%, respectively. 
 
DISCUSSION   
 
In the present study a proteomic analysis of albumin-depleted synovial fluid samples 
taken from the inflamed joints of two RA patients led to the identification of 192 
proteins.  
Since such SF samples are known to contain insoluble material, the soluble fraction of 
one patient and the insoluble fraction of the other were analyzed to obtain a wide 
coverage of the synovial proteome. 
Of these 192 proteins, 107 proteins (56%) were detected in material from both 
patients, in spite of the difference in solubility.   
The molecular weight of the majority of the polypeptides identified, as detected with 
SDS-PAGE, was often lower than the predicted value based upon the calculated mass 
of the corresponding full-length polypeptide. Moreover, several polypeptides were 
identified in multiple gel slices with distinct molecular weights.  
An example is the fibrinogen alpha-chain, which has a calculated mass of 69.8 kDa, but 
was detected in material from the gel corresponding to molecular weights of 
approximately 70,000 to smaller than 14,000. This heterogeneity is most likely caused 
by proteolytic fragmentation. Indeed, previously it has been demonstrated that the 
activity of several proteases is increased in the RA synovium 50;125. 
In a previous study, in which the proteome of six RA SFs was analyzed 126, 24 distinct 
proteins were identified, 15 of which were also detected in the present study.  
These data indicate that as a result of the heterogeneity of the composition of SF 
among distinct patients, the currently available data do not yet represent a 
comprehensive catalogue of proteins that can be found in the SF of RA patients. 
The 192 proteins identified in the present study can be subdivided into 14 groups 
according to their annotated functions (immune response, glycolysis, signal 
transduction, lipid metabolism, blood coagulation, cell mobility/structure/integrity, cell 
death, protein folding, protein synthesis, vesicle formation/protein transport, 
molecular transport, protease inhibition, cell adhesion and other functions).  
Immune response-related processes, e.g. T-cell activation 57, the formation of immune 
complexes  and complement activation 127;128 have been well documented in the RA SF. 
Also apolipoproteins, which are involved in lipid binding and transport, have been 
previously detected in RA SF 129;130.  
It has been shown that the concentration of certain apolipoproteins (ApoA1 and ApoB) 
is increased in RA SF suggesting a role in the inflamed synovium 129. Here, we have also 
identified 14 proteins that are involved in the coagulation cascade.  
One of these is fibrinogen, a protein previously found in the RA synovium 
131
 can be 
converted into fibrin which accumulates in fibrin deposits, a pathological hallmark for 
RA.  
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This association with the coagulation cascade is important, because it has been 
suggested that proteins of the coagulation cascade have proinflammatory properties 
and in this way contribute to the pathogenesis of RA 
132
. 
Coagulation may also be the cause of the relatively high overlap of proteins identified 
in the soluble and insoluble SF fractions; proteins may be trapped in fibrin deposits. 
Furthermore, many of the proteins identified in RA SF represent proteins that are 
known to reside is serum or plasma as well. This is in agreement with previous studies, 
in which a large overlap among the proteomes of synovial fluid and  plasma of RA 
patients was observed 126. 
Fifty-three of the identified polypeptides appeared to be citrullinated on at least one 
position; 105 distinct citrullinated peptides were found. Also here we should note that 
this set will not represent a comprehensive collection of citrullinated polypeptides in 
the RA SF, not only because the mass spectrometry data only partially cover the 
polypeptide sequences (Table 4), but also because of the heterogeneity of 
citrullination patterns observed for different RA patients by western blotting (Figure 1).  
The citrullination of several proteins, fibrinogen 
133
, fibronectin 
50;134
, vimentin 
42;135
, 
albumin and beta-actin 51, in the inflamed joints of RA patients confirms previous 
observations, although citrullinated alpha-fibrinogen and beta-actin so far had not 
been detected in RA SF, but only in synovial tissue. Citrullinated histones have only 
been detected in HL60-cells 63;136.  
In conclusion, our data revealed a total of 53 citrullinated proteins, of which 6 
citrullinated proteins (alpha-fibrinogen, fibronectin, ApoE, MNDA, beta-actin and CypA) 
were detected in both RA SF samples analyzed. Three of the newly identified 
citrullinated proteins (ApoE, MNDA and beta-actin) were not only found in both 
patients that were analyzed in detail, but also frequently occur in SF from other RA 
patients. In view of the heterogeneity of the citrullination (described above) it is likely 
that also citrullinated proteins, which are detected in only one of the two analyzed 
samples, are more frequently present in SF from other patients. A few other 
citrullinated polypeptides previously reported to be present in the inflamed joints of 
RA patients, such as alpha-enolase 137, gamma-fibrinogen 51 and collagen (type I and II) 
53;62 were not detected in the present study. Alpha-enolase and gamma-fibrinogen, 
however, were detected in both RA SFs analyzed (Table 1) and it should be taken into 
account that the mass spectrometry data only covers part of this protein. Therefore, 
the possibility exists that citrullinated residues may have escaped detection, for 
example as a result of relatively low citrullination efficiency or as a result of relatively 
poor ionization of the corresponding peptides.  
An indication that ApoE might play a role in RA came from a recent study in which 
ApoE deficiency was shown to lead to exacerbated collagen-induced arthritis (CIA) in 
mice 138. It is tempting to speculate that the inflammation-associated citrullination of 
ApoE results in similar effects. A role for ApoE in the pathophysiology of arthritis is 
further supported by observations of Asquith and coworkers, who found that ApoE 
deficient mice are resistant to CIA development 139. However, the exacerbation of CIA 
in one study and the resistance to CIA in another are clearly contradictory.  
Although the reason for these discrepancies is not clear yet, they may be related to the 
use of different CIA models; both the mouse strains used and the source of the 
collagen that was used to induce arthritis were different.  
Citrullination: How subtle molecular changes affect loss of self-tolerance in rheumatoid arthritis 
71 
Chapter 3. The RA synovial fluid citrullinome reveals novel citrullinated epitopes 
 
Previously, Matsuo and colleagues identified citrullinated mutant beta-actin in RA 
synovial tissue. Mutant beta-actin differs from wild-type beta-actin at two amino acid 
positions (beta-actin
139VM and beta-actin
295AD) 
51
. Recently, Darrah and co-workers 
have identified beta-actin as a target of PAD2 in ionomycin-activated neutrophils 140. 
They mapped 6 residues (amino acid positions 176, 183, 196, 206, 312 and 372) that 
can be citrullinated, five of which (183, 196, 206, 312 and 372) were indeed found to 
be citrullinated in RA SF in our study.  
MNDA is expressed in the nuclei of granulocytes and monocytes. MNDA is a member 
of the p200 or HIN-200 protein family, which can be induced by interferon (IFN). IFNs 
play a central role in both the innate and adaptive immune responses 
141
.  
Other p200 family members have been implicated in other autoimmune diseases, 
systemic lupus erythematosus and systemic sclerosis 
142
. Finally, it has been reported 
that MNDA binds to nucleophosmin/B23, which also has been identified as a 
citrullinated protein 
63
.  
A fourth novel citrullinated protein detected in RA SF is CypA, of which only one 
citrullinated peptide has been identified in both patients analyzed. This is not the result 
of low sequence coverage, because the coverage was 36% and 43%, for SFS9 and 
SFP38, respectively (Table 4). CypA is part of the enzyme family of peptidyl-prolyl cis-
trans isomerases, which are involved in protein folding. It has been described 
previously by Yang and coworkers that CypA can upregulate metalloproteinase 9, 
which contributes to cartilage and bone destruction in RA patients 143. In agreement 
with our data, CypA has already been described to be present in RA SF. Moreover, it 
has been suggested previously that CypA acts as a cytokine in inflammation 144.  
This is the first study (the second in case of beta-actin) in which citrullinated ApoE, 
MNDA and beta-actin are found to be targets of the immune system in RA.  
For each of these proteins we found immunodominant citrullinated epitopes, and 
peptides containing these epitopes (ApoE197-207, MNDA121-135 and beta-actin190-
216) were recognized by 27% (ApoE197-207), 16% (MNDA121-135) and 27% (beta-
actin190-216) of established RA patients, respectively. Although these frequencies are 
relatively low, these molecules may be valuable ACPA targets for the development of 
(multiplexed) assays to study ACPA fine-specificities 145;146. We have applied Linear 
Discriminant Analysis (LDA) to see if combinations of these peptides are better 
predictors of RA than the individual peptides alone (Table 4). LDA analysis showed that 
a combination of all three citrullinated peptides showed the highest sensitivity (41%) 
and the best diagnostic performance for the identification of RA (area under the 
receiver operator characteristics (ROC) curve 0.83). It remains to be established 
whether ACPA subspecificities targeting one or more of these epitopes are associated 
with clinical phenotypes.  
It is also important to note that the reactivity observed with the synthetic citrullinated 
peptides may not fully reflect the reactivity with the corresponding citrullinated 
antigens. 
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Table 4. Linear discrimination analysis of autoantibodies to citrullinated ApoE, citrullinated MNDA and 
citrullinated beta-actin 
 
Autoantibodies to citrullinated Sensitivity 
(%) 
Specificity 
(%) 
area under ROC curve 
 
ApoE197-207  
MNDA121-135  
beta-actin190-216 
 
41 
 
93 
 
0.83 
ApoE197-207  
MNDA121-135 
38 95 0.82 
ApoE197-207  
beta-actin190-216 
31 94 0.79 
MNDA121-135  
beta-actin190-216 
31 91 0.72 
 
 
Conformational aspects and inaccessibility in the complete proteins may reduce the 
importance of the epitopes identified.  
In addition, the selection of a single epitope, even when this is the most frequently 
targeted epitope, may allow the detection of only a subset of the antibodies directed 
to the corresponding citrullinated antigen. As a consequence, the frequencies of 
autoantibodies to ApoE, MNDA and beta-actin may be higher than those mentioned 
above and this may also explain the higher frequency of anti-citrullinated beta-actin 
antibodies in RA reported by Darrah and coworkers 140. The recognition of the antigens 
in the inflamed joints might be further affected by the fragmentation of the antigens 
(discussed above), which may also lead to the generation of neo-epitopes. The 
presence of citrullinated proteins and ACPA in the synovial fluid of ACPA-positive 
patients will lead to the formation of immune-complexes. Previously, immune-
complexes in the RA SF have been described for vimentin 42. These immune-complexes 
may play an important role in the pathophysiology, because they can activate immune 
cells to produce cytokines, which are the driving force in the chronicity of RA 56. It 
remains to be established to what extent immune complexes containing citrullinated 
ApoE, MNDA and beta-actin are involved in such processes. 
In conclusion, a total of 192 different proteins were identified in RA SF. Fifty-three of 
the identified polypeptides appeared to be citrullinated on at least one position and 
105 distinct citrullinated peptides were found.  Our data revealed 3 novel citrullinated 
proteins in SF of both patients (ApoE, MNDA, and beta-actin) that could elicit a RA-
specific B-cell response against citrullinated residues present in these proteins. 
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MATERIALS AND METHODS 
 
Patient material 
Synovial fluid samples were obtained by joint punctures (arthrocentesis), using needles with a diameter from 
1.6 to 2.2 mm. A sample was immediately centrifuged at 2,500g for 10 minutes at 4°C. Supernatant and 
pellet were separately stored at -80°C in sterile containers. All procedures were finished in less than two 
hours. The pellet fraction was resuspended in EGTA lysis buffer (50 mM Tris-HCl, pH 7.4, 100 mM KCl, 1 mM 
DTE, 0.1% NP40, 10 mM EGTA, 0.5 mM PMSF and Complete protease inhibitor cocktail (Roche)). Supernatant 
fractions were diluted with 4 volumes of EGTA lysis buffer. After sonification, SDS was added (final 
concentration 2%) and the fractions were heated and centrifuges at 12,000g. Supernatants were used for 
further analysis. All samples were taken from patients for diagnostic and therapeutic reasons. No sample was 
taken for research only and all patients signed an informed consent that the remainder of biological samples 
taken for diagnostic purposes may be used anonymously for research. The study was approved by the local 
Medical Ethics Board of the University Medical Center Ljubljana. 
Sera were collected from rheumatoid arthritis (RA; n=80), systemic lupus erythematosus (SLE; n=31), and 
primary Sjőgren’s syndrome (pSS; n=31) patients at the Department of Rheumatology of the Radboud 
University Nijmegen Medical Centre and at the St. Maartenskliniek Nijmegen (The Netherlands).  
Sera from multiple sclerosis (MS; n=32) patients were collected at the MS Center Nijmegen. Type 1 diabetes 
(T1D; n=32) sera were collected at the Department of Internal Medicine of the Radboud University Nijmegen 
Medical Centre (The Netherlands). Sera from healthy individuals (NS; n= 24) were purchased from the 
Sanquin Bloodbank Nijmegen. Sera were stored at -80°C until use. The need for ethical approval to use these 
sera for autoantibody studies was waived by the local ethics committee; patient consent was obtained. 
 
Western blotting  
Proteins from synovial fluid samples (10 g total protein per sample) were separated by SDS-PAGE and 
transferred to nitrocellulose membranes. The blots were blocked in blocking buffer (5% non-fat dried milk 
and 0.1% NP40 in PBS) for 1 hour at room temperature. Subsequently, the blots were incubated with the 
antibody of interest (anti-MNDA 1:100, sc-6051, Santa Cruz Biotechnology, Santa Cruz, CA, USA; anti-ApoE 
1:500, EP1374Y, Epitomics, Burlingame, California, USA; anti-beta-actin 1:5000, A5441, Sigma, St. Louis, 
Missouri, USA or anti-modified citrulline antibody 1:1000, Upstate) in blocking buffer for 1-3 hours at room 
temperature.  
After washing with blocking buffer proteins were detected with an IRDye 800-labeled secondary antibody 
(Molecular Probes, Rockland Immunochemicals, PA, USA), followed by infrared (LI-COR Odyssey) imaging. 
For the detection of citrullinated proteins, blots were chemically modified overnight, as described previously  
121
 prior to the incubation with the anti-modified citrulline antibody. 
 
Mass spectrometry 
Two SF samples were depleted of albumin as described by Colantonio and coworkers 
124
 separated by SDS-
PAGE and stained with colloidal Coomassie Brilliant Blue. Slices excised from the gel were incubated with 20 
μL trypsin solution (15 ng/μL trypsin in 25 mM NH4HCO3 and 5 mM n-octylpyranoglucoside). Peptides were 
extracted by adding 50% ACN, 0.5% TFA, 5 mM n-octylpyranoglucoside and sonification. Subsequently, the 
resulting peptide mixtures were concentrated and desalted using Stop And Go Elution (STAGE) tips as 
described by Rappsilber and co-workers 
147
.  Sample analysis by LC-MS was performed using a Agilent 
nanoflow 1100 liquid chromatograph coupled via a nano-electrospray ion source (Proxeon) to a 7T linear ion 
trap Fourier transform ion cyclotron resonance mass spectrometer (LTQ FT, Thermo Scientific). Peptide 
separations were performed using a 15 cm fused silica emitter (New Objective, PicoTiptm Emitter, Tip: 8 +/- 
1 µm, ID: 100 µm, FS360-100-8-N-5-C15) packed with reversed phase ReproSil-Pur C18AQ 3 µm resin (Dr 
Maisch) 
148
. Peptides were loaded directly onto the analytical column using 0.5% acetic acid and were 
gradually eluted from the column using flow-rates ranging from 300 to 600 nL/min by increasing the 
acetonitril concentration (from 2.4 to 80%). The mass spectrometer was operated in positive ion mode and 
was programmed to analyze the top 4 most abundant ions from each precursor scan using dynamic 
exclusion.  
Precursor scans by the ICR cell were set to cover a range of 350-2000 m/z at a resolution of R=1E6. RAW LC-
MS/MS data files were converted with the aid of DTAsupercharge (http://msquant.sourceforge.net/) into a 
Mascot generic peak list. Peptides and proteins were identified with the Mascot search program (Version 
2.1.03, Matrix Science Inc., Boston, MA, USA) and the NCBInr database, www.ncbi.nlm.nih.gov) using Homo 
sapiens taxonomy.  
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All relevant MS/MS spectra of peptides identified with the modification citrullination were manually 
inspected for the presence of diagnostic b- or y-ions that confirm the modification of 0.985 Da to be present 
on the arginine residue rather than any other residue in the peptide sequence (such as deamidation of 
asparagines and/or glutamines). Citrullinated peptides identified with MS/MS spectra lacking such diagnostic 
ions were excluded from further analysis. Mass deviations for precursor ions were set to 20 ppm, deviations 
for mass of fragment ions were set at 0.8 Da and the maximal number of missed cleavage sites was set at 
two. 
 
Immunoprecipitation 
Mouse monoclonal anti-ApoE antibody, goat polyclonal anti-MNDA antibody and mouse monoclonal anti-
beta-actin were either coupled to Protein A-agarose beads (KEM-En-TEC, Taastrup, Denmark) or to Protein 
G-agarose beads (Thermo Scientific, Waltham, Massachusetts, USA). Antibodies coupled to beads in IPP500 
(500 mM NaCl, 10 mM Tris-HCl, pH 8.0, 0.1% Tween-20 and 0.1% NP40) during 1 hour incubation at room 
temperature. Beads were washed once with IPP500 and twice with IPP150 (150 mM NaCl, 10 mM Tris-HCl, 
pH8.0, 0.1% Tween-20 and 0.1% NP40). Subsequently, beads were incubated with SF, 5-fold diluted in 
IPP150, for 2 hours at 4°C.  
Finally, beads were washed 3 times with IPP150, after which immunoprecipitated proteins were solubilized 
in sample buffer, after which the complete samples were loaded on a SDS-PAGE gel for western blotting 
analyses.  
 
Enzyme-linked immunosorbent assay  
Based upon the identified citrullination sites of ApoE, MNDA and beta-actin citrullinated peptides were 
synthesized (Genscript USA Inc.., Piscataway, New Jersey, USA and Leiden University Medical Centre, Leiden, 
The Netherlands). The peptides (not HPLC purified) were at least 85% pure as deduced from their elution 
pattern in reversed phase HPLC. The following peptides, each in a citrullinated (Cit) and a non-citrullinated 
form, and each with a C-terminal biotin group, were used in these experiments. Peptides from ApoE: 
ApoE177-196, LAVYQAGACitEGAECitGLSAIR and ApoE197-207, ECitLGPLVEQGR; peptides from MNDA: 
MNDA113-125, APAPTACitNKLTSE, MNDA121-135, KLTSEACitGCitIPVAQK and MNDA198-210, 
RQVDARCitNVPQND; and peptides from beta-actin: beta-actin22-45, AGDDAPCitAVFPSIVGCitPCitHQGVMV, 
beta-actin57-68, EAQSKCitGILTLK, beta-actin85-100, IWHHTFYNELCitVAPEE, beta-actin178-191, 
LDLAGCitDLTDYLMK, beta-actin190-216, MKILTECitGYSFTTTAECitEIVCitDIKEKL, beta-actin307-317, 
PGIADDCitMQKEI and beta-actin366-375: GPSIVHCitKCF. 
Enzyme-linked immunosorbent assays (ELISA) were performed as described previously. Each well of a 
multititer plate (Streptawell, Roche) or Costar DNA-BIND 2505, Corning Inc, New York, USA) was coated by 
incubation with 10 μg/ml biotinylated peptide in PBS/0.1% BSA (Streptawell) or PBS500 (PBS containing 500 
mM NaCl; Costar DNA-BIND) overnight at 4°C. Prior to sample incubation, wells of the Costar DNA-BIND 
plates were blocked with 2% BSA in PBS500 (no additional blocking step was incorporated for the Streptawell 
plates, because BSA was present during coating of the peptides).  
After washing three times with wash buffer (PBS, 0.1% Tween-20 or 0.05% Tween-20 for Streptawell or DNA-
BIND plates, respectively) wells were incubated with patient serum samples diluted 100-fold  in PBS, 0.05% 
Tween-20 containing 1% BSA (Streptawell) or in RIA+ buffer (350 mM NaCl, 10 mM Tris-HCl, pH 7.6, 0.01% 
Triton X-100, 0.005% DOC, 0.1% SDS) containing 5% normal sheep serum (Costar DNA-BIND) for 1 hour at 
37°C. After incubation, plates were washed 3 times with wash buffer, followed by incubation at 37 °C with 
HRP-conjugated goat anti-human IgG, IgM, IgA, kappa, lambda (DAKO, Glostrup, Denmark) in PBS, 0.05% 
Tween-20 containing 1% BSA (Streptawell) or in RIA+ buffer containing 5% normal sheep serum (Costar DNA-
BIND). Bound antibodies were detected by the conversion of 3,3’,5,5’-tetramethylbenzidine (TMB). The 
reaction was stopped with 2M H2SO4 and absorbance was measured at 450 nm. 
Cutoff values were determined based upon the values obtained with healthy control sera as described 
previously 
149
. 
 
Statistical analysis 
Statistical analyses were performed using the two-tailed unpaired t-test and P values less than 0.05 were 
considered statistically significant. Linear Discriminant Analysis (LDA) was performed using the DTREG 
software, version 10.6.0 (www.dtreg.com). 
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LIST OF ABBREVIATIONS  
 
ACPA, anti-citrullinated protein antibodies; AMC, anti-modified citrulline; ApoE, apolipoprotein E; CIA, 
collagen-induced arthritis;  CypA, cyclophilin A; ELISA, Enzyme-linked immunosorbent assay; IFN, interferon; 
MNDA, myeloid nuclear differentiation antigen;  LC-MS/MS, liquid chromatography - tandem mass 
spectrometry; MS, multiple sclerosis; NS, normal sera; PAD, peptidylarginine deiminase; pSS, primary 
Sjogren's syndrome; RA, rheumatoid arthritis; SF, synovial fluid; SLE, systemic lupus erythematosus; TB, 
tuberculosis; T1D, type 1 diabetes 
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INTRODUCTION 
 
Rheumatoid arthritis (RA) is a common autoimmune disease, in which several 
autoantigens have been identified, including fibrinogen 
30;51;54
. Fibrinogen consists of 
two copies of each of its three polypeptide chains α, β and γ 52. Fibrinogen is involved 
in the clotting cascade, in which it is converted into fibrin, a process mediated by 
thrombin 
150
. Autoantibodies against citrullinated proteins (ACPA) have been shown to 
be specifically associated with RA and are already present prior to disease onset 106. 
Citrullination, the conversion of peptidylarginine into peptidylcitrulline, of  the 
fibrinogen α and β chains generates antigenic targets for autoantibodies present in the 
serum and synovial fluid of RA patients 30;151.  
For the diagnosis of RA, besides the clinical symptoms, tests for detecting 
autoantibodies, such as rheumatoid factor (RF test) or ACPA (which are generally 
detected with the so-called cyclic citrullinated peptide, CCP, test) can be useful 
11
. 
 ABSTRACT - Rheumatoid arthritis (RA) frequently involves the loss of tolerance to 
citrullinated antigens, which may play a role in the pathogenicity. Citrullinated 
fibrinogen is commonly found in inflamed synovial tissue and is a frequent target 
of autoantibodies in RA patients. To obtain insight into the B-cell response to 
citrullinated fibrinogen in RA, its autoepitopes were systematically mapped using 
a new methodology.  
Human fibrinogen was citrullinated in vitro by peptidylarginine deiminases (PAD), 
subjected to proteolysis and the resulting peptides were fractionated by ion 
exchange chromatography. The peptide composition of the citrullinated peptide-
containing fractions was determined by high resolution tandem mass 
spectrometry. The recognition of these fractions by patient sera was 
subsequently analyzed by imaging surface plasmon resonance on microarrays.  
In total about two-third of the 81 arginines of human fibrinogen were found to be 
susceptible to citrullination by the human PAD2, the human PAD4 or the rabbit 
PAD2 enzymes. Citrullination sites were found in all three polypeptide chains of 
fibrinogen, although the α-chain appeared to contain most of them. The analysis 
of 98 anti-CCP-positive RA sera using the new methodology allowed the 
identification of three major citrullinated epitope regions in human fibrinogen, 
two in the α- and one in the β-chain.  
A comprehensive overview of citrullination sites in human fibrinogen was 
generated. The multiplex analysis of peptide fractions derived from a post-
translationally modified protein, characterized by mass spectrometry, with 
patient sera provides a versatile system for mapping modified amino acid-
containing epitopes. The citrullinated epitopes of human fibrinogen most 
efficiently recognized by RA autoantibodies are confined to three regions of its 
polypeptides. 
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Figure 1. Autoepitope mapping of citrullinated 
fibrinogen. Schematic overview of the novel 
method used to characterize the citrullinated 
epitopes on human fibrinogen recognized by RA 
patient autoantibodies. 
 
Autoantibodies to citrullinated human 
fibrinogen may have great value for the 
diagnosis of RA 
152
.  
Van der Cruyssen and colleagues 
compared an anti-citrullinated fibrinogen 
ELISA with the anti-CCP test and detected 
similar diagnostic performance 
153
. The 
role of citrullinated proteins and ACPA in 
the pathophysiology of RA is not fully 
understood, but it has been shown that 
citrullinated fibrinogen can induce 
arthritis in genetically susceptible (DR4-IE 
transgenic) mice 151.  
Recently, Ho and others found that mice 
that were immunized with citrullinated 
fibrinogen developed arthritis and 
fibrinogen-reactive T cells which produce 
the proinflammatory cytokines IL-6, IL-17, 
TNF-α, and IFN-γ and that these mice 
possess rheumatoid factor, circulating 
immune complexes and anti-CCP, all of 
which are characteristics of human RA 
55
. 
In vitro studies by Clavel and co-workers 
showed that immune-complexes 
consisting of ACPA and citrullinated 
fibrinogen can induce macrophage 
secretion of TNF-α, which is an important 
mediator of inflammation 44.  In humans, 
an association was detected between the 
occurrence of the RA susceptible HLA-
DR1 allele and the presence of anti-
citrullinated fibrinogen antibodies 154. 
Finally, circulating immune complexes 
containing citrullinated fibrinogen were 
found in a large subset of ACPA-positive 
RA patients 133. These findings suggest a 
crucial role for fibrinogen in RA 
pathogenesis. Several studies have 
addressed the position of citrullinated 
autoepitopes in human fibrinogen 
52;151;152;155;156. Most of these studies were performed with synthetic citrullinated 
fibrinogen peptides in combination with ELISA detection. Here, we describe a novel 
method to map the epitopes of post-translationally modified proteins and apply this 
method, which is schematically illustrated in Figure 1, to map the autoepitopes of 
citrullinated fibrinogen recognized by RA sera.  
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RESULTS 
 
Identification of citrullination sites in human fibrinogen 
To generate a map of the citrullinated autoantigenic epitopes on human fibrinogen, 
the protein was first citrullinated in vitro using recombinant hPAD2 and hPAD4, as well 
as rabbit muscle PAD (rmPAD2). To check the resulting citrullination of the protein, the 
reaction products were analyzed by SDS-PAGE and Coomassie brilliant blue staining.  
 
Bands corresponding to the α-, β- and γ-chains of fibrinogen were detected and upon 
incubation with PAD the migration of the α-chain and, although to a much lesser 
extent, that of the β-chain were changed (Figure 2A). To confirm that this migration 
shift was due to citrullination, blots containing the same samples were analyzed using 
the anti-modified citrulline antibody procedure (Figure 2B).  
The results showed that all fibrinogen chains were citrullinated by all PADs, although 
citrullination by hPAD4 appeared to be less efficient than that of the other PADs. In 
agreement with its migration shift, the α-chain displayed the highest levels of 
citrullination upon incubation with hPAD2 and rmPAD2. To exclude that the lower 
levels of fibrinogen citrullination by hPAD4 was due to differences in the specific 
activity of the PAD enzymes, the same amount of fibrinogen was incubated with 
increasing amounts of hPAD4 (up to 20 U/mg substrate).  
B A 
C 
B 
C 
Figure 2. In vitro citrullination of human fibrinogen.  (A) Human fibrinogen (lane 1) was citrullinated in 
vitro with the recombinant hPAD2 (lane 2), hPAD4 (lane 3) and rmPAD2 (lane 4). The reaction products 
were analyzed by SDS-PAGE and Coomassie Brilliant Blue staining (A) or by western blotting followed 
by detection of citrullinated proteins by anti-modified citrulline antibodies after modification of 
proteins on the blot (B, C). Panel C represents a longer exposure of the upper region of the blot shown 
in panel B. The positions of the -, - and -chains of fibrinogen are indicated. Lane M contains a 
molecular weight marker and the molecular weights of the marker proteins are indicated on the left. In 
panel B lane C contains deiminated soybean trypsin inhibitor as a positive control for the detection of 
citrullination. 
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However, this did not lead to increased levels of citrullination (data not shown), 
suggesting that hPAD4 is more restrictive in citrullination of fibrinogen than hPAD2 and 
rmPAD2. 
 
To obtain a comprehensive overview of the residues in human fibrinogen that are 
citrullinated by hPAD2 and hPAD4, citrullinated fibrinogen was proteolytically 
digested with three different enzymes (trypsin, chymotrypsin, GluC), to optimize the 
sequence coverage and to eliminate the influence of citrullination on cleavage. All 
digests were analyzed by LC-MS/MS using both CID and ETD fragmentation to obtain as 
much sequence information as possible.  
This allowed the identification of 42 citrullinated residues, 27 of which were found in 
the α-chain, 11 in the β-chain and 4 in the γ-chain of human fibrinogen (Figure 3).  
The total coverage of the mature fibrinogen polypeptide sequences obtained by this 
approach was similar in all experiments, approximately 91% for the α-chain, 86% for 
the β-chain and 89% for the γ-chain. The majority of the citrullination sites were 
identified in fibrinogen treated with hPAD2. In the α-chain, 27 arginines were 
deiminated by hPAD2, 17 of which were also citrullinated by hPAD4.  
No arginines that were specifically deiminated by hPAD4 were detected. In the β-chain, 
6 arginine residues were deiminated by both hPAD2 and hPAD4, 3 only by hPAD2 and 2 
only by hPAD4. Finally, in the γ-chain 4 citrullination sites were identified, 3 for each of 
the two PADs, 2 of which were citrullinated by both enzymes.  
Figure 3. Citrullination sites in human fibrinogen. Human fibrinogen was citrullinated in vitro by 
hPAD2, hPAD4 or rmPAD2 and citrullinated residues were determined by proteolytic digestion followed 
by mass spectrometry. The positions of the citrullination sites are schematically depicted in the three 
polypeptide chains of fibrinogen: hPAD2, filled circles; hPAD4, open circles; rmPAD2, filled triangles.  
The grey boxes at the N-termini of the fibrinogen chains represent signal peptides (for all chains) and 
fibrinopeptides (for the α- and β-chains). Beneath each fibrinogen chain (α, β or γ), previously detected 
citrullination sites have been depicted; hPAD2, filled circles; hPAD4, open circles . Amino acid 
numbering is relative to the start of the signal peptides. 
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A similar analysis of residues of human fibrinogen that are citrullinated by rmPAD2 was 
performed, which allowed the identification of 40 citrullinated residues, 23 in the α-
chain, 13 in the β-chain and 4 in the γ-chain.  
Although the majority of these residues was also deiminated by hPAD2 (17 in the α-
chain, 7 in the β-chain and 2 in the γ-chain), some deiminated residues were 
specifically detected in either the rmPAD2- or hPAD2-treated material (Figure 2), which 
might be related either to PAD specificity or undersampling by the mass spectrometer. 
 
Generation of citrullinated human fibrinogen peptides 
To investigate which of the identified citrullinated residues in human fibrinogen are 
important for the recognition by autoantibodies in RA sera, in vitro citrullinated 
fibrinogen was proteolytically digested and fractionated by ion exchange 
chromatography. To this end, fibrinogen was citrullinated with rmPAD2, because the 
specific activity of this enzyme is higher than that of hPAD2 and, as a consequence, the 
amount of PAD protein needed was lower. Citrullinated fibrinogen was in this case 
digested with either trypsin (T), chymotrypsin (C) or Lys-N (L) to generate different 
pools of citrullinated peptides 157. 
 
Recognition of citrullinated fibrinogen peptide fractions by RA sera 
The (pooled) SCX fractions were immobilized in discrete spots on the surface of iSPR 
sensor discs and the reactivity of 98 anti-CCP-positive and 4 anti-CCP-negative RA sera 
with these fractions was monitored by iSPR measurements, which we previously have 
shown to represent a suitable system to detect autoantibody reactivities against 
multiple targets simultaneously 158;159. Data generated with iSPR can be depicted in a 
sensorgram, in which the resonance angle shift is plotted against time.  
A 
Figure 4. Analysis of 
autoantibody reactivity in 
patient sera by iSPR. (A) 
Sensorgrams showing the 
reactivity of seven sera to 
citrullinated peptides. The 
reactivity of 7 RA sera with 4 
different spots on the array was 
determined by iSPR monitoring. 
These spots contained either 
citrullinated fibrinogen fractions 
(C8, L34 or T24) or a positive 
control peptide (pos). In the 
sensorgrams the angle shifts in 
mill degrees (m) are plotted as 
a function of time. (B) 
Reconstructed image of an iSPR 
sensor chip showing the 
resonance at 24 spots at a 
certain angle and a certain time 
point during scanning of the 
array. 
 
B 
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An example of a sensorgram generated with this material is depicted in Figure 4, which 
illustrates the reactivity of 7 RA sera with 3 fibrinogen peptide fractions (C8, L34 and  
T24) and with a synthetic citrullinated peptide, which was used as a positive control.  
The (resonance) angle shift resulting from the association of serum antibodies to 
peptides on the sensor disc surface was determined for each serum and each spot 
(Figure 4A, inset).  The use of 24 spots per chip (Figure 4B) allowed the simultaneous 
analysis of multiple fractions, strongly reducing the total time required for the 
experiment and increased the throughput of patient sera.  
 
Table 1. Recognition of citrullinated fibrinogen peptide-containing fractions by RA sera   
 
 
a 
Fractions that are recognized by at least 25% of the RA sera with reactivities exceeding a cut-off value of the 
mean plus 8 times the standard deviation of anti-CCP-negative sera.  
b
 Fractions that are recognized by at 
least 25% of the RA sera with reactivities exceeding a cut-off value of the mean plus 2 times the standard 
deviation of anti-CCP-negative sera.   
c 
The remaining fractions that were analysed.  Fractions are named 
after proteases used for digestion; T (trypsin), C (chymotrypsin) or L (Lys-N). 
 
As a total of 29 fractions were analyzed, two chips, together containing all fractions as 
well as positive controls, were analyzed with all sera. 
  
Strongly 
reactive 
fractions
a
  
 
% Reactive 
sera 
 Moderately reactive 
fractions
b
   
% Reactive 
sera 
 Non reactive 
fractions
c
  
T32 75  T31 54  C12 
T27 57  L34 47  C14 
C8 51  C10 44  C22 
T28 51  L33 43  C25 
T26 50  C27 36  C31 
L37 46  L27 36  C34 
L28 39  C29 33  L24 
T29 39  C28 30  L26 
T24 36  C30 25  L29 
      L30 
      L31 
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 The results clearly show that the efficiency by which specific fractions were recognized 
strongly differs between individual sera. For example, serum 1 in Figure 4A is not 
reactive with any of the citrullinated fibrinogen peptides, although it clearly contains 
antibodies recognizing the positive control peptide, whereas serum 4 is clearly reactive 
with at least two of the citrullinated fibrinogen fractions.  
Figure 5. Mapping of major citrullinated fibrinogen epitopes recognized by RA sera. The citrullinated 
peptides present in the most strongly reactive fractions are schematically aligned with the - and -
chains of fibrinogen. Asterisks indicate the citrullinated residues in the peptides. Citrullinated peptides 
(obtained by in vitro citrullination with rmPAD2) that are present in the most reactive fractions of at 
least two of the three proteolytic digests are highlighted in dark grey, whereas the other peptides in 
these fractions are indicated with the light grey boxes. 
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The individual digests were separated using strong action exchange (SCX) 
chromatography followed by mass spectrometry to identify the citrullinated peptides 
present in the different fractions. 
Adjacent fractions with largely overlapping peptide compositions were pooled, giving a 
total of 29 fractions with different sets of citrullinated fibrinogen peptides that were 
selected for iSPR analysis. 
We decided to classify the fibrinogen peptide fractions based upon their reactivity with 
patient sera as defined by angle shifts above a well-defined cutoff value and upon the 
percentage of sera that showed reactivity (see Methods). 
Nine of the 29 fractions were strongly recognized by RA sera, while an additional 9 
fractions showed moderate levels of reactivity with RA sera (Table 1).  
The citrullinated peptides present in the strongly reactive fractions are schematically 
aligned with the fibrinogen α- and β-chains in Figure 5. This shows that the most 
efficiently recognized citrullinated peptides correspond to three regions of human 
fibrinogen. The citrullinated residues present in these regions are 216, 218, 573 and 
591 in the α-chain and 60, 72 and 74 in the β-chain (Figure 5).  
DISCUSSION 
 
In this paper we have applied a novel method to map citrullinated epitopes of human 
fibrinogen that are recognized by RA patient sera. This method is widely applicable, not 
only for epitopes generated by post-translational modifications, but also for epitopes 
consisting of only standard amino acids. Three regions, two in the α- and one in the β-
chain, containing major epitopes for RA-autoantibodies were identified.  
The presence of citrullinated fibrinogen in the inflamed synovium of rheumatoid 
arthritis patients 30 and the detection of RA-associated autoantibodies against 
citrullinated fibrinogen imply that this protein is a genuine autoantigen in RA 
52
 and 
previous studies have already demonstrated that the citrullination of fibrinogen is 
complex, with deiminated arginines on all three chains and at various positions within 
these chains. Our combined data identified 54 arginine residues that can be 
deiminated by hPAD2, hPAD4 or rmPAD2 (Figure 3 and Figure 5).  
Thirty two of these are associated with the α-chain, 17 with the β-chain and 5 with the 
γ-chain. All previously reported citrullination sites were found in our study (Figure 3) 
52;155. In addition, 26 novel citrullination sites were identified, 12 in the α-chain 
(positions 69, 84, 114, 135, 181, 186, 216, 218, 263, 353, 443 and 458), 10 in the β-
chain (positions 47, 224, 246, 285, 376, 410, 421, 436, 445 and 485) and 4 in the γ-
chain (positions 40, 223, 282 and 417). 
In total, 54 of the 81 arginines (66%) in human fibrinogen were found to be susceptible 
to citrullination (Figure 6). When comparing individual PADs, both hPAD2 and rmPAD2 
deiminate 39 residues, whereas 28 residues can be citrullinated by hPAD4. 
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The higher number of residues citrullinated by PAD2 compared to PAD4 is in 
agreement with observations that the amino acid context of the peptidylarginine is 
more important for PAD4 than for PAD2 155. 
The digestion of citrullinated fibrinogen with three distinct proteases to analyze 
autoantibody reactivities with the fractionated peptides implied that a large part of the 
(citrullinated) protein was covered by peptides suitable for both LC-MS/MS analysis 
and immobilization. An important advantage of iSPR is that it can be used to monitor 
the reactivity of patient sera with multiple antigenic molecules simultaneously, which 
is less time-consuming and more accurate than other current methods to screen sera, 
such as ELISA. The iSPR results obtained with the fractionated proteolytic digests of 
fibrinogen revealed that RA sera are reactive with specific regions of citrullinated 
fibrinogen.  
Fibrinogen -chain 
 
  1 MFSMRIVCLV LSVVGTAWTA DSGEGDFLAE GGGVRGPRVV ERHQSACKDS DWPFCSDEDW 
 61 NYKCPSGCRM KGLIDEVNQD FTNRINKLKN SLFEYQKNNK DSHSLTTNIM EILRGDFSSA 
121 NNRDNTYNRV SEDLRSRIEV LKRKVIEKVQ HIQLLQKNVR AQLVDMKRLE VDIDIKIRSC 
181 RGSWSRALAR EVDLKDYEDQ QKQLEQVIAK DLLPSRDRQH LPLIKMKPVP DLVPGNFKSQ 
241 LQKVPPEWKA LTDMPQMRME LERPGGNEIT RGGSTSYGTG SETESPRNPS SAGSWNSGSS 
301 GPGSTGNRNP GSSGTGGTAT WKPGSSGPGS AGSWNSGSSG TGSTGNQNPG SPRPGSTGTW 
361 NPGSSERGSA GHWTSESSVS GSTGQWHSES GSFRPDSPGS GNARPNNPDW GTFEEVSGNV 
421 SPGTRREYHT EKLVTSKGDK ELRTGKEKVT SGSTTTTRRS CSKTVTKTVI GPDGHKEVTK 
481 EVVTSEDGSD CPEAMDLGTL SGIGTLDGFR HRHPDEAAFF DTASTGKTFP GFFSPMLGEF 
541 VSETESRGSE SGIFTNTKES SSHHPGIAEF PSRGKSSSYS KQFTSSTSYN RGDSTFESKS 
601 YKMADEAGSE ADHEGTHSTK RGHAKSRPVR GIHTSPLGKP SLSP 
 
Fibrinogen -chain 
 
  1 MKRMVSWSFH KLKTMKHLLL LLLCVFLVKS QGVNDNEEGF FSARGHRPLD KKREEAPSLR 
 61 PAPPPISGGG YRARPAKAAA TQKKVERKAP DAGGCLHADP DLGVLCPTGC QLQEALLQQE 
121 RPIRNSVDEL NNNVEAVSQT SSSSFQYMYL LKDLWQKRQK QVKDNENVVN EYSSELEKHQ 
181 LYIDETVNSN IPTNLRVLRS ILENLRSKIQ KLESDVSAQM EYCRTPCTVS CNIPVVSGKE 
241 CEEIIRKGGE TSEMYLIQPD SSVKPYRVYC DMNTENGGWT VIQNRQDGSV DFGRKWDPYK 
301 QGFGNVATNT DGKNYCGLPG EYWLGNDKIS QLTRMGPTEL LIEMEDWKGD KVKAHYGGFT 
361 VQNEANKYQI SVNKYRGTAG NALMDGASQL MGENRTMTIH NGMFFSTYDR DNDGWLTSDP 
421 RKQCSKEDGG GWWYNRCHAA NPNGRYYWGG QYTWDMAKHG TDDGVVWMNW KGSWYSMRKM 
481 SMKIRPFFPQ Q 
 
Fibrinogen -chain 
 
  1 MSWSLHPRNL ILYFYALLFL SSTCVAYVAT RDNCCILDER FGSYCPTTCG IADFLSTYQT 
 61 KVDKDLQSLE DILHQVENKT SEVKQLIKAI QLTYNPDESS KPNMIDAATL KSRIMLEEIM 
121 KYEASILTHD SSIRYLQEIY NSNNQKIVNL KEKVAQLEAQ CQEPCKDTVQ IHDITGKDCQ 
181 DIANKGAKQS GLYFIKPLKA NQQFLVYCEI DGSGNGWTVF QKRLDGSVDF KKNWIQYKEG 
241 FGHLSPTGTT EFWLGNEKIH LISTQSAIPY ALRVELEDWN GRTSTADYAM FKVGPEADKY 
301 RLTYAYFAGG DAGDAFDGFD FGDDPSDKFF TSHNGMQFST WDNDNDKFEG NCAEQDGSGW 
361 WMNKCHAGHL NGVYYQGGTY SKASTPNGYD NGIIWATWKT RWYSMKKTTM KIIPFNRLTI 
421 GEGQQHHLGG AKQAGDV 
 
Figure 6. Amino acid sequence of the three human fibrinogen chains. Arginine residues are 
highlighted; arginines that can be citrullinated by either hPAD2, hPAD4 or rmPAD2 are highlighted 
with the black boxes. 
 
 
. 
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These regions are present in the fibrinogen sequence around the citrullinated residues 
at position 216, 218, 573 and 591 of the α-chain and at positions 60, 72 and 74 of the 
β-chain. Previously, several studies have reported the reactivity of RA sera with 
citrullinated epitopes of fibrinogen.  
The data related to the epitopes identified in our study are summarized in Table 2 
52;151;152;155;155;156
. Although some overlap between these data is observed, also clear 
differences are present, which may at least in part be due to the differences in the 
peptides that were used and the procedures that were applied to immobilize these 
peptides. Using synthetic peptides the N-terminal region of the α-chain of human 
fibrinogen (with citrullinated residues at positions 38 and 42) was observed to be 
frequently targeted by RA sera 
151
. Because these residues were not detectably 
citrullinated by rmPAD2, our data do not allow conclusions concerning the recognition 
of this region of fibrinogen by RA sera.  
In contrast, citrullination of the arginine residues at positions 216 and 218 of the α-
chain have not been reported in previous studies, in which fibrinogen was citrullinated 
by hPAD2 or hPAD4 (Figure 3) 
155;156
, which is most likely due to the inclusion of 
rmPAD2 in the present study. The poor recognition of synthetic peptides comprising 
this region of fibrinogen by RA sera in previous studies 52;152 might be explained by 
differences in the presentation of the epitope(s) by (partially) different peptides. 
Currently we are using synthetic citrullinated peptides derived from the data presented 
in Figure 5 to verify the presence of major epitopes targeted by RA autoantibodies at 
these positions in fibrinogen and to investigate their diagnostic and prognostic value in 
more detail.  
The citrullinated epitopes of fibrinogen reactive with RA sera are particularly relevant 
for diagnostic applications, since citrullinated human fibrinogen displays a sensitivity 
and specificity very similar to the widely used anti-CCP test for ACPA detection 153. The 
use of individual citrullinated peptides in a multiplex assay, however, enables a better 
quality control of diagnostic test performance and the results of this study indeed can 
be used to rationally design the peptides for such multiplex systems. The need for 
multiplex ACPA analysis systems has recently increased by the observations that the 
so-called fine-specificity of these antibodies has a predictive value for the way the 
disease will progress 145;146;153. It would be particularly interesting to analyze the ACPA 
response to the citrullinated fibrinogen epitopes in various stages of (early) RA and to 
compare the reactivity profiles with clinical features, which may provide opportunities 
for more personalized treatment. 
Knowledge on the citrullinated autoepitopes targeted by the antibodies in the 
inflamed synovia of RA patients is also important for a better understanding of the 
pathophysiology, because the resulting immune complexes may directly contribute to 
the progression and chronicity of the disease 160. 
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Table 2. Citrullinated fibrinogen epitopes detected also in previous studies  
 
a
 Arginines that can be citrullinated by either hPAD2, hPAD4 or rmPAD2 are highlighted with the black boxes.  
b 
The position of the citrullinated residues is given between brackets. 
c
 Nakayama-Hamada and colleagues 
only showed the identified citrullination sites and not which peptides containing the sites were found. 
n.d.: not determined 
________________________________________________________________________________________ 
In conclusion, a new method was developed for the comprehensive analysis of 
epitopes that are formed by post-translational modifications using the (enzymatic ally 
modified) protein of interest as starting material.  
This method, in which chromatographic fractionation of proteolytic digests is 
combined with mass spectrometry and surface plasmon resonance imaging on 
microarrays, allows the simultaneous mapping of modified residues and epitopes.  
Peptide used 
a
  Citrullination 
sites  
Fibrinogen 
 chain 
b
 
Percentage 
of reactive 
sera (%) 
Reference 
 
RDRQHLPLIKMKPVP 
 
216, 218 
 
α 
 
0 
 
52
 
                    LPSRDRQHLPLIKMK 216, 218 α 0  
               IAKDLLPSRDRQHLPLIK 216 α 18 
152
 
               IAKDLLPSRDRQHLPLIK 218 α 0  
               IAKDLLPSRDRQHLPLIK 216, 218 α 0  
  573 α 25 
52
 
       SGIFTNTKESSSHHPGIAEFPRGKSSSY 573 α n.d. 
155
 
c) 573 α n.d.  
                        RGDSTFESKSYKMAD 591 α 0 
52
 
                     SYNRGDSTFESKSYK 591 α 20  
               QFTSSTSYNRGDSTFESKS 591 α n.d.  
c) 591 α n.d.  
 ARGHRPLDKKREEAPSLRPA 44,47,53,60 β 3 
152
 
 ARGHRPLDKKREEAPSLRPA 47,53,60 β 9  
 ARGHRPLDKKREEAPSLRPA 44,53,60 β 6  
        DKKREEAPSLRPAPP 53,60 β 0 
52
 
 ARGHRPLDKKREEAPSLRPA 53,60 β 12  
 ARGHRPLDKKREEAPSLRPA 60 β 12  
 ARGHRPLDKKREEAPSLRPA 44, 60 β 0  
 ARGHRPLDKKREEAPSLRPA 47, 60 β 36  
 ARGHRPLDKKREEAPSLRPA 44,47,60 β 12  
                              RARPAKAAATQKKVERKA 72 β 0  
                              RARPAKAAATQKKVERKA 74 β 0  
                  RPAPPPISGGGYRAR 60,72,74 β 28 
52
 
                           GGYRARPAKAAAT 72,74 β 0  
                              RARPAKAAATQKKVERKA 72,74 β 0 
152
 
c) 53,60,72,74 β n.d.  
                              RARPAKAAATQKKVERKA 72,87 β 0 
152
 
                              RARPAKAAATQKKVERKA               74,87 β 0  
                              RARPAKAAATQKKVERKA 72,74,87 β 0  
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Using this method, fifty four citrullination sites and three citrullinated epitope regions 
frequently recognized by ACPA in the sera of RA patients were identified in human 
fibrinogen, one of the main autoantigenic proteins in this disease. 
 
MATERIALS AND METHODS 
 
In vitro citrullination of fibrinogen 
To generate deiminated fibrinogen, 1 mg of immunoglobulin-depleted human fibrinogen (Sigma-Aldrich) was 
in vitro citrullinated by either human PAD2 (hPAD2; 1 U), human PAD4 (hPAD4; 1 U) or rabbit muscle PAD 
(rmPAD2; 1 U; Sigma-Aldrich) in deimination buffer (40 mM Tris-HCl, pH 7.5, 5 mM CaCl2 and 10 mM DTT) 
and incubated at 37 °C for 3 hours. After incubation, the reaction mixtures were dialyzed against PBS 
overnight. 
The recombinant hPAD2 and hPAD4 were expressed and purified as described previously 
110
. The activity of 
both recombinant proteins was determined with a colorimetric assay 
110
. 
 
Western blot analysis 
Human fibrinogen was separated by SDS-PAGE and transferred to nitrocellulose membranes. For the 
detection of citrullinated proteins, blots were chemically modified overnight as described previously  
161
. 
After blocking the blots in blocking buffer (5% non-fat dried milk and 0.1% NP40 in PBS) for 1 hour at room 
temperature, they were incubated with the anti-modified citrulline antibody (Upstate) in blocking buffer for 
3 hours at room temperature. Finally, the blots were washed with blocking buffer and bound antibodies 
were visualized with an IRDye 800-labeled secondary antibody (Molecular Probes, Rockland 
Immunochemicals, PA) and monitored by infrared (LI-COR Odyssey) imaging.  
 
Enzymatic digestion of citrullinated fibrinogen 
Different proteases were used for the generation of citrullinated fibrinogen peptides to achieve optimal 
sequence coverage in mass spectrometry analyses and to obtain citrullinated epitopes in different sequence 
contexts for iSPR analyses. 
Citrullinated fibrinogen was reduced using 50 mM DTT, alkylated in 100 mM iodoacetamide and digested 
with trypsin (all PADs), chymotrypsin (all PADs), Lys-N (rmPAD2 only), or GluC (hPAD2 and hPAD4), in a 1:100 
ratio by overnight incubation at 37°C. 
 
Separation of fibrinogen peptide fragments 
Peptides obtained by digestion of fibrinogen citrullinated by rmPAD2 were separated using strong cation 
exchange (SCX) chromatography, which was performed using an Agilent 1100 HPLC system (Agilent 
Technologies) with two C18 Opti-Lynx (Optimized Technologies, Oregon OR) guard columns and a 
polysulfoethyl A SCX column (PolyLC, Columbia, MD; 200 mm x 2.1 mm inner diameter, 5 µm, 200Å), 
essentially as described previously 
162
. Ten percent of each fraction was analyzed by LC-MS/MS. Fractions 
containing a large overlap in citrullinated peptides were pooled prior to SPR analysis. This led to a total of 29 
fractions, derived from either the chymotrypsin (C), Lys-N (L) or trypsin (T) digestion. Each selected fraction 
was desalted and dried prior to immobilization on the sensor disc surface. 
 
LC-MS/MS 
Digested citrullinated fibrinogen samples were analyzed by nano-LC-MS/MS on an LTQ-Orbitrap-XL using 
electron transfer induced dissociation (ETD) (hPAD2 and hPAD4) and/or an LTQ-FTICR (all PADs) mass 
spectrometer using collision induced dissociation (CID) (Thermo, San Jose, CA) connected to an Agilent 1200 
series nano-LC system.  
Peptides were separated on C18 with a multi-step gradient of 0.6% acetic acid (buffer A) and 0.6% acetic 
acid/80% acetonitril (buffer B).  
Raw MS data were converted to peak lists using Bioworks Browser software, version 3.1.1 and searched with 
Mascot against the Swiss-Prot database, using the appropriate enzyme and allowing citrullination of 
arginine, deamidation of asparagine and oxidation of methionine as variable modifications.  
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The spectra from the hPAD2 and hPAD4 fibrinogen incubations were searched with a precursor mass 
tolerance of 20 ppm and a product mass tolerance of 0.9 Da, allowing 2 miscleavages, with peptide 
identifications accepted with a Mascot score greater than 25. For the SCX separated rmPAD2 modified 
peptides, precursor tolerance was 5 ppm, product mass tolerance 0.9 Da, allowing 1 miscleavage and 
peptide identifications were accepted with a slightly lower Mascot score of at least 20 to be able to better 
identify overlap between adjacent fractions. 
 
Preparation of the microarrays and iSPR analyses 
To prepare the fibrinogen peptides for immobilization on the surface plasmon resonance (SPR) sensor discs, 
it was chosen not to use the GluC protease, which is known for its incomplete and heterogeneous cleavage, 
making it not very suitable for this application. Instead, Lys-N was used, which cleaves at the N-terminal side 
of lysine residues, thereby generating peptides that would always be immobilized in the same orientation, 
because both primary amines available for crosslinking are located at the N-terminus of the peptide. In 
addition to LysN, trypsin and chymotrypsin were used to digest human fibrinogen citrullinated in vitro with 
rmPAD2. The latter PAD was used for these experiments, because its specific activity is higher than that of 
the recombinant human PADs, implying that lower quantities could be used, which reduces the presence of 
PAD-derived peptides in the citrullinated fibrinogen fractions. 
Fibrinogen peptide fractions were immobilized on an iSPR chip containing a dextran hydrogel linked to a gold 
layer on a round glass surface (HC200, Xantec Bioanalytics GmbH).  
In short, immobilization of the fibrinogen peptide fractions was initiated by activation of the dextran 
hydrogel, which is achieved by creating a reactive N-hydroxysuccinimide ester with the carboxyl groups of 
the dextran matrix via the reaction which occurs when 0.8 M N-hydroxysuccinimide (NHS) and 0.2 M N-ethyl-
N’-(dimethylaminopropyl) carbodiimide hydrochloride (EDC) are mixed and added to the sensor disc surface. 
After incubation for 20 minutes the sensor disc was washed with 0.25% acetic acid, pH 4.5 and dried under 
nitrogen for 30 minutes. The protease-digested, citrullinated fibrinogen SCX fractions, human IgG (to 
visualize the array) and control synthetic peptides (citrullinated peptides and their arginine-containing 
counterparts) were spotted on the surface of the sensor discs using a noncontact spotter
 
(1 nl droplets with 
spotting concentration of 1 ng/nl in 50 mM MES, pH 5.4) and placed in a humidity chamber at room 
temperature for 1 h. Finally, the unreacted groups were blocked by incubation with 1 M ethanolamine, pH 
8.0 for 10 minutes. The sensor discs were rinsed with PBS and kept wet until use. 
The incubation with patient sera, and washing and regeneration of the coated sensor discs were performed 
as described previously 
158;159
. In contrast to previous studies, a new valveless sample injection method in 
combination with high mass transport of analytes was used.  
 
Multiplex iSPR analyses of fibrinogen peptide recognition by patient sera 
Sera from rheumatoid arthritis patients were obtained from the Department of Rheumatology, University 
Medical Center St. Radboud, Nijmegen, The Netherlands.  
The use of autoimmune patient sera for autoantibody studies has institutional review board approval and 
patients provided informed consent. Prior to use, sera were 50-fold diluted in PBS-0.03% Tween-20. Using 
the IBIS-iSPR instrument a diluted serum sample plug of 80 μl was injected and 20 μl was guided backward 
and forward over the microarray of fibrinogen peptide fractions in a flow cell with 30 μl/s to allow 
autoantibody binding to the immobilized peptides.  
To obtain quantitative results for antibody binding to the peptide fractions, the data were analyzed by the 
SPRint software. Spots were classified as being strongly or moderately recognized by sera when at least 25% 
of the sera were reactive with these fractions with angle shifts higher than the mean plus 8, respectively 2, 
standard deviations of the angle shift observed for a number of anti-CCP-negative RA sera.  
 
LIST OF ABBREVIATIONS 
 
ACPA, anti-citrullinated protein antibodies; CCP, cyclic citrullinated peptide; CID, collison induced 
dissociation; EDC, N-ethyl-N’-(dimethylaminopropyl) carbodiimide hydrochloride; ETD, electron transfer 
induced dissociation; FTICR, Fourier transform ion cyclotron resonance; HPLC, high-performance liquid 
chromatography; LC-MS/MS, liquid chromatography - tandem mass spectrometry; LTQ, linear trap 
quadrupole; NHS, N-hydroxysuccinimide; PAD, peptidylarginine deiminase; RA, rheumatoid arthritis; RF, 
rheumatoid factor; rmPAD2, rabbit muscle PAD; SCX, strong cation exchange; iSPR, surface plasmon 
resonance imaging 
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INTRODUCTION 
 
Rheumatoid arthritis (RA) is one of the most common autoimmune diseases, for which 
many autoantigens have been identified over the last decades. The most remarkable 
but yet most common targets of autoantibodies in RA are proteins containing the 
amino acid citrulline. This group of proteins includes, among others, histones and 
fibrin(ogen) 30;51;163. Autoantibodies against citrullinated proteins (ACPA) are almost 
exclusively present in RA and can be present years before disease onset 106. Detection 
of ACPA or other autoantibodies is a common part of the clinical diagnosis of RA. ACPA 
are often detected using the so-called cyclic citrullinated peptide, CCP test 
11
.  
Fibrinogen is a heteromultimeric protein consisting of two copies each of three 
different peptide chains (α, β and γ) 52. It plays an essential role in the clotting cascade, 
where it is proteolytically cleaved by thrombin to form the clotting protein fibrin 150. 
Citrullinated forms of the α and β chains of fibrinogen are known to be present in the 
serum and synovial fluid of RA patients and can be targets for ACPA 
30;151
.  
The role of citrullinated proteins and antibodies recognizing these proteins in the 
pathophysiology of RA is not fully understood, but specific HLA alleles (HLA-DR4 and 
HLA-DR1, HLA-DR10 and HLA-DR14) have been linked to a predisposition to develop RA 
and the associated MHC molecules were found to show increased ability to present 
peptides containing a citrulline residue 
154;164
.   
ABSTRACT - Rheumatoid arthritis (RA) is an autoimmune disease characterized by 
inflammation of the joints and the presence of autoantibodies directed against 
proteins containing the non-standard arginine-derived amino acid citrulline. The 
protein fibrinogen, which has an essential role in blood clotting, is one of the most 
prominent citrullinated autoantigens in RA, not in the last place because it can be 
found in the inflamed tissue of affected joints. Here, we set out to analyze the 
presence of citrullinated endogenous peptides in the synovial fluid of RA and 
arthritic control patients. Endogenous peptides were isolated from the synovial 
fluid of RA patients and controls by filtration and solid phase extraction. The 
peptides were identified and quantified using high resolution liquid 
chromatography-mass spectrometry.  
Our data reveal that the synovial fluid of RA patients contains soluble endogenous 
peptides derived from fibrinogen, containing significant amounts of citrulline 
residues and in some cases also phosphorylated serine. Several citrullinated 
peptides are found to be more abundantly present in the synovial fluid of RA 
patients compared to patients suffering from other inflammatory diseases affecting 
the joints. 
The increased presence of citrullinated peptides in RA patients points towards a 
possible specific role of these peptides in the immune response at the basis of the 
recognition of citrullinated peptides and proteins by RA patient autoantibodies. 
 
 
Citrullination: How subtle molecular changes affect loss of self-tolerance in rheumatoid arthritis 
96 
Chapter 5. Elevated levels of fibrinogen-derived endogenous citrullinated peptides in SF of RA patients 
 
 
Importantly, HLA-DR4 transgenic mice are susceptible to develop arthritis when 
immunized with citrullinated fibrinogen 
151
.  
Recently, Ho and others found that mice that were immunized with citrullinated 
fibrinogen developed arthritis and fibrinogen-reactive T cells which produce the 
proinflammatory cytokines IL-6, IL-17, TNF-α, and IFN-γ and that these mice possess 
rheumatoid factor, circulating immune complexes and anti-CCP antibodies, all of which 
are characteristics of human RA 
55
. Inhibition of the enzymes responsible for the 
generation of citrulline residues in proteins, the peptidylarginine deiminases (PADs), 
has been shown to reduce symptoms in mouse models of RA 165. Immune-complexes 
consisting of ACPA and citrullinated fibrinogen can also be found in a large part of the 
ACPA-positive RA patients 
133
 and are known to induce macrophage secretion of TNF-α, 
an important mediator of inflammation in RA 
44
.  
Although the presence of citrullinated fibrinogen protein has attracted the most 
attention lately, it is known that fibrinogen-derived peptides can be present in the 
synovial fluid of inflamed joints 
166
 and that (citrullinated) peptides can be potent 
activators of cells of the immune system 
151;167
. Here, we analyzed the synovial fluid 
obtained from 11 RA patients and 10 patients with related inflammatory diseases of 
the joint for the presence of endogenous soluble citrullinated peptides by LC-MS/MS. 
We found that fibrinogen derived citrullinated peptides were significantly more 
abundant in the fluid of the RA patients compared to the control patients, while their 
non-citrullinated counterparts were present at similar levels.  
 
RESULTS 
 
To assess the presence of citrullinated endogenous peptides in the synovial fluid of RA 
patients, synovial fluid and serum was collected from 11 RA patients and 10 patients 
with other inflammatory diseases of the joint.  
 
Figure 1. Identified citrullinated 
peptides at various identification 
scores. Graph showing the average 
percentage of all identified 
peptides that contain at least one 
citrulline residue at varying 
identification threshold scores in 
the synovial fluid of RA patients 
(black line) and control patients 
(dashed grey line). Bars indicate the 
median absolute deviations and 
indicated with asterisks are the 
scores at which a statistically 
significant difference (p<0.05) was 
observed, as determined by a 
Mann-Whitey test. 
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The ACPA (anti-citrullinated protein antibody) status of all RA patients was assessed by 
ELISA using the CCP2 test (data not shown). Endogenous peptides with a size smaller 
than 10 kDa were isolated from the synovial fluid by ultrafiltration and solid phase 
extraction.  
 
Identification of endogenous citrullinated peptides 
The synovial fluid derived peptides were analyzed by LC-MS/MS on a high-resolution 
LTQ-FT-ICR mass spectrometer and the resulting spectra were searched against all 
human proteins in the Swissprot database, allowing for citrullination, deamidation and 
oxidation as variable modifications. Because citrullination leads to an additional mass 
of nominally one Dalton compared to regular arginine residues, such searches are 
easier prone to false positives stemming from the misidentification of 
13
C isotopes or 
modifications which lead to similar nominal mass increases (e.g. deamidation of 
asparagines or glutamine). Such false, randomly matched, identifications are expected 
to generally have lower identification scores, because the identification score itself is 
calculated using the probability that an observed match between experimental data in 
the MS/MS spectra and a database sequence is random. We plotted the average 
relative number of peptides containing citrulline residues at various cutoff scores for 
patient and control samples (Figure 1). This showed that at lower scores the 
percentage of identified citrullinated peptides was almost 25% in patient samples and 
that this value dropped when higher cutoff scores were used leveling off at 
approximately 10% at cutoff scores of 35 and higher. Therefore, we chose to include 
only peptides identified with a score of at least 35 for further analysis. This analysis 
also showed that, irrespective of score cutoff, the average number of citrullinated 
peptides identified in RA patients was higher than in control patients. Because we were 
mainly interested in citrullinated peptides elevated in the RA patients, we generated a 
first list of candidate peptides based on their spectral counts in the two patient groups. 
We selected all peptides that were identified in at least 2 more RA patients than 
control patients and had an overall spectral count which was 2.5 times higher in the RA 
patients compared to controls. This resulted in a list of 17 citrullinated peptides, 15 of 
which we identified as being derived from the alpha chain of fibrinogen (Table 1). This 
similar to previous reports 166 and is not unexpected, as (citrullinated) fibrinogen alpha 
is known to be highly abundant in the synovial fluid proteome 54 and, unlike many 
other proteins, undergoes efficient proteolysis as part of the blood clotting cascade. 
While other proteins might be even more abundantly present in the synovial fluid (e.g. 
albumin or antibodies) 168, these would not be detected in this study, because they are 
not as commonly proteolytically processed as fibrinogen. Figure 2A shows the LC-MS 
chromatogram of the synovial fluid of patient S13, with all major peaks corresponding 
to fibrinogen-derived peptides indicated to illustrate that these peptides dominate the 
chromatogram. 
Given the difficulties with the reliable identification of citrullinated peptides described 
above, further analyses were performed to unambiguously confirm the citrullination of 
each of these 17 peptides. Misidentification of 13C isotopes was prevented by choosing 
a stringent precursor tolerance (5 ppm) for the initial searches, taking into account that 
13
C leads to a larger mass difference (1.0036 Da) than citrullination (0.9802 Da). 
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Deamidation, on the other hand, cannot be discriminated from citrullination based 
upon mass alone.  
However, deamidation does not change the number of charged residues in the peptide 
(under the acidic conditions used for LC-MS), whereas the conversion of arginine to 
citrulline neutralizes a positive charge. 
 
Table 1. List of citrullinated peptides identified more often in RA patients compared to control patients.  
 
Sequence Protein Accession Score  
DSGEGDFLAEGGGVcR Fibrinogen α chain FIBA_HUMAN 87.8 
SGEGDFLAEGGGVcR Fibrinogen α chain FIBA_HUMAN 67.8 
EGDFLAEGGGVcR Fibrinogen α chain FIBA_HUMAN 73.2 
FLAEGGGVcR Fibrinogen α chain FIBA_HUMAN 50.9 
EEVSGNVSPGTRcR Fibrinogen α chain FIBA_HUMAN 51.5 
EEVSGNVSPGTRcRE Fibrinogen α chain FIBA_HUMAN 69.8 
EEVSGNVSPGTcRREY Fibrinogen α chain FIBA_HUMAN 60.0 
EEVSGNVSPGTRcREY Fibrinogen α chain FIBA_HUMAN 48.8 
ELEcRPGGNEITRGGSTSY Fibrinogen α chain FIBA_HUMAN 50.1 
NcRGDSTFESKSY Fibrinogen α chain FIBA_HUMAN 69.0 
DEAGSEADHEGTHSTKcRGHA Fibrinogen α chain FIBA_HUMAN 40.8 
GSTGNcRNPGSSGTGGTATWKPGSSGP Fibrinogen α chain FIBA_HUMAN 59.1 
SETEScRGSESGIFTNTK Fibrinogen α chain FIBA_HUMAN 49.6 
SSSYSKQFTSSTSYNcRGDSTF Fibrinogen α chain FIBA_HUMAN 41.9 
TcRGGSTSYGTGSETESPRNPS Fibrinogen α chain FIBA_HUMAN 52.0 
TSEASSSSSSSSSSSRScRScRSL Peroxisome proliferator-
activated receptor gamma 
coactivator-related protein 1 
PPRC1_HUM 68.1 
 
GLADNTNDLEKcRcR 
 
Plasma membrane calcium-
transporting ATPase 3 
 
AT2B3_HUMAN 
 
40.5 
 
Note: cR indicates the position of a citrulline residue 
 
 
Therefore, we anticipated citrullination to have a pronounced effect on ionization and 
fragmentation of the peptide, and on the elution time of the peptide in the reversed 
phase separation preceding our MS analysis.  
We analyzed the retention times of all peptides in Table 1 and compared them with 
the corresponding non-citrullinated peptides.   
This revealed that on average citrullinated peptides eluted 5 minutes later from the 
C18 column than their arginine-containing counterparts (Figure 2B), in agreement with 
their increased hydrophobicity. We also analyzed the precursor mass spectra and 
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fragmentation spectra for all of these peptides and found that citrullination caused the 
dominant precursor charge state to be lower for peptides with a charge of 3 and higher 
(Figure 3), whereas deamidation had no such effect (data not shown). Also the MS/MS 
spectra changed upon citrullination, as anticipated, with more prominent b-ions 
showing up when the converted arginine was on the C-terminal part of the peptide and 
increased levels of y-ions when it was located more N-terminally (Figure 3). 
 
Quantification of endogenous citrullinated peptides 
Having robustly established the citrullinated identity of these peptides, we set out to 
analyze their abundance in the synovial fluid. From the sequence of the peptides, it 
was apparent that mostly two regions of fibrinogen were identified with multiple 
peptides, with different termini, probably due to endogenous proteolytic activity. 
These two regions span amino acids 20-35 (sequence ADSGEGDFLAEGGGVR) and 414-
433 (sequence EEVSGNVSPGTRREYHTEKL) of the fibrinogen alpha-chain.  
The first sequence corresponds to the so-called fibrinopeptide A, a signal peptide 
generated from the N-terminus of fibrinogen alpha during blood clotting. 
 
 
 
 
Figure 2. Chromatography of synovial fluid and fibrinogen-derived peptides. (A) A base peak 
chromatogram of the LC-MS/MS analysis of the peptides in the synovial fluid of RA patient S13, 
showing the complexity of the sample. All base peaks derived from the alpha chain of fibrinogen 
are indicated with “F”, with citrullinated and phosphorylated peptides indicated with “cF” and “pF”, 
respectively. (B) The extracted ion chromatograms (XIC) of peptide DSGEGDFLAEGGGVR (m/z 
733.33), which elutes at a retention time (RT) of 53.18 minutes and the citrullinated version of the 
same peptide (m/z 733.83), eluting at 61.08 minutes. Note that in the bottom chromatogram also a 
peak is visible at the elution time of the non-citrullinated peptide, corresponding to the 
13
C isotopic 
peak of that peptide, which has a mass very close to the citrullinated peptide and is therefore also 
extracted by the algorithm. The relative areas of the two extracted chromatograms are indicated at 
the y-axis of the XICs. 
A B 
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Because of their prominent presence, we decided to focus on these regions, and to 
include other peptides covering these sequences in further analyses.  
We determined the relative abundance of all selected peptides in all samples by 
calculating the area of their extracted ion chromatograms (XIC) in the LC-MS analyses, 
(as is shown for peptide DSGEGDFLAEGGGVR in Figure 2B), normalized using spiked 
(citrullinated) synthetic peptides.  
Figure 3. Identification of citrullinated peptides. MS1 (left) and MS/MS (right) spectra of two different 
fibrinogen-derived peptides (DSGEGDFLAEGGGVR in panel A and NRGDSTFESKSY in panel B) from 
synovial fluid samples. In the MS1 spectra, the peak(s) corresponding to the respective peptide are 
marked with their m/z and charge state and the peak of which the MS/MS spectrum is shown is 
marked with the red m/z value. In the corresponding MS/MS spectra, y-ions are marked in blue, b-ions 
are marked in red and all other annotated ions are marked in green. Please note that parents ions are 
not present in the MS/MS spectra generated with the instrumentation and settings used. 
A 
B 
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Figure 4A shows a heat map displaying the abundance of each of these citrullinated 
peptides for fibrinogen region 20-35 in the synovial fluid samples, suggesting that 
some of them are more often present in high amounts in RA patients compared to 
controls. This effect can be attributed both to an increase in the total amount of 
peptide present and to an increased level of citrullination.  
Therefore, we also calculated the extract ion chromatogram areas for all corresponding 
non-citrullinated peptides (Figure 4B). This revealed that the increased levels observed 
for the citrullinated peptides were not seen for their non-citrullinated counterparts, 
suggesting an increased level of citrullination. A similar analysis of region 414-433 was 
performed and this analysis showed a higher abundance of both the citrullinated and 
the non-citrullinated peptides in the RA patients (data not shown). 
To visualize the changed levels of citrullination for the peptides covering amino acids 
AA20-35 of fibrinogen alpha, we also calculated the average relative amount of 
selected citrullinated peptides versus their non-citrullinated counterpart by calculating 
the ratio between the observed areas for these peptides. 
This revealed that the non-citrullinated peptides are detected in roughly 100-fold 
higher amounts (shown in Figure 5 by the approximate average ratio of 0.01), but this 
does not reflect actual abundances because the arginine containing peptides will be 
detected much more efficiently due to their higher basicity and thus ionization 
efficiency 169. Still, the data can be interpreted relatively to each other and although 
the difference between individual patients is large, it is clear that a significant increase 
of the citrullinated variants of the peptide was observed in the RA patients (Figure 5). 
For all combinations of corresponding citrullinated and non-citrullinated peptide 
sequences shown in Figure 5, a t-test on the log transformed areas revealed significant 
differences between RA patients and control patients with p-values of <0.05.  
In addition, for both sets also the categorical Fisher’s exact test (using cutoff 0.01) 
confirmed the significant differences with p < 0.05. 
 
Synovial fluid contains multiply modified fibrinopeptide A 
Interestingly, fibrinopeptide  A also contains a known phosphorylation site on 
fibrinogen alpha (S22) 170, which is most likely generated by a casein kinase II (CK2) 
family kinase 171. 
To determine if the presence or absence of phosphorylation was in any way linked to 
the citrullination of R35, we extended our database search to include this possibility 
and were able to identify two peptides (with sequences ADpSGEGDFLAEGGGVcR and 
DpSGEGDFLAEGGGVcR) containing both a phosphorylated S22 and a citrullinated R35 
in a number of the patients (Figure 6A and Figure 6B). We then also determined the 
XIC areas of these peptides in all patients, showing that the peptides containing both 
modifications showed a similar behavior to the peptides containing only the 
citrullination site (e.g. more present in RA patients), whereas peptides containing only 
the phosphorylation site were equally abundant in all patients (Figure 6C).  
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Figure 4. Abundance of fibrinopeptide A derived peptides in RA patients and controls.  Heatmap displaying the relative abundance (as 
determined from the extracted ion chromatograms, XIC) of citrullinated peptides (A) and their non-citrullinated counterparts (B) in RA patients 
and control patients. Because abundances for different peptide sequences cannot be directly compared due to their different behaviour in the 
mass spectrometer, the color coding is applied per peptide sequence with the patient containing the highest amount of each particular peptide 
colored in red, the lowest colored in green and the other patients colored according to the color scale shown on the right of the panel. White 
asterisks indicate in which patient the highest abundance of a specific peptide was observed. For the RA patients, the code of CCP2+ patients is 
shown in yellow and of CCP2- patients in red. Patients are sorted according to the average abundance of all listed peptides, shown at the bottom 
of each panel. 
A 
B 
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A final fibrinopeptide A derived phosphopeptide containing a citrulline residue with 
the sequence pSGEGDFLAEGGGVcR was identified with low identification scores in 
some of the samples but was found to be present in only very low amounts and was 
therefore not included in this analysis (data not shown).  
 
DISCUSSION 
 
Many citrullinated proteins have been identified in the inflamed joints of RA patients 
and a number of these have been shown react in vitro with ACPA. A prominent 
candidate to be the main target for ACPA is fibrin(ogen), which is known to be present 
in large amounts in inflamed joints and which is known to be present in a citrullinated 
form in the synovial fluid of RA patients 54;134. 
ACPA can indeed bind to citrullinated fibrinogen, in particular the alpha chain. 
Recently, it was shown that in inflamed joints also significant amounts of peptides can 
be found that are derived from fibrinogen due to endogenous proteolytic activity 166.  
Here we showed that citrullinated versions of these peptides can be found in the 
synovial fluid of inflamed joints and that these peptides appear to be more abundant 
in RA patients than in patients suffering from other inflammatory joint diseases, which 
may be consistent with a role for these citrullinated fibrinogen peptides in immune 
system activation. Although there was significant diversity in the levels of citrullinated 
peptides in the control group, with especially patient S2 (ankylosing spondylitis) 
showing very high levels, no obvious relation with their diagnosed disease was 
apparent. 
 
A 
B 
Figure 5. Relative abundance of citrullinated peptides and their non-citrullinated counterparts. Bar 
graphs showing the ratio between the abundance of a specific citrullinated peptide versus its non-
citrullinated variant in RA patients (black bars) and control patients (gray bars) on a base 10 logarithmic 
scale. The ratios for peptide GDFLAEGGGVR (A) and for peptide SGEGDFLAEGGGVR (B) are shown. When 
no signal for the peptide was detected, an value equivalent to the background signal was assigned for this 
calculation. If both the signal of the citrullinated and the non-citrullinated peptide were missing, the ratio 
is shown as not determined (n.d.). Patients are sorted per group according to the observed ratios.  
 
A B 
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Figure 6. The presence of phosphorylated and citrullinated peptides in synovial fluid.  Panels A and B show tandem MS 
spectra of peptides ADpSGEGDFLAEGGGVcR and DpSGEGDFLAEGGGVcR, respectively, containing both a phosphorylated 
serine 22 at as well as a citrullinated arginine 35. Fragment ions used for the identification are colored blue if they contain 
the N-terminus of the peptide (y-ions), red if they contain the C-terminus of the peptide (b-ions) and green for all other 
fragment ions. Fragments showing a “neutral loss” of the phosphate group, and thus confirming the presence of a 
phosphorylated residue are marked with “-98”. The corresponding identification scores (Mascot scores) are shown in each 
of the spectra. Panel C shows the heatmap of the XIC intensities of the identified S22 phosphorylated alpha fibrinogen 
peptides in RA and control patients, with (top panel) and without (bottom panel) citrullination at position 35. Color coding 
is applied per peptide sequence with the patient containing the highest amount of peptide colored in red, the lowest 
colored in green and the other patients colored according to the color scale shown on the right of the panel. White 
asterisks indicate in which patient the highest abundance of a specific peptide was observed. For the RA patients, the code 
of CCP2+ patients is shown in yellow and of CCP2- patients in red. Patients are sorted according to the average intensity of 
all listed peptides, shown at the bottom of each panel. 
A 
B 
C 
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This diversity between the patients in the control group suggests that the citrullinated 
peptides arise from inflammatory events that can also occur in diseases other than RA, 
which is not unexpected as many rheumatic diseases show overlap in the symptoms 
observed. Ideally, non-inflamed material would be analyzed as a control, but in healthy 
individuals the amount of synovial fluid is too small, as this increases significantly as a 
result of the inflammation. The citrullinated peptides we found to be most abundantly 
present in RA patients covered mainly two distinct regions in the alpha chain of 
fibrinogen, amino acids 20-35 and 414-433. These regions have been shown to be 
susceptible to citrullination in the past and it was shown that the arginine residues in 
these sequences (R35, R425 and R426) can be citrullinated by both the PAD2 as well as 
the PAD4 enzymes 
172
, both known to be present in inflammatory cells in the synovium 
74
. Together, these PAD enzymes are known to be able to citrullinate two-thirds of all 
arginine residues in fibrinogen 172, but little is still known about which citrullinates sites 
contribute the most to eliciting the anti-citrulline immune response. The fact that 
endogenous peptides with these specific citrulline residues circulate in the synovial 
fluid, makes them prime candidates for having a role in the immune response against 
citrullinated epitopes. The fibrinogen region between amino acids 414-433 is known to 
be autoantigenic in RA patients 52;172, but for the citrullinated fibrinopeptide A (amino 
acids 20-35) no data on autoantigenicity is available, most likely because it is not part 
of the mature fibrinogen protein which has been used in such studies most frequently. 
Interestingly, the fact that fibrinopeptide A contains a C-terminal arginine residues 
makes it an excellent substrate for PAD enzymes, which are able to efficiently convert 
such residues to citrulline (data not shown).Both sequence elements were represented 
by a variety of peptides, differing in either their N- or C-terminal sequence (Figures 4), 
most likely due to in vivo proteolytic activities.  
While it is difficult to predict the enzyme responsible for their generation, proteases 
abundantly present in inflammatory cells, such as matrix metalloproteases, elastases 
or caspases are likely involved. The two cleavage sites generating the full aa20-35 
fragment, however, are obvious, as this corresponds exactly to the borders of 
fibrinopeptide A, which is released from the A-alpha chain by cleavage at the N-
terminal side of aa20 by the signal peptidase and at the C-terminal side of aa35 by 
thrombin 150;173.  
The latter cleavage is one of the first steps of the clotting cascade and therefore the 
presence of (derivatives of) fibrinopeptide A is not very surprising, although its 
presence in a citrullinated fashion has not been reported before.  
Because thrombin cleavage at that position is dependent on the presence of an 
arginine residue, the citrullination of the C-terminal arginine of fibrinopeptide A has 
most likely occurred after thrombin cleavage.  
Citrullination of R35 in the uncleaved fibrinogen protein would inhibit thrombin 
cleavage and might therefore have implications on the efficiency of clotting in inflamed 
joints 174. The cleavage generating the N-terminus of the aa414-433 fragment is most 
likely mediated by cathepsin D, which can cleave fibrinogen at that position in the 
process of clearing fibrin cloths 175. 
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Fibrinogen is certainly not the only citrullinated antigen present in synovial fluid, as for 
example also citrullinated fibronectin and vimentin have been found 
134
.  
However, the presence of high levels of endogenous citrullinated peptides derived 
from the protein is quite unique to fibrinogen and could potentially provide a direct 
link between with the generation of an immune response targeting citrullinated 
epitopes. From a diagnostic point of view, such peptides might be very interesting to 
be used to discriminate RA from closely related inflammatory diseases that also affect 
the joints. This could be achieved either by employing targeted mass spectrometric 
techniques or by the development of other methods, for example antibody based, that 
would allow the diagnostic detection of these citrullinated peptides in synovial fluid 
from inflamed joints.  
 
MATERIALS AND METHODS 
 
Synovial fluid samples 
Synovial fluid samples were obtained from 11 RA patients and 10 patients with other inflammatory diseases 
(4 with psoriatic arthritis, 2 with ankylosing spondylitis, 2 with gout, 1 with osteoarthritis and 1 with 
ochronosis). Synovial fluid was obtained by joint punctures (arthrocentesis), using needles with a diameter 
from 1.6 to 2.2 mm. A sample was immediately centrifuged at 2,500g for 10 minutes at 4°C. Supernatant and 
pellet were separately stored at -80°C. All procedures were performed within two hours. 
 
Isolation of peptides from synovial fluid 
Peptides were isolated from synovial fluid based on the protocol recently described by Kamphorst et al. 
166
. 
First, intact proteins were removed from the synovial fluid by ultracentrifugation. Spin filter columns with a 
10 kDa cutoff were first washed with 100 µl ethanol by centrifugation for 10 min at 11,000g and 4°C and 
then with 100 µl 50 mM NH4HCO3 pH 7, also for 10 minutes at 11,000 g and 4°C. Next, 50 µl of synovial fluid 
was mixed with 235 ul of 50 mM NH4HCO3 pH 7 and 15 µl DMSO and was passed through the spin filter by 
centrifugation for 60 minutes at 11,000g and 4°C. The spin filter was then washed again with 100 µl 50 mM 
NH4HCO3 pH 7 for 10 minutes at 11,000g and 4°C and the filtrates of the last two steps were combined and 
acidified with 5 µl formic acid (FA). Next, SepPak C18 (Waters) disposable cartridges with a capacity of 50 mg 
were activated with 1 ml acetonitril (ACN) and conditioned with 1 ml 2.5% ACN / 1% FA. After passing the 
filtrates over the cartridges, they were washed with 1 ml 2.5% ACN / 1% FA. Finally, peptides were eluted 
with 150 µl 80% ACN / 1% FA and dried by vacuum centrifugation.  
For MS analysis, dried peptide samples were reconstituted in 50 µl of 5% FA. Five µl of each sample was 
spiked with 1 µl of internal standard, containing 3 standard peptides with m/z of 556.28, 477.78, and 497.60.  
 
Identification and quantitation of endogenous peptides by LC-MS/MS 
Isolated synovial fluid peptides were analyzed by nano-scale liquid C18 chromatography using an Agilent 
1100 series LC system coupled to an LTQ-FTICR mass spectrometer (Thermo Scientific). The mass 
spectrometer was operated in the data-dependent mode to automatically switch between MS and MS/MS 
acquisition and the five most intense ions were fragmented in the linear ion trap using collisionally induced 
dissociation.  
Obtained MS/MS spectra were analyzed by database searching against all human proteins in the SwissProt 
database using the Mascot software platform (Matrix Science). The search criteria included methionine 
oxidation, arginine citrullination and asparagine and glutamine deamidation as variable modifications.  
 The peptide tolerance was set to 5 ppm and the MS/MS tolerance to 0.6 Da. All searches were done without 
enzyme restrictions and peptides were, unless described differently, identified with a minimum Mascot score  
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LIST OF ABBREVIATIONS  
ACPA, anti-citrullinated protein antibodies; CCP, cyclic citrullinated peptide;  ELISA, Enzyme-linked 
immunosorbent assay; IL, interleukin; IFN, interferon; LC-MS/MS, liquid chromatography - tandem mass 
spectrometry; LTQ-FT-ICR, linear quadrupole ion trap Fourier-transform ion cyclotron resonance mass 
spectrometer;  MHC, major histocompatibility complex; MS, mass spectrometry; PAD, peptidylarginine 
deiminase; RA, rheumatoid arthritis; SF, synovial fluid; TNF, tumor necrosis factor  
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Chapter 6 
 
 
Anti-citrullinated 
fibronectin antibodies in 
rheumatoid arthritis are 
associated with HLA-
DRB1 shared epitope 
alleles. 
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INTRODUCTION 
 
Citrullination or deimination is a post-translational modification, in which a 
peptidylarginine is converted into a peptidylcitrulline by the enzyme family of 
peptidylarginine deiminases (PAD). Citrullinated proteins occur at inflamed sites in 
healthy individuals as well as in patients 
31
. However, autoantibodies directed against 
citrullinated proteins (anti-citrullinated protein/peptide antibodies, ACPA) are very 
specific for rheumatoid arthritis (RA). More than 70% of RA patients display ACPA, 
measured via the anti-CCP2 test, in their sera 5;106. These antibodies are frequently 
present prior to disease onset and can predict the development of RA 176;177.  
It is still not fully understood how RA originates and develops, although there is 
experimental evidence for several steps in this process 160. Both genetic and 
environmental factors have been demonstrated to contribute to the development of 
the disease and ACPA production. The association of several HLA-DRB1 alleles, which 
all share a highly conserved motif that is known as the shared epitope (SE), has already 
been reported many years ago 4;37.  
ABSTRACT - Fibronectin is one of the most abundant proteins present in the 
inflamed joint. Here, we characterized the citrullination of fibronectin in the joints 
of rheumatoid arthritis (RA) patients and studied the prevalence, epitope 
specificity and HLA association of autoantibodies against citrullinated fibronectin 
in RA.  
Citrullinated residues in fibronectin isolated from RA patient synovial fluid were 
identified by mass spectrometry. The corresponding citrullinated and non-
citrullinated peptides were synthesized and used to analyze the presence of 
autoantibodies to these peptides in RA sera and sera from other diseases and 
healthy controls by ELISA. The data were compared with risk factors like shared 
epitope HLA alleles and smoking, and with clinical features. Five citrullinated 
residues were identified in fibronectin from RA synovial fluid. RA sera reacted in a 
citrulline-dependent manner with two out of four citrullinated fibronectin 
peptides, one of which contains two flanking citrulline residues, in contrast to non-
RA sera, which were not reactive. The most frequently recognized peptide (FN-
Cit1035,1036, LTVGLTXXGQPRQY, in which X represents citrulline) was primarily 
targeted by anti-CCP2-positive RA patients. Anti-FN-Cit1035,1036 autoantibodies 
were detected in 50% of established anti-CCP2-positive RA patients and in 45% of 
such patients from an early arthritis clinic. These antibodies appeared to be 
predominantly of the IgG isotype and to be associated with HLA shared epitope 
alleles (OR = 2.11). 
Fibronectin in the inflamed synovia of RA patients can be citrullinated at least at 
five positions. Together with the flanking amino acids three of these citrullinated 
residues comprise two epitopes recognized by RA autoantibodies. Anti-
citrullinated fibronectin peptide antibodies are associated with HLA shared 
epitope alleles. 
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Other genes that have been identified as risk factors for RA include PTPN22, the 
TRAF1-C5 locus, PADI4, STAT4, IRF5 and CTLA-4 
107;178;179;180
.  
Smoking has been demonstrated to be an environmental risk factor for RA and also for 
ACPA production in RA patients carrying SE alleles 181;182. Other environmental risk 
factors that have been suggested to enhance the chance of developing RA include the 
exposure to mineral oil, diet restrictions and coffee intake 
182;183
. However, these data 
still need confirmation. 
Many citrullinated autoantigens (e.g. fibrinogen, vimentin, alpha-enolase) and ACPA 
directed towards these citrullinated proteins have been identified in RA 28;30;42;52;123. 
Currently, the CCP2 test, which is based on a synthetic citrullinated peptide not related 
to proteins occurring in the inflamed joints of RA patients, is the golden standard 
16;184;185
 for ACPA testing. ACPA have recently been included in the new ACR/EULAR 
criteria for the classification of RA , because they are present early in disease and can 
predict disease development and outcome 
18;176
. The ACPA response in established RA 
patients is very heterogeneous and includes antibodies directed to many citrullinated 
proteins 
51;137;186
. Because it has been suggested that ACPA play an important role in 
the development of the disease, it is important to  learn more about the autoantigens 
that could be involved in the generation of ACPA 160. Several citrullinated proteins 
occurring in the inflamed joints of RA patients have been identified previously. In part 
their citrulline-containing epitopes have been mapped, particularly using synthetic 
peptides 52;57 or material from cultured (non-synovial) cells (e.g. HL-60 cells) 49. It 
remains to be established whether these epitopes are relevant from a 
pathophysiological point of view. ACPA tests based upon citrullinated autoantigenic 
proteins may provide information on ACPA fine-specificities 187;188 and may aid the 
differentiation between clinically distinct RA patient subgroups,  although 
accumulating evidence point to a limited value of ACPA fine-specificity determination 
in relation to clinical phenotype 189;190. 
One of the citrullinated proteins in inflamed synovial tissue identified previously is 
fibronectin (FN) 50. FN is a glycoprotein, which can be a component of the extracellular 
matrix (insoluble form) or present in body fluids (soluble form). FN is involved in a 
variety of processes, such as wound healing, haemostasis, thrombosis and 
embryogenesis. Several findings have been published linking (citrullinated) FN with RA. 
For example, citrullinated FN was found to be present in synovial tissue and synovial 
fluid (SF) of RA patients 50;134. It has also been detected in pannus tissue and in immune 
complexes present in sera of RA patients 
191;192
. FN might play a role in articular 
cartilage destruction, because it has been observed that FN fragments can stimulate 
the production of multiple mediators of matrix destruction, such as various cytokines 
and metalloproteinases 193;194. However, the presence and characteristics of anti-
citrullinated fibronectin antibodies in RA patients have not been studied yet.  
In the current study, we have mapped citrullinated residues of FN isolated from the SF 
of RA patients and have used this information to investigate the B-cell response to 
citrullinated FN in RA. 
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Figure 1. Identification of (citrullinated) FN in RA synovial fluid. A.  RA synovial fluid samples were depleted of albumin and separated by SDS-PAGE and stained with 
colloidal Coomassie Brilliant Blue. Subsequently, 18 equal slices were excised from the stained gel for both samples. The polypeptides present in the slices were digested 
with trypsin and analyzed by LC-MS/MS. The presence of citrullinated proteins in the gel was visualized by western blotting using anti-modified citrulline (AMC) 
antibodies after modification of the proteins on the blot. The positions of molecular mass markers are indicated on the left (kDa). B. The positions of FN peptides 
detected in RA SF with LC-MS/MS for each of the 18 gel slices of both patient samples are schematically aligned with isoform 1 of fibronectin (FN1). The white bars 
represent peptides detected in RA1, the black bars peptides detected in RA2 and the grey bars peptides detected in both patients. The positions of the citrullinated 
residues detected are marked with asterisks. C. Schematic overview of the 15 different FN isoforms, resulting from alternative splicing events, documented in the 
UniProtKB database. The positions of the main alternatively spliced segments EDA, EDB and IIICS are indicated. 
 
A 
B 
C 
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RESULTS 
 
Citrullinated fibronectin in synovial fluid samples of RA patients 
To study the immune response to citrullinated FN in RA, first the positions of the 
citrulline residues in FN isolated from the inflamed joints of RA patients were mapped. 
One supernatant fraction and one pellet fraction from synovial fluid (SF) samples 
obtained from two different RA patients (RA1 and RA2, respectively)  were depleted of 
albumin by a differential precipitation procedure as described previously 124. This 
resulted in two pellets fractions for each RA SF sample were separated by SDS-PAGE 
and stained with colloidal Coomassie Brilliant Blue (CBB) (Figure 2).  
 
 
Subsequently, 18 equal slices, covering the largest polypeptides (slice number 1, 
molecular weight > 94,000) to the smallest polypeptides (slice number 18, molecular 
weight < 14,000) were excised from the stained gel for both samples (Figure 1A). The 
polypeptides present in the slices were digested with trypsin and analyzed by LC-
MS/MS. The identity of polypeptides and the positions of citrullinated residues were 
determined by database searches using Mascot. To confirm the presence of 
citrullinated residues and to distinguish from deamidation of glutamine or asparagine 
residues, the peptide fragmentation patterns were inspected manually. One of the 
citrullinated proteins found in the SF of both patients was FN.  
Figure 2. Overview of the handling of synovial fluid samples.   
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Figure 1B shows a schematic overview of all the FN peptide sequences obtained. This 
indicates that (fragments of) FN were present in material from many gel slices, 
indicative of a large variety of FN polypeptide lengths in SF samples. 
FN is a protein for which at least 15 different isoforms exist (Figure 1C); the canonical 
isoform (FN1) comprises a polypeptide 2386 amino acids, in which 3 repeats can be 
discerned 
195
. FN-derived peptides that were found by these analyses covered most of 
the FN1 isoform, although for several regions no peptides were detected, which may at 
least in part be due to poor ionization efficiencies. For one of the alternatively spliced 
segments, extra domain A (EDA), no peptides were found in the data obtained, 
whereas several peptides demonstrating the absence of EDA were present. For IIICS, 
another alternatively spliced region, some peptide sequences were obtained with 
material from the high molecular weight fractions.  
Altogether, the mass spectrometry data covered 53% and 28% of the FN isoform 1 
sequence for RA1 and RA2, respectively (Figure 1B).  
A search for deiminated arginines identified four citrullinated FN regions containing 
five citrullinated residues, located at amino acid positions 241, 1035, 1036, 1162 and 
2356 (Figure 1B). 
 
Table 1. Sequences of synthetic fibronectin peptides 
 
 
Peptide 
name 
 
 
Peptides identified in RA SF
a
 
 
 
Synthetic peptide
a
 
 
 
Citrulline  
residues 
identified             
in RA1 
 
Citrulline 
residues 
identified       
in RA2 
 
FN-Cit241 
 
DTRTSYXIGDTWSK, TSYXIGDTWSK 
 
 
DTRTSYXIGDTWSZO 
 
 
X 
 
X 
FN-Arg241  DTRTSYRIGDTWSZO   
 
FN-Cit1035,1036 
 
LTVGLTXXGQPR, 
AQITGYRLTVGLTXR 
 
LTVGLTXXGQPRQYZO 
 
 
X 
 
X
b
 
FN-Arg1035,1036  
 
LTVGLTRRGQPRQYZO   
FN-Cit1162 DGQEXDAPIVNK LRDGQEXDAPIVNZO 
 
X X 
FN-Arg1162  
 
LRDGQERDAPIVNZO 
 
  
FN-Cit2356 RPGGEPSPEGTTGQSYNQYSQXYHQR YNQYSQXYHQRTNZO 
 
 
 
X 
 
FN-Arg2356  YNQYSQRYHQRTNZO   
 
a 
X: citrulline; Z: aminohexanoic acid; O: biotinylated lysine  
b 
Only citrulline at position 1035 was identified 
 
 
In RA1 four citrullinated residues were identified (positions 241, 1035, 1036 and 1162), 
whereas in the second patient (RA2) four citrullinated residues were identified 
(positions 241, 1035, 1162 and 2356) (Figure 1A and Table 1).  
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Anti-citrullinated fibronectin peptide antibodies are specific for RA and are associated 
with the ACPA response     
To investigate the antigenicity of citrullinated FN peptides comprising the citrullination 
sites identified were synthesized, as well as their arginine-containing counterparts 
(Table 1). A single peptide was synthesized for the flanking citrullination sites at 
positions 1035 and 1036, similar to the peptide identified in RA SF.  
The recognition of these peptides by antibodies in established RA patient sera (n=23) 
was analyzed by ELISA. Two of these peptides, which contained either a citrulline at 
position 241 or at position 1162 (FN-Cit241 and FN-Cit1162, respectively), were not 
recognized by RA sera. 
In contrast, the other two 
peptides (FN-Cit1035,1036 and FN-
Cit2356) were reactive with RA 
sera, and for both this reactivity 
appeared to be citrulline-
dependent (Figure 3A-D). To 
substantiate these data and to 
obtain an indication of the 
frequency by which these 
peptides are recognized, sera 
from a second, larger cohort of 
80 established RA patients were 
analyzed. Also these sera were 
found to be frequently reactive 
with the FN-Cit1035,1036 and FN-
Cit2356 peptides (Figure 3E-F). 
Forty-three percent of these 
sera appeared to recognize FN-
Cit1035,1036, whereas 8 percent 
was reactive with FN-Cit2356.  
To analyze the disease-
specificity of antibodies to these 
citrullinated FN peptides, sera 
from 31 multiple sclerosis (MS), 
32 type 1 diabetes (T1D), 31 
primary Sjőgren’s syndrome 
(pSS), 31 systemic lupus 
erythematosus (SLE) and 29 
tuberculosis (TB) patients, and 
from 32 healthy individuals, in 
parallel with 75 established RA 
sera, were analyzed by ELISA. 
The results showed that less 
than 2 percent of the control sera were reactive with FN-Cit1035,1036, whereas 1 percent 
displayed reactivity with FN-Cit2356 (Figure 4).  
A B 
C D 
E F 
Figure 3. Recognition of citrullinated fibronectin 
peptides by RA sera. The four fibronectin peptide sets 
(A, FN-Arg/Cit241; B, FN-Arg/Cit1035,1036; C, FN-Arg/Cit1162; 
D, FN-Arg/Cit2356) were analyzed by ELISA with 23 sera 
from established RA patients. Two peptide sets (E, FN-
Arg/Cit1035,1036; F, FN-Arg/Cit2356) were analyzed with a 
larger cohort obtained from established RA sera (n=80). 
OD450 = optical density at 450 nm. 
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Recently, it was shown that RA patients can be divided into two subsets based upon 
the presence or absence of ACPA in their sera and the CCP2 test appeared to be very 
suitable to differentiate between these subsets 
196
.  The analysis of anti FN-Cit1035,1036 
reactivity in 131 anti-CCP2-positive and 28 anti-CCP2-negative RA sera (Figure 5) 
showed that the anti-citrullinated fibronectin antibodies were hardly present in anti-
CCP2-negative RA sera, corroborating the idea that these antibodies are part of the 
ACPA response in anti-CCP2-positive RA patients. The combined analyses of the 
established RA sera resulted in a prevalence of 50 percent for the autoantibodies to 
peptide FN-Cit1035,1036 (Table 2), LTVGLTXXGQPRQY (X represents citrulline), in CCP2-
positive established RA sera (n=82). 
Autoantibodies against citrullinated fibronectin peptide are present early in the disease                  
Autoantibodies against CCP2 peptides have been demonstrated to be detectable very 
early in the disease. Moreover, their presence in pre-disease sera predicts the 
development of RA 8;176;177. The diversification of the ACPA response was found to 
occur mainly in the pre-disease stage. To investigate whether autoantibodies against 
citrullinated FN are also detectable in the early stages of RA development, a number of 
sera from early arthritis (EAC) patients (CCP2-negative, n=23; CCP2-positive, n=24) was 
analyzed. 
 
D 
A B 
Figure 4. Recognition of citrullinated fibronectin peptides by diseased and healthy control sera.  The 
peptides FN-Arg/Cit1035,1036 and FN-Arg/Cit2356 were used to study the specificity of the anti-FN 
antibodies. (A) Reactivity of RA sera and control sera to FN-Cit1035,1036. (B) Reactivity of RA sera and 
control sera to FN-Cit2356. (C) Reactivity of RA sera and control sera to FN-Arg1035,1036. (D)  Reactivity of 
RA sera and control sera to FN-Arg2356. RA (n=75); pSS = primary Sjőgren’s syndrome (n=31); MS = 
multiple sclerosis (n=31); SLE = systemic lupus erythematosus (n=31); T1D = type 1 diabetes (n=32); TB 
= tuberculosis (n=29); NS = normal human sera (n = 32). Broken lines indicate cutoff values (mean + 
2*SD of NS data); OD450 = optical density at 450 nm. 
 
A B 
C D 
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Table 2. Sensitivity and specificity of anti-citrullinated fibronectin antibodies 
a
Based upon CCP2-positive sera 
 
As observed before for the established RA sera, also the EAC sera reactive with the FN-
Cit1035,1036 peptide represented a subgroup of the anti-CCP2-positive patients (Figure 
6A). To substantiate these data and to obtain an indication of the frequency by which 
the FN-Cit1035,1036 peptide was recognized, additional CCP2-positive early arthritis sera 
(n= 278) were analyzed.  
Forty five percent of these CCP2-positive EAC sera appeared to be reactive with the 
citrullinated fibronectin peptide containing citrulline residues at positions 1035 and 
1036 (Figure 6B and Table 2). Only a small fraction of these early arthritis sera (4 %) 
displayed some reactivity with the corresponding arginine-containing peptide (Figure 
6B).  It is known that after disease onset ACPA isotype switching may occur 197. To 
investigate isotype switching of antibodies to citrullinated FN, 23 anti-FN-Cit1035,1036-
positive sera for which both samples taken at baseline and approximately 7 years after 
disease onset were available, were selected and analyzed in ELISA with isotype-specific 
(IgG, IgM and IgA) secondary antibody conjugates.  
Patient group n anti-FN-Cit1035,1036 positive Sensitivity (%) Specificity (%) 
Established RA
a
 82 41 50.0  
Early RA
a
 278 124 44.6  
Controls 186 3 1.6 98.4 
       non-RA 154 3 1.9 98.1 
       Healthy 32 0 0 100 
Figure 5. Anti-citrullinated fibronectin peptide antibodies 
in relation to anti-CCP2 positivity. The peptide set FN-
Arg/Cit1035,1036 was used to study the presence of anti-FN 
antibodies in anti-CCP2 positive (n=138) and anti-CCP2 
negative (n=28) RA sera. The broken line indicates the cut-
off value (mean + 2*SD of data obtained with normal 
human control sera); OD450 = optical density at 450 nm. 
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At baseline (t=0), 87% 
of the reactive sera 
contained 
immunoglobulins of the 
IgG isotype (Figure 7A), 
whereas 13% contained 
IgM (Figure 7C) and 4% 
contained IgA (Figure 
7E) type reactivities. 
After a median follow-
up time of 7 years (t=7) 
the frequency of IgG 
type antibodies to FN-
Cit1035,1036 was slightly 
decreased to 74% 
(Figure 6B). In these 
patients the frequency 
of IgM type anti- FN-
Cit1035,1036 antibodies decreased to 4% (Figure 7D) In contrast, at this stage the 
frequency of IgA type antibodies to this citrullinated FN peptide increased to 13% 
(Figure 7F). All IgM- and IgA-positive patients were also positive for IgG, whereas the 
simultaneous presence of IgM and IgA reactivities in the same patients was observed in 
one patient.  
Except for two patients, in which the IgG type anti-FN-Cit1035,1036 antibodies 
disappeared, the presence of these IgG antibodies did not markedly change in time 
(Figure 7G). 
Anti-citrullinated fibronectin peptide antibodies are associated with HLA SE alleles 
The HLA-DRB1*01, HLA-DRB1*04, HLA-DRB1*10 and HLA-DRB1*14 alleles comprise 
the group of HLA SE alleles, which are associated with RA 164. The reactivity to FN-
Cit1035,1036 was compared with the HLA-DRB1 alleles of the 278 early arthritis patients.  
The results showed that the presence of HLA SE alleles is associated w ith the 
production of anti-citrullinated fibronectin antibodies, because patients carrying HLA 
SE alleles are more than two times more likely to have autoantibodies against 
citrullinated fibronectin (OR = 2.11; Table 3). When addressing individual HLA-DRB1 
alleles, only HLA-DRB1*04 (OR =1.5), and HLA-DRB1*10 (OR = 1.57) showed a weak to 
moderate association with the presence of anti-FN-Cit1035,1036 antibodies. Although a 
more pronounced association was observed with HLA-DRB1*08 (OR = 2.45) and HLA-
DRB1*16 (OR = 2.43), these data should be interpreted with care because the carriage 
of these alleles is rare and the data are based on only a low number of patients (data 
not shown).  
Interestingly, a negative association was observed between the presence of anti-
citrullinated fibronectin antibodies and two additional HLA-DRB1 alleles, HLA-DRB1*09 
and HLA-DRB1*11 (OR = 0.19 and OR = 0.41, respectively). 
 
D 
Figure 6. Anti-citrullinated fibronectin peptide antibodies in early 
arthritis patient sera. (A) Sera from anti-CCP2-negative (n=23) and 
anti-CCP2-positive (n=24) early arthritis patients were analyzed in 
the FN-Cit1035,1036 ELISA. (B) Sera from anti-CCP2-positive early 
arthritis patients (n=278) were analyzed in the FN-Cit1035,1036 ELISA. 
The broken line indicates the cut-off value (mean + 2*SD of data 
obtained with normal human control sera); OD450 = optical density 
at 450 nm. 
. 
. 
 
A B 
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In addition, the potential relationship of smoking with the production of anti-
citrullinated fibronectin antibodies was assessed and a weak association was found (OR 
= 1.42; data not shown).  
We did not observe significant associations between the presence of anti-citrullinated 
fibronectin antibodies and clinical parameters such as VAS score, HAQ score, Ritchie 
index or swollen joint count at baseline (data not shown).  
 
 
 
 
 
 
 
 
 
Figure 7. Anti-FN-Cit1035,1036 antibodies are predominantly of the 
IgG isotype. Sera from a subset of anti-FN-Cit1035,1036-positive early 
arthritis patients (n=23) taken at baseline (t=0) and after a median 
follow-up of seven years later (t=7) were analyzed for different anti-
FN-Cit1035,1036  antibody isotypes in ELISA. (A)  IgG isotype reactivity 
at t=0. (B)  IgG isotype reactivity at t=7. (C) IgM isotype reactivity at 
t=0. (D) IgM isotype reactivity at t=7. (E)  IgA isotype reactivity at 
t=0. (F) IgA isotype reactivity at t=7 (G) Anti-FN-Cit1035,1036 IgG 
reactivity at t=0 and t=7. The broken lines indicate the cut-off values 
determined by normal human control sera.  
 
A B 
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E F 
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Table 3. Association of anti-citrullinated fibronectin antibodies and HLA-DRB1 alleles in anti-CCP2-positive 
early arthritis patients 
 
 
a 
Based upon information obtained from 240 RA patients. 
b
 Based upon information obtained from 270 RA 
patients. OR = odds ratio; 95% CI = 95% confidence interval. 
 
 
  anti-cit FN neg. (%)
a
 anti-cit FN pos. (%)
a
 OR  (95% CI) 
 
Smoking
b
 
 
- 
 
63 (46.7) 
 
40 (38.1) 
 
1.42 (0.85-2.39) 
+     72 (53.3) 65 (61.9) 
HLA SE alleles
c
 - 39 (26.5) 57 (14.6) 2.11 (1.13-3.92) 
+ 108 (73.5) 213 (85.4) 
Figure 8. Anti-FN-Cit1035,1036  in relation to other ACPA. 
The reactivity of EAC sera (n=228) with FN-Cit1035,1036 was compared with the presence of 
antibodies to other citrullinated peptides, which are derived from vimentin (1-16: 
STCitSVSSSSYCitCitMFGG and 59-74: VYATCitSSAVCitLCitSSVP), fibrinogen (α-fibrinogen 27-43: 
FLAEGGGVCitGPRVVERH; β-fibrinogen 36-52: NEEGFFSACitGHRPLDKK) and α-enolase (5-20: 
KIHACitEIFDSCitGNPTV. A. Fraction of patients recognizing 0 – 6 citrullinated peptides. B. Heat 
map showing the presence of antibodies to the citrullinated peptides obtained by an 
unsupervised cluster analysis. Red and green mark positive and negative sera, respectively. 
Missing values are depicted in grey. 
 
A 
B 
Citrullination: How subtle molecular changes affect loss of self-tolerance in rheumatoid arthritis 
122 
Chapter 6. Anti-citrullinated fibronectin antibodies in RA are associated with SE alleles  
 
 
DISCUSSION  
 
The analysis of citrullinated proteins in the synovial fluids of two rheumatoid arthritis 
patients revealed a.o. fibronectin as a multiply citrullinated protein in both patients. 
Two of the four synthetic peptides that were derived from the citrullinated regions of 
FN appeared to be reactive with ACPA in the sera of RA patients. The most frequently 
targeted FN peptide, FN-Cit1035,1036, which contains two adjacent citrullines, was 
recognized by 50% of established and 45% of early ACPA-positive RA patients. Like 
ACPA in general, anti-FN-Cit1035,1036 antibodies appeared to be associated with HLA-
DRB1 shared epitope alleles. 
FN is a complex protein, characterized by the presence of three types of repeats in its 
polypeptide sequence, for which many isoforms resulting from alternative splicing 
events have been described (Figure 1C).  
The UniProtKB database provides details of 15 isoforms, with isoform 1 (FN1 in Figure 
1C) as the canonical sequence. The overall sequence coverage of the mass 
spectrometry datasets relative to FN1 comprises 53% and 28% for both synovial fluid 
samples, respectively. It is likely that multiple FN isoforms are expressed in the 
inflamed synovia of RA patients and our data do not allow drawing conclusions on their 
relative abundance. Three regions of FN are especially prone to alternative splicing; at 
the protein level these are termed extra domain A (EDA), extra domain B (EDB) and 
type III connecting segment (IIICS).  
Although peptides were found that match part of the IIICS sequence, no peptides were 
detected for EDA and EDB.  
Moreover, a few peptides provide evidence for the absence of EDA and EDB in the 
isoform(s) they originate from, because their sequences covered the regions 
immediately N- and C-terminal from EDA or from EDB.  
The EDA domain, also designated EIIIA, has been implicated in inflammation, because 
it was shown to be involved in Toll-like receptor (TLR) 4 activation 198. Although our 
data do not support the presence of EDA-containing FN isoforms in the synovial fluid of 
RA patients, it has been demonstrated previously that EDA-containing FN is produced 
in the RA synovium and is expressed abundantly in RA SF 199. Moreover, recently 
Lefebvre and colleagues showed that EDA-containing FN stimulated leukotriene 
synthesis and  neutrophil recruitment via TLR activation in a mouse model  200. 
Although we could not detect any peptides in the EDA region, our data do not exclude 
the presence of EDA-containing FN isoforms in RA synovial fluid samples, because we 
have only analyzed a limited number of patients or because of technical limitations, 
such as ionization efficiencies.  
The interpretation of the data is further complicated by the fact that FN-derived 
peptides were found in material from many gel slices, which indicates a high 
heterogeneity of FN polypeptide lengths. It is likely that this is at least in part due to 
the presence of proteolytic enzymes in the synovial fluid from inflamed joints, which 
cleave the FN polypeptides in different fragments. It is known that during inflammation 
proteases are active in synovial fluid and can contribute to RA pathogenesis 
200
. 
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Indeed, the fragmentation of FN in inflammatory SF 201, as well as in cartilage of RA and 
osteoarthritis patients 
202
 has been reported previously.  
Our analyses identified 5 citrullinated residues in FN from RA patient SF. Except for two 
adjacent citrullines; these residues are found in distant regions of the FN polypeptide 
chain. Our data do not provide information on the extent to which these residues are 
citrullinated in RA SF and it is likely that differences between patients exist. This is 
substantiated by the observation that in material from RA2 for the region containing 
the two adjacent citrullines only one of these two residues (1035) was found to be 
citrullinated, whereas both were citrullinated in RA1. Two other studies have 
previously reported the presence of citrullinated FN in SF and synovial tissue of RA 
patients 
50;134
. However, these studies did not reveal the positions of the citrullinated 
residues. Our data do not exclude the possibility that FN is also citrullinated at other 
positions in RA SF, because material from only two patients was analyzed in detail and 
the sequence coverage was not more than 53%. Moreover, if citrullination enhances 
FN’s susceptibility to proteolytic cleavage, citrullinated peptides may have escaped 
detection as a result of cleavages by endogenous proteases that cleave the 
polypeptide close to the citrullinated residue. 
A synthetic peptide approach to investigate the recognition of citrullinated epitopes of 
FN by RA autoantibodies revealed that the major autoepitope is located in the region 
containing the two adjacent citrullines (amino acids 1035 and 1036). Only one of the 
other three citrullinated peptides was recognized by some RA sera.  
The fact that RA sera were only reactive with two of these peptides is consistent with 
the results of other studies showing that the amino acids flanking the citrulline residue 
contribute to the formation of auto-epitopes 31. 
Several studies 52;57;203 with synthetic citrullinated peptides (derived from vimentin, 
fibrinogen and alpha-enolase) showed that not all peptides containing citrullinated 
residues are recognized by patient sera, indicating that not only the citrulline is 
important, but also the amino acids surrounding the citrullinated residue. However, it 
should be noted that the use of synthetic peptides in general does not allow the 
identification of reactivities with conformational and/or discontinuous epitopes. 
Therefore, our data do not exclude the possibility that the citrullinated residues 
identified are part of conformational epitopes and that autoantibodies to these 
epitopes may be present in RA patient sera.  
Although autoantibodies to FN have been detected in RA as well as SLE patients before 
204
, our data are the first to describe antibodies that target FN in a citrulline-dependent 
manner. The autoantibodies that can be detected with the FN-Cit1035,1036 peptide 
represent a subset of ACPA, which is substantiated by the lack of correlation between 
the levels of reactivity with CCP2 and with FN-Cit1035,1036 (data not shown). 
 In total, 50% of the (anti-CCP2-positive) established RA patients showed reactivity to 
FN-Cit1035,1036, compared to two percent of the controls (non-RA and healthy 
individuals; Table 2). 
The possibility existed that the anti-FN-Cit1035,1036 subset of ACPA overlapped with 
another subset that has been identified previously, as a result of epitope similarities. 
ACPA fine-specificity data were available for most of the EAC patient sera.  
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The reactivity of these sera with FN-Cit1035,1036 was compared with their reactivity with 
two citrullinated peptides derived from vimentin (vimentin-1-16: 
STCitSVSSSSYCitCitMFGG; vimentin-59-74: VYATCitSSAVCitLCitSSVP), two peptides 
derived from fibrinogen (α-fibrinogen-27-43: FLAEGGGVCitGPRVVERH; β-fibrinogen-
36-52: NEEGFFSACitGHRPLDKK) and one peptide derived from alpha-enolase (alpha-
enolase-5-20: KIHACitEIFDSCitGNPTV) 
190
. These analyses showed that most of the EAC 
sera recognized multiple citrullinated epitopes (Figure 8A). A large overlap of anti-FN-
Cit1035,1036 with reactivities to any of the other peptides was observed, as might be 
expected from previous data 123;146. However, some sera appeared to react exclusively 
with FN-Cit1035,1036 and not with the other citrullinated epitopes (Figure 8B).  
These data are underscoring the large heterogeneity of the ACPA response in RA and 
indicate that the anti-FN-Cit1035,1036 antibodies are one of the most abundant ACPA 
subclasses that can be detected with synthetic peptides derived from citrullinated 
synovial proteins.  
Taken together, these data indicate that this citrullinated FN peptide may be used to 
investigate the fine-specificity of ACPA in more detail and may be complementary to 
other citrullinated molecules in ACPA profiling. 
The anti-FN-Cit1035,1036 antibodies present in early arthritis patients appeared to be 
predominantly of the IgG isotype. Only a small percentage of sera was found to contain 
IgM or IgA type anti-FN-Cit1035,1036 antibodies. After a median follow-up of seven years, 
the IgG type reactivities were hardly changed, whereas the prevalence of IgM reactivity 
against FN-Cit1035,1036 was decreased, and that of IgA was somewhat increased. 
Similar observations have been reported for samples from undifferentiated arthritis 
patients (who developed RA) taken either at baseline or after one year follow-up 188.  
It remains an open question whether the anti-citrullinated FN antibodies play a 
pathophysiological role. 
FN-containing immune complexes are likely to be formed in the inflamed joints of RA 
patients and this may occur already early during disease development. Further studies 
will be required to elucidate whether citrullinated FN is involved in the inflammatory 
process. 
The presence of anti-citrullinated FN antibodies in the early arthritis patients was 
associated with HLA SE alleles (OR = 2.11). Of the individual SE alleles, only HLA-
DRB1*04 and HLA-DRB1*10 showed a weak association with the presence of anti-
citrullinated FN peptide antibodies. Previously, Snir and co-workers demonstrated that 
antibodies against multiple citrullinated antigens (e.g. vimentin, fibrinogen, alpha-
enolase and the C1-epitope of type II collagen) were associated with SE alleles, 
particularly with HLA-DRB1*04 123;154. Our data show a negative association of HLA-
DRB1*09 and HLA-DRB1*11 with the presence of anti-citrullinated FN peptide 
antibodies (OR = 0.19 and OR = 0.41, respectively). This may be in agreement with the 
previously reported association of the HLA-DRB1*0901 haplotype with reduced levels 
of anti-CCP antibodies 205. Paradoxically, HLA-DRB1*09 has been reported previously to 
be associated with RA in Asian as well as Caucasian individuals 206;207. In addition, 
because ACPA-positive RA patients comprise a strong prevalence for SE-allelles, other 
HLA-DRB1 alleles are less frequently present than SE-alleles and seem to be protective. 
Citrullination: How subtle molecular changes affect loss of self-tolerance in rheumatoid arthritis 
125 
Chapter 6. Anti-citrullinated fibronectin antibodies in RA are associated with SE alleles  
 
 
Therefore the negative association observed with HLA-DRB1*09 and HLA-DRB1*11 
could also merely be the result of skewing 
208
. 
We did not detect a significant association between clinical phenotype and the 
presence of anti-citrullinated fibronectin in ACPA-positive RA patients.  Recently, 
Scherer and colleagues also observed no effect on radiographic joint damage in 
patients that were positive for several citrullinated epitopes 
189
. Nevertheless, a weak 
correlation between the presence of autoantibodies against citrullinated FN and 
smoking, a risk factor for ACPA generation, particularly in individuals that carry the SE 
alleles 36;181, was observed.  
In conclusion, five citrullinated residues were identified in fibronectin isolated from the 
inflamed joints of RA patients. An epitope containing two adjacent citrullines at 
positions corresponding to residues 1035 and 1036 appeared to be most frequently 
recognized by RA sera.  
Our data not only show that antibodies against citrullinated FN are present in RA 
patients, but also demonstrate that the anti-FN antibodies represent a subgroup of 
anti-CCP2 antibodies and that they can already be detected very early in the disease. 
Moreover, anti-FN-Cit1035,1036 antibodies are associated primarily with HLA SE alleles. 
 
MATERIALS AND METHODS 
 
Patient material  
Synovial fluid (SF) samples from RA patients were a kind gift from Prof. Dr. B. Bozic (Dept. of Rheumatology, 
University Medical Center, Ljubljana, Slovenia). After SF samples were obtained by joint punctures 
(arthrocentesis), using needles with a diameter from 1.6 to 2.2 mm, they were immediately centrifuged at 
2,500g for 10 minutes at 4°C to separate insoluble and soluble components into pellet and supernatant 
fractions, respectively.  
Supernatant and pellet fractions were separately stored at -80°C within two hours after taking the samples. 
The pellets were resuspended in EGTA lysis buffer (50 mM Tris-HCl, pH 7.4, 100 mM KCl, 1 mM DTE, 0.1% 
NP40, 10 mM EGTA, 0.5 mM PMSF and protease inhibitor cocktail). Supernatant fractions were diluted in 5 
volumes of EGTA lysis buffer.  
After sonification, SDS was added (final concentration 2%) and the fractions were heated and centrifuged at 
12,000g. Supernatants were used for further analysis. 
Sera from (established) rheumatoid arthritis (RA; n=110), systemic lupus erythematosus (SLE; n=31), and 
primary Sjőgren’s syndrome (pSS; n=31) patients were collected at the Department of Rheumatology of the 
University Medical Centre Nijmegen and the St. Maartenskliniek Nijmegen (The Netherlands).  
Sera from multiple sclerosis (MS; n=31) patients were collected at the MS Centrum Nijmegen (The 
Netherlands). Type 1 diabetes (T1D; n=32) sera were obtained from the Department of Immunohaematology 
and Blood Transfusion of the Leiden University Medical Centre (Leiden, The Netherlands).  
Early arthritis sera (EAC; n=301) were collected at the Department of Rheumatology of the Leiden University 
Medical Center (Leiden, The Netherlands) 
209
. Tuberculosis (TB; n=29) sera were collected at Department of 
Internal Medicine, Tel Aviv Medical Center, Israel. Sera from healthy individuals (NS; n=32) were collected at 
the Sanquin Blood Bank in Nijmegen. Sera were stored at -70°C until use.  
ACPA levels in RA sera were measured using a commercial CCP2 ELISA kit (Euro-Diagnostica A.B., Malmo, 
Sweden).  
These studies were approved by the local ethics committees; the need for patient consent was waived by the 
local ethics committees. 
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Sample preparation and tandem mass spectrometry analysis 
Two SF samples from RA patients, the supernatant fraction of one and the pellet of the other, were depleted 
of albumin as described by Colantonio and coworkers 
124
, separated by SDS-PAGE and stained with colloidal 
Coomassie Brilliant Blue. Each lane of the gel, containing material from an individual SF sample, was sliced 
into 18 pieces and the polypeptides in these gel slices were digested after the addition of 20 µl trypsin 
solution (15 ng/µl trypsin in 25 mM NH4HCO3 and 5 mM n-octylpyranoglucoside). Peptides were extracted by 
adding 50% acetonitril, 0.5% trifluoroacetic acid, 5 mM n-octylpyranoglucoside followed by sonication. The 
protein digests resulting from each of the gel slices were separately analyzed by nano-LC-MS/MS (using a 
LTQ Fourier Transform Ion Cyclotron Resonance mass spectrometer). Data was converted by BioWorks 
SEQUEST (Thermo Electron) into a peak list, which allowed peptide identification with the Mascot Search 
database. Additionally, citrullination sites were checked manually. Mass deviations for precursor ions were 
set to 20 ppm and deviations for the mass of fragment ions were set at 0.8 Da. Fixed modifications, besides 
citrullination, such as oxidation and methylation were taken along during the analysis.  
 
Synthesis of citrullinated fibronectin peptides 
Peptides (Table 1) were synthesized by a solid-phase procedure using Fmoc chemistry as described 
previously 
210
. The peptides were at least 90% pure as deduced from their elution pattern on reversed phase 
HPLC.  
 
Enzyme-linked immunosorbent assay 
Enzyme-linked immunosorbent assays (ELISA) with the fibronectin peptides were performed as described 
previously.  Briefly, each well of a microtiter plate (Streptawell, Roche) was coated with 1 μg biotinylated 
peptide in 0.1 ml PBS/0.1% BSA overnight at 4°C. After washing three times with PBST0.1 (PBS, 0.1% 
Tween20), wells were incubated with serum samples 100-fold diluted at in PBST0.05 (PBS, 0.05% Tween20) 
containing 1% BSA for 1 hour at 37°C. After incubation, plates were washed 3 times with PBST0.1, followed by 
an incubation at 37°C with HRP-conjugated goat anti-human IgG, IgM, IgA, kappa, lambda (DAKO) or with 
either HRP-conjugated rabbit anti-human IgG, rabbit anti-human IgM or rabbit anti-human IgA (DAKO). 
Bound antibodies were detected by the conversion of 3,3’,5,5’-tetramethylbenzidine (TMB) and, after 
terminating the reaction by the addition of sulfuric acid, the absorbance was measured at 450 nm. Cut-off 
values were determined as the mean value plus two times the standard deviation of normal human control 
sera. 
ACPA fine specificity ELISA assays using peptides derived from citrullinated vimentin, fibrinogen and alpha-
enolase were performed as described previously 
145;190
.  
Statistics 
A two-tailed unpaired t-test with a CI of 95% was used to observe differences in reactivity between RA sera 
and non-RA sera with respect to the citrullinated peptides. 
Univariate logistic regression analyses were performed for testing the association between several single risk 
factors (SE alleles as well as smoking) and anti-citrullinated fibronectin peptide antibodies in early arthritis 
patients. A Mann-Whitney U test was performed to address associations with the clinical phenotype (HAQ 
score, VAS score, swollen joint count and Ritchie index) of the early arthritis patients. 
 
LIST OF ABBREVIATIONS  
 
ACPA, anti-citrullinated protein antibodies; CBB, coomassie brilliant blue; CCP, cyclic citrullinated peptide; CI, 
coincidence interval; EAC, early arthritis clinic; FN, fibronectin; HAQ, health assessment questionnaire; HLA, 
human leukocyte antigen; LC-MS/MS, liquid chromatography - tandem mass spectrometry; 
 LTQ, linear trap quadrupole; MS, multiple sclerosis; NS, normal sera; OR, odds ratio; PAD, peptidylarginine 
deiminase; pSS, primary Sjogren's syndrome; RA, rheumatoid arthritis; RF, rheumatoid factor; SE, shared 
epitope; SF, synovial fluid; SLE, systemic lupus erythematosus; TB, tuberculosis; T1D, type 1 diabetes; VAS, 
visual analog scale 
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INTRODUCTION 
 
Rheumatoid arthritis (RA) is a common autoimmune disease, which affects 
approximately 1% of the population. It is generally accepted that upon a probably 
environmental trigger in genetically susceptible individuals the development of RA can 
be initiated. This may lead to a joint inflammation and the infiltration of immune cells, 
particularly macrophages and neutrophils. These cells produce “first-line” cytokines 
(such as TNF-α), which promote autoimmunity and which in turn will activate other 
immune cells to produce “secondary” cytokines that maintain chronic inflammation in 
the synovial joint and ultimately lead to cartilage destruction. These cytokines can be 
considered as the driving force behind the chronic inflammation that is observed in RA, 
because these cytokines act on different cell types (vascular endothelial cells, 
osteoclasts, synovial fibroblasts and hematopoietic cells) that are involved in the 
pathogenesis. Until now, there is no treatment to cure RA 211. Therefore, there is a 
great need to identify potentially therapeutic targets that function as key-players in the 
pathogenesis of RA. Plasma membrane-associated proteins studied here include two 
members of the signaling lymphocyte activation molecule family, SLAMF7 (also known 
as CS1, CRACC and CD319) and SLAMF8 (also known as BLAME) and a member of the 
ABSTRACT – In this study the goal was to identify novel genes involved in the 
pathophysiology of rheumatoid arthritis (RA). 
RNA was isolated from synovial tissue from RA patients and was analyzed using 
human genome array and quantitative reverse transcription-polymerase chain 
reaction techniques. Recombinant proteins were expressed and purified and used 
to select single chain antibody fragments from phage display libraries. The 
expression of the corresponding proteins was studied by western blotting, 
immunohistochemistry and fluorescent-activated cell sorting. The effect of the 
recombinant proteins on the activation of peripheral blood mononuclear cells was 
assessed by a multiplexed cytokine immunoassay.  
SLAMF7, SLAMF8 and ADAM28 mRNAs were found to be upregulated in the 
synovium of RA patients. Single chain variable fragments directed against SLAMF7, 
SLAMF8 and ADAM28 were generated. The antibody fragments recognized the 
cognate proteins in western blotting, in IHC and in flow cytometry on the surface of 
peripheral blood mononuclear cells. The activation of these cells by the 
extracellular domains of SLAMF7, SLAMF8 and ADAM28 was studied by IL-10, IL-13, 
IL17 and IFN-γ secretion. Incubation with SLAMF7 or SLAMF8 resulted in elevated 
levels of IL-10 production. 
RA is associated with the increased expression of SLAMF7, SLAMF8 and ADAM28 in 
the inflamed synovium. Signaling through SLAMF7 and SLAMF8 may play a role in 
the pathophysiology of RA by stimulating the production of IL-10 by peripheral 
blood mononuclear cells. 
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ADAM (a disintegrin and metalloprotease domain) family, ADAM28 (also known as 
MDCL).  
SLAM family members belong to the plasma membrane-associated immunoglobulin 
superfamily. So far, nine SLAM proteins have been identified, which show differences 
in their expression on the surface of hematopoietic cells 212. SLAMF7 is known to be 
expressed on natural killer (NK) cells, (a large subset of) CD8+ and (a small subset of) 
CD4+ T-lymphocytes and B-lymphocytes 
212;213
. SLAMF7 signals via Ewing’s sarcoma-
activated transcript-2 (EAT-2) and EAT-2 related transducer (ERT) acting on the 
downstream signaling mediators phospholipase Cγ1 (PLCγ1), phospholipase Cγ2 
(PLCγ2), and phosphatidylinositol 3-kinase (PI3K), which are implicated in NK cell-
mediated cytotoxicity and B-cell proliferation 
214;215;216
. Activating (e.g. NK-cells) as well 
as inhibitory functions (e.g. T-lymphocytes) have been observed for SLAMF7 
216;217
. 
Interestingly, SLAMF7 has been reported to serve as a self-ligand 216;216. Less is known 
about SLAMF8. SLAMF8 contains a cytoplasmic domain devoid of any signaling motifs. 
It is known that SLAMF8 is expressed by B-lymphocytes, dendritic cells (DCs) and 
activated monocytes 
218
. ADAM28 is mainly expressed by lymphocytes (and to a lesser 
extent by macrophages/monocytes and neutrophils) and can bind to integrin α4β1 
219;220. This will result in lymphocyte adhesion (via vascular cell adhesion molecule-1; 
VCAM-1) and lymphocyte migration 220. Furthermore, ADAM28 has been suggested to 
be involved in several cancers 220;221;222 and  in arthritis (proteoglycan degradation) 222.  
The elevated expression of SLAMF7, SLAMF8, and ADAM28 in the RA synovium 
prompted us to analyze the possible role of these proteins in the pathophysiology of 
RA in more detail.  
 
RESULTS 
 
Identification of differentially expressed genes in RA  
Total RNA was isolated from synovial tissue of RA and OA patients as well as from 
control individuals, which did not have any inflammatory disease. After cDNA synthesis 
(using T7(dT)24
 
primer) and generation of biotinylated cRNA (using T7 RNA polymerase 
and biotin-labeled ribonucleotides), microarrays (U133Plus 2.0  oligonucleotide arrays 
from Affymetrix) were probed with the cRNAs. The results showed that 31 genes 
showed elevated expression levels in synovial tissue of RA (and OA) patients (Table 1). 
Three of these genes were selected for further studies based upon the available 
information on their biological activities and plasma membrane association. SLAMF7, 
SLAMF8 and ADAM28 were upregulated in RA patients compared to control individuals 
and compared to OA patients. In addition, SLAMF7, SLAMF8 and ADAM28 appear to be 
more expressed in RA patients with a higher disease activity (RAhigh) compared to RA 
patients with lower disease activity (RAlow) (Table 1). The differential expression of 
these genes was verified by qPCR using gene-specific primers. GAPDH served as a 
reference gene for the normalization of expression levels. The results confirmed that 
the mRNA levels of SLAMF7, SLAMF8 and ADAM28 were strongly upregulated in RA 
patients compared to control individuals (Figure 1). 
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 Table 3. Differentially expressed genes in synovial tissue  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Numbers indicate fold change in mRNA expression. Positive values refer to upregulated genes and negative 
values to downregulated genes. RA = rheumatoid arthritis; RAhigh= RA patients with high disease activity; 
RAlow= RA patients with low disease activity; C = healthy individuals; OA = osteoarthritis. 
 
Gene Symbol RA vs. C OA vs. C RA vs. OA RAhigh vs. RAlow 
POSTN 15.32 11.09 1.38 -3.14 
MMP9 13.82 24.24 -1.75 -2.92 
MMP13 12.33 25.94 -2.1 -1.91 
IL8 11.94 11.54 1.03 4.18 
TREM1 10.86 11.47 -1.06 1.24 
TNFRSF17 9.6 -1 9.65 16.11 
SLAMF8 8.79 2.58 3.41 3.51 
ADAMDEC1 8.61 -1.24 10.65 15.81 
CXCL10 8.46 -1.13 9.58 10.71 
SLAMF7 7.82 1.27 6.14 14.54 
CXCL6 7.79 2.36 3.3 5.02 
CXCL9 7.64 -1.84 14.08 15.36 
TNFSF11 7.31 10.47 -1.43 -2.13 
BCL2A1 7.28 3.52 2.07 2.01 
EMR2 6.17 1.79 3.45 4.01 
ADAM28 5.9 1.61 3.68 5.98 
CXCL3 5.64 5.73 -1.02 2.84 
KCNN4 5.54 7.84 -1.42 -2.02 
CCL20 5.46 2.27 2.4 3.09 
TNFRSF10D 5.35 6.63 -1.24 -5.15 
CKS2 5.1 5.08 1 -1.48 
SLC11A1 5.01 3.37 1.49 1.32 
GZMK 4.02 -1.5 6.04 12.9 
CFB 3.47 1.88 1.85 2.8 
CR1 3.41 1.42 2.41 9.51 
PSMB9 2.91 1.22 2.39 2.41 
MAPK13 2.68 2.62 1.02 1.19 
GZMB 2.28 2.73 -1.2 3.16 
PSMB8 2.24 1.26 1.78 2.15 
CDKN1A 2.18 3.42 -1.57 -1.41 
STK38==NDR1 1.86 1.64 1.13 1.28 
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Generation of scFvs against SLAMF7, SLAMF8 and ADAM28 
SLAMF7, SLAMF8 and ADAM28 are single-pass type I membrane proteins. In addition, 
for ADAM28 a soluble (or secreted) isoform has been described. The latter, sADAM28, 
is known to be secreted by lymphocytes 220. The extracellular domains of these 
receptors were chosen for further studies, a.o. the generation of single-chain antibody 
fragments to these domains. To this 
end, cDNAs encoding the extracellular 
domains were cloned and expressed as 
GST- and His-tagged proteins in E. coli.  
To generate single-chain antibody 
fragments (scFvs) the recombinant 
proteins were used to screen naïve scFv 
phage display libraries. After 3 selection 
rounds with alternating GST- and His-
tagged proteins, a significant increase in 
phage titer was observed. Individual 
clones were further screened for full-
length inserts with PCR. Reactive clones 
were digested with a multi-cutter to 
discriminate between distinct clones. 
After the selection of individual clones 
with full-length inserts, two distinct 
scFvs were obtained for SLAMF7 
(indicated with A4 and A5), as well as 
one scFv for each of SLAMF8 and 
ADAM28. The specific binding of these 
scFvs to the cognate antigens was 
confirmed by monoclonal phage ELISA 
(data not shown). After stabilization of 
the scFvs (by fusing them to a mouse Cκ 
domain, also containing a VSV-G-tag 
and a His-tag), the specificity of these 
scFvs was further explored by western 
blotting. All 4 scFvs recognized both the 
GST- and His-tagged versions of the 
proteins that were used for their 
selection. Their specificity was 
substantiated by the lack of reactivity 
with any of the other recombinant 
proteins (Figure 2).  
 
SLAMF7, SLAMF8 and ADAM28 are expressed in the RA synovium 
To investigate the expression of SLAMF7, SLAMF8 or ADAM28 in the synovium of RA 
patients at the protein level, paraformaldehyde-fixed tissue sections were incubated 
with the scFvs and immunohistochemically stained.  
Figure 1. SLAMF7, SLAMF8 and ADAM28 mRNA 
are upregulated in RA. RNA samples isolated from 
synovial membrane biopsies from RA patients and 
control individuals (C) were subjected to 
quantitative RT-PCR using primers specific for 
SLAMF7 (A), SLAMF8 (B) and ADAM28 (C). 
Expression levels are normalized based upon 
GAPDH expression levels. AU: arbitrary units. 
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As a positive control a scFv generated 
simultaneously against IL-7R ( chain) 
was taken along, because previously the 
IL-7 signaling pathway was identified to 
play an important role in RA 
pathogenesis, mainly in lymphoid 
neogenesis 223 and IL-7R has been found 
to be upregulated in the RA synovium 
compared to the synovium from OA 
patients 
224
. SLAMF7 (Figure 3A and B), 
SLAMF8 (Figure 3C and D) and ADAM28 
(Figure 3E and F) protein expression was 
observed in several cells present in the 
RA synovium. Staining with the scFv 
against IL-7R resulted in a similar 
staining pattern, with the highest levels 
of expression in a restricted number of 
specific cells (Figure 3G).  
To obtain more information about the 
cell types that are SLAMF7-, SLAMF8- 
and/or ADAM28-positive, tissue 
sections were stained with antibodies to 
several marker molecules, including CD3 
(T-lymphocyte marker), CD20 (B-
lymphocyte marker), and CD68 
(monocyte/macrophage marker). Both 
CD3 and CD20 staining was relatively 
abundant in the synovial tissue sections 
(Figure 3H and I, respectively). 
Incubations with the anti-CD68 
antibody, however, did not result in any 
staining (data not shown). These results 
suggest that the cells displaying the 
highest levels of SLAMF7, SLAMF8 and 
ADAM28 expression in these tissues are not lymphocytes.  
 
 
 
 
 
 
 
Figure 2. Reactivity of scFvs with SLAMF7, 
SLAMF8 and ADAM28. The recombinant His- and 
GST-tagged extracellular domains of SLAMF7, 
SLAMF8 and ADAM28 were separated by SDS-
PAGE and either stained by Coomassie Brilliant 
Blue (CBB) or transferred to nitrocellulose. The 
resulting western blots were stained with the 
scFvs. The positions of molecular weight markers 
are indicated on the left. 
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White blood cells express 
SLAMF7, SLAMF8 and 
ADAM28 at their cell 
surface                             In 
spite of the fact that our 
immunohistochemical data 
do not support high 
SLAMF7, SLAMF8 and 
ADAM28 expression by RA 
synovial lymphocytes, 
SLAM family members 
(including SLAMF7 and 
SLAMF8) have been 
reported previously to be 
expressed by T- and B-
lymphocytes, NK cells, DCs  
and macrophages, whereas 
ADAM28 was found in T- 
and B-lymphocytes 219;220.  
To investigate whether the 
scFvs bind to the cognate 
plasma membrane-
associated proteins first a 
human lymphoblastoid cell-
line (Jurkat) was used and 
the binding was assessed 
by flow cytometry. The 
Jurkat cells could be divided 
into three sub-populations, 
the reason for which is not 
clear yet (Figure 4A). The 
relative abundance of each 
sub-population was not 
significantly affected by the 
incubation with scFvs 
(compare Figure 4B with 
Figure 4C-4F).  
 
 
 
 
 
 
 
Figure 3. Immunolocalization of SLAMF7, SLAMF8 and ADAM28 
in RA synovial membrane. Synovial tissue sections of RA patients 
were incubated with the scFvs against SLAMF7 (A and B) SLAMF8 
(C and D) ADAM28 (E and F) and IL-7R (G) and visualized by 
immunohistochemical staining. T- and B-lymphocytes were 
stained with anti-CD3 (H) and anti-CD20 (I) antibodies, 
respectively.  Sections incubated with only the secondary antibody 
were analyzed as a control (J). Sections were counterstained with 
hematoxylin. The insets show higher magnifications of the regions 
indicated by arrows.  
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Each of the scFvs resulted in increased fluorescence (Figure 4C-E) compared to cells not 
incubated with a scFv (Figure4B) or cells incubated with a control scFv (directed to the 
cytosolic histidyl-tRNA synthetase; Figure 4F).  
This suggested that scFvs directed to SLAMF7, SLAMF8 and ADAM28 indeed recognize 
the corresponding proteins on the surface of these cells. 
 
Next leukocytes from a healthy individual were used to address the recognition of 
SLAMF7, SLAMF8 and ADAM28 on the cell surface by the scFvs. Also with PBMC, at 
least three populations of cells could be discerned; two sub-populations displaying 
relatively defined features (red and green in Figure 5A) and a third sub-population 
representing the residual cells. Most likely these sub-populations correspond to 
lymphocytes, monocytes and granulocytes, respectively.  
Figure 4. The scFvs recognize SLAMF7, SLAMF8 and 
ADAM28 on the cell surface of Jurkat cells. Flow 
cytometric analysis of Jurkat cells (A: forward (FSC) 
and side (SSC) scatter) stained with scFvs directed to 
SLAMF7 (C), SLAMF8 (D), ADAM28 (E) or to histidyl-
tRNA synthetase (F) and anti-mouse Alexa-fluor 488 
(FL-1). B shows the results for the incubation with the 
secondary antibody only. The three colors correspond 
to the three sub-populations identified in panel A. 
 
 
 
Figure 5. SLAMF7, SLAMF8 and ADAM28 are 
expressed on the cell surface of peripheral blood 
mononuclear cells. Flow cytometric analysis of PBMC 
(A: forward (FSC) and side (SSC) scatter) stained with 
scFvs directed to SLAMF7 (D), SLAMF8 (E) and 
ADAM28 (F) and anti-mouse Alexa-fluor 488 (FL-1). B 
shows the results obtained with cells not incubated 
with any antibody. C shows the results for the 
incubation with the secondary antibody only. Black, 
red and green correspond to the three sub-
populations identified in panel A. 
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Each of the scFvs appeared to lead to enhanced fluorescent staining of all 
subpopulations, indicating that the scFvs do recognize the corresponding proteins on 
the cell surface and that these proteins are indeed present on the cell surface of 
(subsets of) PBMC. 
 
SLAMF7 and SLAMF8 induce IL-10 production in white blood cells 
In spite of the fact that the expression of SLAMF7, SLAMF8 and ADAM28 in PBMC is 
well documented 214;220;225, their ligands and/or substrates are not well defined.  
The SLAMF receptors might serve as self-ligands 216. To investigate whether signaling 
via the SLAMF7 and SLAMF8 receptors might play a role in RA, PBMC were incubated 
with the recombinant extracellular domains of these receptors and the activation of 
the cells was assessed by measuring the production of IL-10, IL-13, IL-17 and IFNγ. As a 
positive control, the cells were stimulated with PMA/ionomycin. It has been described 
that PMA with or without ionomycin can stimulate the production of these cytokines in 
PBMC (IL-10, IL-13 and IFNγ) 
226;227
 and T-lymphocytes (IL-17) 
24
. Stimulation of PBMC 
with PMA/ionomycin did not lead to a significant increase in IL-13, IL-17 and IFNγ 
production (data not 
shown), whereas a 
strong increase in IL-
10 levels was 
observed. Similarly, 
PBMCs incubated 
with either 
recombinant His-
SLAMF7 or His-
SLAMF8 displayed a 
massive increase in IL-
10 secretion (Figure 
6), and no detectable 
effects on the 
production of the 
other cytokines (data not shown). Enhanced IL-10 production was not observed when 
PBMCs were incubated with recombinant His-ADAM28, which served as a negative 
control. 
 
DISCUSSION 
 
Previously, several genomic profiling studies have been performed to identify novel 
players in the pathogenesis of RA 
223;228;229;230
. In the present study a microarray-based 
genome-wide transcriptome analysis identified 31 upregulated genes in the RA 
synovium. These genes may represent putative novel therapeutic targets for RA. The 
mRNA of three of these genes (SLAMF7, SLAMF8 and ADAM28) was observed to be 
upregulated in RA patients compared to healthy controls and OA patients and their 
elevated expression levels appeared to correlate with the disease activity.  
Figure 6. Enhanced IL-10 production by PBMCs stimulated with 
SLAMF7 or SLAMF8. PBMCs were incubated with either 
PMA/ionomycin, recombinant His-SLAMF7, His-SLAMF8 or His-ADAM28. 
Cytokine production was measured after overnight culturing by a 
Luminex-based addressable bead system. Only the results for IL-10 are 
shown. The experiment was performed in duplicate and the error bars 
represent the range with regard to the mean. 
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Although these proteins were known to be expressed by inflammatory cells, it was 
unknown whether they might be involved in the pathophysiology of RA 
214;220
. 
SLAMF7 is a member of the signaling lymphocyte activating-molecule family 
212
.  
SLAMF7 is thought to play a  role in NK cell activation and induces B-cell proliferation 
and cytokine production 212.  
It has also been reported that SLAMF7 is expressed by a subset of T-cells (CD4
+
CD28
-
), 
which is more abundant in chronic inflammatory diseases such as RA 
216
. SLAMF8 is 
also known to play a role in B-cell signaling 212. ADAM28 belongs to the gene family of 
disintegrins and metalloproteinases and, although ADAM28 has been implicated in 
several cancers, little is known about the biological function of this protein 
222;231
. 
Nevertheless, it is known that several metalloproteinases are associated with joint 
destruction and disease activity 
231
. ADAM28 plays a role in cartilage destruction in OA  
and therefore the higher expression of ADAM28 in RA compared to OA suggests this 
may be true in RA as well.  
The scFvs generated against these proteins were used to detect SLAMF7, SLAMF8 and 
ADAM28 in synovial tissue sections of RA patients, which demonstrated that the 
highest levels of expression of each of these proteins, was observed in only a limited 
number of cells which were randomly distributed in the synovial tissue. In spite of the 
fact that SLAMF7, SLAMF8 as well as ADAM28 have been reported to be expressed by 
lymphocytes, staining of the sections by lymphocyte markers strongly suggested that 
the most intensively stained cells are not lymphocytes. Llinàs and co-workers 
previously managed to detect SLAMF7 expression in B-lymphocytes by 
immunohistochemistry, although the signals were weak. With flow cytometry they 
found SLAMF7 in 60-80% of the T– and B–lymphocytes. In the latter study SLAMF8 was 
not detected by immunohistochemistry and was found in only 20% of the B-
lymphocytes and none of the T-lymphocytes by flow cytometry 232. De Salort and 
coworkers reported that SLAMF7 was highly expressed in B-lymphocytes, although its 
expression decreased during maturation of these cells 233. Because the maturation 
status of the B-cells in the RA synovium was not taken into account, the possibility 
exists that this has affected our results. In this regard it is also important to note that 
the B-lymphocyte marker used, CD20, is not expressed by the cells in the relatively late 
stages of maturation (plasmablasts or plasma cells) 234. More research will be required 
to uncover the identity of the cells in the synovium that are most intensively stained by 
the scFvs and to investigate whether or not their target proteins are expressed by 
lymphocytes infiltrated in the synovium of RA patients.  
Stimulation of PBMC with PMA/ionomycin did not lead to increased IL-13, IL-17 and 
IFNγ levels, which is not in line with the results of previous reports 226;227;235.  
The lack of induction of the secretion of these cytokines is not due to a general lack of 
cell stimulation, because IL-10 production was strongly enhanced. Similar observations 
were made after stimulation of PBMC with the extracellular domains of SLAMF7 and 
SLAMF8. Our data are consistent with previous observations pointing to a relationship 
between SLAM signaling and IL-10 production. Baev and colleagues showed that SLAM 
provides co-stimulatory signals needed for the secretion of IL-10. Moreover, they 
demonstrated that defective SLAM signaling underlies the development of 
autoimmunity in non-obese diabetic mice 
236
.  
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Furthermore, anti-SLAM monoclonal antibodies increased the production of IL-10 by in 
vitro activated synovial fluid mononuclear cells of RA patients 
237
.  
IL-10 is an anti-inflammatory cytokine, which acts as a crucial mediator during an 
immune response.  
It has been shown that IL-10 can inhibit the synthesis of proinflammatory cytokines 
(e.g. TNFα, IL-1, and GM-CSF), as well as HLA class II expression by human monocytes 
stimulated with LPS 
238
. IL-10 is produced by several cell types including subsets of T-
lymphocytes (Th1, Th2 Th17 and Treg cells), B-lymphocytes, NK cells, dendritic cells 
(DCs) and monocytes/macrophages, and is involved in the regulation of the immune 
response (reviewed by 
239;240
). Furthermore, it is known that IL-10 production by 
macrophages (and DCs) can be induced by pathogens (or pathogen-derived molecules) 
241
, and in T-lymphocytes IL-10 production is dependent on strong T-cell receptor (TCR) 
triggering (high antigen concentration) 242. Taken together, these data strongly suggest 
that SLAMF7 and SLAMF8 signaling in T-cells is involved in regulating the immune 
response by up-regulating IL-10 expression.  
Our data support a role for SLAMF7, SLAMF8 and possibly also ADAM28 in the 
pathophysiology of RA. Many questions, however, remain with regard to the 
mechanism and consequences of their activation, the mode of signal transduction, the 
molecular and cellular effects and the way in which this affects the disease process.  
  
MATERIALS AND METHODS 
 
Patient material 
Synovial tissue samples (9 biopsies from RA patients, 2 biopsies from osteoarthritis (OA) patients and 5 
biopsies from healthy individuals) were taken during surgery or by fine-needle arthroscopy under camera 
supervision.  The tissue samples were stored at the tissue bank under liquid nitrogen till further processing. 
Sera from RA patients were collected at the Department of Rheumatology of the Radboud University 
Nijmegen Medical Centre. Sera from patients with other autoimmune diseases (systemic lupus erythematosus 
and multiple sclerosis) were collected at the Department of Rheumatology of the Radboud University 
Nijmegen Medical Centre (systemic lupus erythematosus, SLE) and at the MS Center Nijmegen (multiple 
sclerosis, MS).  
 
RNA isolation and oligonucleotide array 
Total RNA was isolated from synovial tissue and purified with an affinity resin (RNeasy Kit for fibrous tissues, 
Qiagen) according to the manufacturer’s instructions. Quantity and purity were assessed by using a NanoDrop 
2000c (Thermo Scientific, Wilmington, USA) and an Agilent 2100 bioanalyzer (Santa Clara, CA, USA) according 
to the manufacturer’s instructions. Total RNA was stored at -80°C until further processing.  
100 ng of total RNA was used as starting material for cDNA preparation. Generation of biotinylated cRNA and 
subsequent hybridization to U133Plus 2.0 oligonucleotide arrays (Affymetrix, Santa Clara, CA),  washing and 
staining were performed according to Affymetrix Expression Analysis Technical Manual for two-cycle 
amplification 
243
. The arrays were then scanned using a GeneChip®Scanner (Affymetrix) and analyzed by 
using Affymetrix GeneChip Operating Software (GCOS version 1.4) according to the manufacturer’s 
instruction. 
 
High level analysis of oligonucleotide array 
Array normalization, expression value calculation, clustering and principal component analysis were 
performed using DNA-Chip Analyzer version 1.3 
244
 (www.dchip.org). The Invariant Set Normalization method 
and the model-based method were used for computing expression values. These values were expressed as 
mean and standard errors. Criteria of >2-fold expression and significance at p<0.05 were applied for the 
comparison unless stated otherwise.  
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Quantitative RT-PCR 
RNA samples were reverse transcribed by using oligo-dT primers and MMLV reverse transcriptase. Primers 
were designed with Primer Express (Applied Biosystems, Foster City, CA) and synthesized by Biolegio 
(Malden). Quantitative (q)PCR was performed using the ABI/Prism 7000 sequence detection system (Applied 
Biosystems, Foster City, CA) using
 
10 ng cDNA and SYBR Green Master mix. 
 Quantification of the PCR signals was
 
performed by comparing the cycle threshold value (Ct) of the gene of 
interest of each sample with the Ct values of
 
the reference gene GAPDH (Ct), and expressed as 2
-Ct 
multiplied by arbitrary factor. Fold change is calculated as the mean ratio between the relative transcript 
levels. The sequences of primer sets used are  
SLAMF7-forward: 5’-ACACAATCCCTCACACTAATAGAACAA-3’, 
SLAMF7-reverse: 5’- ATTTCCACAGTGGAGTAAACCGTAT-3’, 
SLAMF8-forward: 5’- TGTGGCCTATTCCTGCATTG-3’, 
SLAMF8-reverse:  5’- GCGTGACTGTGGCCAAGTC-3’, 
ADAM28-forward: 5’-TTGCAAGTGTCCTTCTACAATATGTG -3’, 
ADAM28-reverse: 5’- GCGTGACTGTGGCCAAGTC -3’, 
GAPDH-forward: 5’-TTCCCCATGGTGTCTGAGC-3’ and 
GAPDH-reverse: 5’-ATCTTCTTTTGCGTCGCCAG-3’ 
 
RT-PCR, cloning and recombinant protein expression 
Specific cDNAs were generated by a PCR approach using reverse transcribed mRNA isolated from a synovial 
tissue biopsy of an RA patient as starting material. The oligonucleotides used for the generation of cDNAs are 
SLAMF7-forward: 5’-CACCATGAAGCAAGTTGACTCTATTGTC-3’,  
SLAMF7-reverse: 5-CTAGGAGGAAATCTGGGTCATCAGC-3’, 
SLAMF8-forward: 5’-CACCATGCGTGAGGCTATCTGG -3’ 
SLAMF8-reverse: 5’-TTACTTTGTAGGAGGCCTTCCCTG-3’ 
ADAM28-forward: 5’-CACCATGTTGCAAGGTCTCCTG -3 and 
ADAM28-reverse: 5’- TCCTTTGACCATGGTTAAACACTG -3’ 
The SLAMF7, SLAMF8 and ADAM28 cDNAs were cloned into the pENTR/TEV/TOPO vector according the 
manufacturer’s protocol (Gateway, Invitrogen). For bacterial expression, cDNAs were subsequently 
transferred to the pDEST15 (N-terminal GST-tag) and pDEST17 (N-terminal His-tag) vectors by recombination 
according to the protocol provided by the manufacturer (Invitrogen). Fusion proteins were expressed in 
Bl21(DE3)pLysS after induction with 0.4 mM IPTG. The proteins were purified using glutathione-Sepharose 
4B and Ni-NTA beads, respectively. 
Phage display 
For phage display, human single fold scFv libraries I and J (Tomlinson I and J) (Cambridge, UK) were used. 
These libraries comprise over more than 100 million scFv fragments, which are cloned in the pIT2-phagemid 
vector.  Selection rounds were performed according to the manufacturer’s protocol. In short, 10 μg/ml of 
fusion proteins, using alternating GST- and His-tagged proteins, were coated to the surface of a tube (NUNC) 
and incubated with phages with a titer of 10
12
-10
13 
cfu/ml in 2% MPBS (panning or selection round).  After 
each round of panning (three rounds in total, the non-binders were washed away and the bound phagemids 
were eluted and amplified by infection of TG1 cells. After each round, the titer of eluted phages (in cfu) was 
determined, a polyclonal phage ELISA and colony PCR were performed, to detect an enrichment in titer and 
the presence of full insert, respectively. Individual clones were picked from the phage titration plates and 
used for a PCR approach using primers LMB3, 5’-CAGGAAACAGCTATGAC-3’, and FdSeq1, 5’-
GTAACGATCTAAAGTTTTGTCG-3’, to detect full-length inserts. After three rounds monoclonal scFvs were 
screened for binding and then used for further analysis. 
To discriminate between distinct scFvs, positive clones were digested with the multi-cutter Bst-NI and 
separated on a 4% agarose gel. Positive clones were stabilized by cloning the phagemid constructs into the 
PUC119-vsv-his-Cκmouse vector.  
 
ELISA with soluble antibody fragments 
Two µl of overnight cultures of individual clones were transferred to another 96 wells plate containing 100 µl 
2xTY medium supplemented with 100 µg/ml ampicilin and 0.1% glucose. This plate was grown until OD600 ~ 
0.9. scFv were produced by induction with 1 mM IPTG and overnight culturing. 
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For scFv ELISA the supernatants obtained by centrifugation were used followed by detection with anti-myc-
tag (1:20 in 3%BSA/PBS) and HRP-labeled goat anti-mouse immunoglobulins (1:2000 in 3% BSA/PBS, DAKO). 
Bound antibodies were detected by the conversion of 3,3’,5,5’-tetramethylbenzidine (TMB) and absorbance 
was measured at 450 nm. 
 
 
Western blotting 
Recombinant proteins were separated by SDS-PAGE and transferred to nitrocellulose membranes. Dot blots 
were generated by spotting 5 µl of patient serum on nitrocellulose membranes. The blots were blocked in 
blocking buffer (5% non-fat dried milk and 0.1% NP40 in PBS) for 1 hour at room temperature. Subsequently 
blots were incubated with the scFv of interest (1:10) in blocking buffer for 1 hour at room temperature. After 
washing with blocking buffer proteins were detected with a HRP-conjugated antibody, followed by 
chemiluminescence.  
 
Immunohistochemistry 
Synovial tissue sections (6 μm) were fixed with 4% paraformaldehyde, treated for 15 minutes with 3% H2O2 in 
methanol, washed with PBS and incubated with 20% normal sheep serum, 1% BSA in PBS prior to incubation 
with the scFv for 1 hour at room temperature. After washing with PBS, sections were incubated for 1 hour at 
room temperature with HRP-conjugated antibody (DAKO), directed towards the kappa domain, 500-fold 
diluted in 1% BSA/PBS. The sections were developed for 10 minutes using 0.5 mg/ml diaminobenzidine in 50 
mM Tris-HCl, pH 7.6 and 0.035% H2O2 and counterstained with hematoxylin. Finally, sections were 
rehydrated and embedded in Permount. 
 
Fluorescence-activated cell sorting (FACS)  
Leukocytes were isolated using a Ficoll gradient. In short, heparinized blood was diluted twice with PBS-
citrate and added on top of a Ficoll cushion. After centrifugation for 20 min at 500g, PBMC (peripheral blood 
mononuclear cells) were collected from the interphase and washed several times with PBS. PMN 
(polymorphonuclear) cells were collected by resuspending the pellet, after removal of residual Ficoll, in lysis 
buffer (155 mM NH4Cl, 10 mM KCO3, 0.1 mM EDTA, pH 7.3). Erythrocytes were lysed for 10 min and washed 
with PBS. Lysis was performed twice, until the majority of the red blood cells were removed.  
Leukocytes or Jurkat cells (human T-cell lymphoblast-like cell-line) were grown in RPMI 1640 medium 
supplemented with 10% FCS, 1% sodium pyruvate and 1% penicillin-streptomycin (Gibco). After washing 
with PBS 0.5*10
6
 cells were taken up in 1 ml 1% sodium azide/PBS. Cells were then incubated with scFv, in 
3% BSA/PBS for 1 hour at room temperature. After washing with PBS, cells were incubated with Alexa-fluor 
488 labeled anti-mouse IgG antibody for 30 minutes. After washing with PBS, cells are taken up in 1% 
paraformaldehyde/PBS prior to visualization of the stained cells using a Becton Dickinson FACScan flow 
cytometer. The flow cytometry data were analyzed using the WinMDI program. 
 
PBMC activation assay 
PBMC were isolated and cultured as described above for 1 hour. The cells were subsequently cultured 
overnight at 37°C in the presence or absence of a stimulus, 25 ng/ml phorbol 12-myristate 13-acetate (PMA), 
1.5 μM ionomycin (Sigma) or 50 ng/ml His-tagged recombinant protein (the extracellular domains of 
SLAMF7, SLAMF8 and ADAM28).  
IL-10, IL-13, IL-17 and IFN-γ levels were measured using commercially available kits (BioSource International, 
Camarillo, California, USA) according to the manufacturer’s instructions. Cytokine levels were measured and 
analyzed with the Bio-Plex system (Bio-Rad: Hemel Hempstead, UK ). 
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ABBREVIATIONS 
 
ADAM, a disintegrin and metalloprotease domain; DCs, dendritic cells; EAT-2, Ewing’s sarcoma-activated 
transcript-2; NK cells, natural killer cells; OA, osteoarthritis; PBMC, peripheral blood mononuclear cells; PMA, 
phorbol 12-myristate 13-acetate; PMN, polymorphonuclear leukocytes; RA, rheumatoid arthritis; scFv, single 
chain variable fragment; SLAM, signaling lymphocyte activation molecule 
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Partially based upon:  
 
 Walther J. van Venrooij, Joyce J.B.C. van Beers, Ger J.M. Pruijn. Nature Reviews 
Rheumatology; 2011,  7 (7): 391-398. 
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In 1800, rheumatoid arthritis (RA) was first described by the French surgeon Augustin 
Jacob Landré-Beauvais (1772–1840). Since then a lot of research has been performed, 
but after two centuries still many aspects of the pathogenesis of RA remain unclear. It 
has been shown that multiple factors, cells and processes are involved in the 
pathogenesis of rheumatoid arthritis (RA) making it a difficult disease to treat (Figure 
1) 
33;55;151;245;246;247;248;249;250;251;252
.  
The research described in this thesis is focused on one specific part of RA, namely the 
finding that patients suffering from RA produce antibodies directed to peptides and 
proteins containing citrulline (anti-citrullinated protein/peptide antibodies, ACPA), a 
modified form of the amino acid arginine 
5
. The citrullinated proteins present in the 
synovial joint of RA patients and the B-cell response towards these autoantigens 
leading to the formation of ACPA are addressed in the previous chapters of this thesis.  
 
Figure 1. The RA cycle and its key players. An inflammation (of the joint) will lead to an infiltration of 
immune cells (Step 1), which contain PAD enzymes. After PAD activation (Step 2), due to a rise in the 
intracellular calcium concentration during cell death (Step 1), proteins can be citrullinated. The 
apoptotic cell will normally be removed by neighboring phagocytic cells. However, when the number of 
dying cells is too high or when there is a defect in clearance of apoptotic cell remnants, the cells may 
become necrotic and release their contents into the extracellular space. PAD enzymes will then also 
citrullinate extracellular proteins (Step 2). In a small percentage of individuals citrullinated proteins may 
be exposed to the immune system eliciting an immune response and ACPA may be formed (Step 3). This 
ultimately will result in immune complex formation (Step 4), followed by an up-regulation of pro-
inflammatory cytokines (Step 5), which are regarded as the driving force of the chronic inflammation 
that is typical for RA. Several factors that can affect the RA cycle are depicted in italics. 
 
 
 
Citrullination: How subtle molecular changes affect loss of self-tolerance in rheumatoid arthritis 
146 
Chapter 8. General discussion 
 
 
Current RA diagnosis - Is the CCP2 test as good as it gets? 
Currently, RA is diagnosed according to criteria defined by a joint working group of the 
ACR (American College of Rheumatology) and the EULAR (European League Against 
Rheumatism). Due to the widespread usage of the CCP2 test and other ACPA tests in 
routine settings, this serologic parameter was recently included in the 2010 
Rheumatoid Arthritis Classification Criteria. In this new classification system 
parameters were selected that are detectable at early stages of disease, rather than 
defining the disease by its late-stage features as was done in the 1987 ACR criteria 18. 
Since it is likely that these new classification criteria will be rapidly adopted in daily 
practice 
17
, it is important to know which ACPA test is best suited for the clinician. 
According to literature the CCP2 test is still recognized as the golden standard of ACPA 
testing 
11;12
. The CCP2 peptide(s) used in these tests is of synthetic nature. Ideally, one 
would like to have a diagnostic test based upon citrullinated peptides or proteins that 
are present in the inflamed RA joint and thus represent natural ACPA targets. 
In recent years several new ACPA tests have become commercially available (MCV, 
CCP3 and other). In some publications ACPA tests have been mentioned as being 
somewhat more sensitive (for example the anti-MCV test) 12;153;253 than the CCP2 test. 
However, in such cases the test almost always shows a lower specificity as well 16;184. 
The application of a number of new ACPA targets, ApoE (ApoE-Cit198), MNDA (MNDA-
Cit127,129), beta actin (beta actin-Cit196,206,210) or FN (FN-Cit1035,1036), in ELISA 
demonstrated that these displayed higher specificities but lower sensitivities when 
compared to the commercially available CCP2 test (Table 1). These data suggest that 
the natural ACPA targets can be useful for the analysis of ACPA heterogeneity and fine-
specificity, but that for the most sensitive detection of any ACPA reactivity the CCP2 
peptides(s) are preferred despite the lack of similarity to a natural ACPA target. 
 
Table 1. The specificity and sensitivity of the anti-citrullinated protein autoantibodies discussed in this 
thesis compared to anti-CCP2 
 
a 
Only the most frequently targeted peptide of each protein (ApoE-Cit198; MNDA-Cit127,129; beta-actin-
Cit196,206,210; FN-Cit1035,1036) was used to determine these data. 
b 
Accumulated data from 188 studies published 
between 2002 and March 2012. 
 
 
It is difficult to compare commercial diagnostic tests from different companies, 
because each company maintains their own conditions to determine cut-off values.  
Diagnostic tests should be compared only at stratified conditions (e.g. comparison of 
sensitivities at a fixed clinical specificity) to obtain clear and comparable results.  
Citrullinated peptide(s)
a
 Specificity 
(%) 
Sensitivity 
(%) 
 
CCP2
b
 
 
95 
 
70 
 
Apolipoprotein E 
 
96 
 
27 
Myeloid nuclear differentiation antigen 97 16 
Beta-actin 98 27 
Fibronectin 98 46 
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In agreement with our findings, several published articles showed that when 
comparing different commercial ACPA tests, at a stratified specificity, none of the 
presently available commercial ACPA tests has a higher sensitivity than the CCP2 test 
15;16;185;254;255;256. 
In Chapter 6 it was shown that sera from anti-CCP2-positive RA patients show different 
reactivities towards different citrullinated peptides. This is not a novel phenomenon, 
because it was already shown by Ioan-Facsinay and co-workers that anti-CCP2 
antibodies are a collection of ACPA and that ACPA target numerous citrullinated 
proteins and not a specific antigen 187.  Moreover, sera from patients with higher ACPA 
levels can recognize more citrullinated epitopes 
257
.  
So, although individual testing of ACPA directed to peptides derived from either ApoE, 
MNDA, beta-actin or fibronectin shows lower sensitivities, these peptides might be 
useful in a multiplex assay, such as iSPR, for testing ACPA fine-specificities and 
identifying ACPA profiles that might be clinically meaningful.  
 
The ACPA response   
In our RA cycle hypothesis (see Figure 1 and 160) we postulated that active PAD 
enzymes (and citrullinated cellular proteins) are released when the apoptotic clearance 
mechanism fails to remove the dying cell remnants in time. It can be speculated that 
the released citrullinated proteins may function as the first citrullinated antigens to be 
seen by the immune system. The released and activated PAD enzymes will, in addition, 
citrullinate many other arginine-containing proteins in the synovium, leading to the 
exposure of an additional array of citrullinated peptides to the immune system. The 
resulting diversification of the ACPA pool is an early step in the RA cycle and occurs 
before the disease is clinically recognized.  
Recent studies seem to confirm most steps of this RA cycle. Jansen and coworkers have 
described the predictive value of ACPA in early arthritis 258. Moreover, Van der Woude 
and colleagues showed that epitope spreading of the ACPA response occurs before 
disease onset with an increase in the number of citrullinated antigens recognized. 
Furthermore, they showed that this extensive recognition pattern of different 
citrullinated peptides by patients who present with undifferentiated arthritis is 
associated with rapid disease progression to RA in the first year of follow-up 146. The 
recognition of multiple citrullinated antigens is only observed in anti-CCP2-positive RA 
154. This is in agreement with the observations described in this thesis. In the synovial 
fluid of RA patients, 53 different citrullinated proteins were identified and in each of 
the 5 citrullinated proteins (fibronectin, fibrinogen, ApoE, MNDA and beta-actin) that 
were studied in detail citrullinated B cell epitopes were identified (Figure 2). 
Nevertheless, only a subset of citrullinated regions of these proteins was efficiently 
recognized by ACPA from RA patients. The question remains why so many citrullinated 
proteins are present in the RA SF and why certain citrullinated proteins elicit an 
immune response. This is likely at least in part due to the promiscuous nature of PAD 
enzymes and the selectivity of the HLA molecules. 
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Figure 2. The ACPA response is 
heterogeneous. 
Overview of the citrullinated residues 
(indicated by asterisks) identified in 6 proteins 
(fibronectin (FN), fibrinogen alpha-chain 
(Fiba), vimentin (Vim), ApoE, MNDA and beta-
actin) by mass spectrometry in the 
experiments described in Chapter 3. Several 
synthetic citrullinated (X) and the 
corresponding control (R) peptides (the 
relative position of which is indicated by lines) 
were used to detect citrulline-dependent 
autoantibody reactivity in RA sera by ELISA, 
the results of which are indicated by the 
graphs (for a selected number of peptides). 
Only the citrulline-dependent reactivities are 
depicted in this graph. 
 
 
 
Citrullination: How subtle molecular changes affect loss of self-tolerance in rheumatoid arthritis 
149 
Chapter 8. General discussion 
 
 
PAD4 has been demonstrated to be associated with RA in Asian populations and the 
susceptibility alleles have been suggested to lead to an increase of the production of 
citrullinated proteins/peptides, resulting in an enhanced risk of disease development 
107.  
An association between PAD4 and RA in Caucasians still remains inconclusive, because 
the data are contradictive 
259;260;261
. Nevertheless, we have detected elevated levels of 
citrullinated fibrinogen peptides present in RA SF compared to SF from patients 
suffering from other inflammatory diseases affecting the joints. It is not clear, whether 
these peptides were citrullinated by PAD4 or by another PAD isotype.  
Recently, some insight into the substrate specificities of individual PAD isotypes has 
been obtained 
248;262
. Clear differences between the arginine-containing amino acid 
sequences preferred by PAD2 and PAD4 were observed. These data are substantiated 
by a study of Knuckley and colleagues, who showed that amino acid substitutions 
differentially affect the citrullination of peptides by individual PAD enzymes 
263
.  
When the citrullinated peptides identified by mass spectrometry in SF samples from RA 
patients (Chapter 3) were compared, it was observed that certain amino acids tend to 
be present more often than would be expected based upon their natural occurrence 
(Figure 3A). When the overrepresented amino acids were compared with citrullinated 
sequences from different proteins (fibrinogen, vimentin, alpha-enolase, fibronectin, 
ApoE, MNDA and beta-actin) 146;154, one citrullination site of the fibrinogen alpha chain 
and one vimentin stood out. Four and three amino acids, respectively, of these 
sequence elements match overrepresented amino acids, whereas both lack 
underrepresented amino acids (Figure 3B). Interestingly, this fibrinogen sequence 
contains residue 591, which is present in a region known to be targeted by 
autoantibodies 52;152.   
The relative frequency of amino acids flanking citrullinated residues in synovial fluid 
proteins was compared with similar data obtained with experiments addressing the 
substrate specificity of PADs 248;264 to investigate whether this gives a clue which PAD 
enzyme(s) is (are) important in generating citrullinated epitopes in RA. Not all of 
these studies provide sequences preferred by PADs, but they indicate that 
differences between optimal substrates for distinct PAD isotypes do exist 264;265. 
Assohou-Luty and colleagues showed that certain amino acids occur at least two-fold 
more frequently at the respective positions in citrullination sites than their natural 
occurrence for both PAD2 and PAD4 248. A comparison of the amino acids 
overrepresented at each position (–5 to +5) in RA SF with the preferred amino acids 
detected by Assohou-Luty and coworkers, suggested that both PAD2 and PAD4 are 
involved in the citrullination of synovial proteins (Figure 3C). 
It is important to note that several members of the HLA-DRB1 family (the so-called SE-
alleles; HLA-DR4 and HLA-DR1, HLA-DR10 and HLA-DR14) are associated with RA and 
that negatively charged peptides are better recognized by these SE-alleles, which 
contain a net positively charged binding pocket 37. Of the 105 citrullinated sequences 
found in RA SF 53% contained a net negative charge, 29% a net positive charge and 
18% were not charged at all. This suggests that negatively charged peptides are 
citrullinated more easily than positively charged or neutral peptides.  
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Based upon these observations we conclude that the citrulline-specific immune 
response in RA not only depends on the amino acid sequence of the target protein, but 
also on the net charge of the targeted region.  
 
Environmental and genetic factors associated with ACPA-positive RA – What makes 
some individuals susceptible for RA? 
Citrullinated proteins are not specific for RA 
32
. Normally, citrullinated proteins do not 
elicit an immune response, but in about 1% of the population this does occur. The 
production of ACPA is thought to be strongly dependent on the genetic background of 
the patient. Several genetic factors have been associated with RA, such as PTPN22 and 
the already mentioned HLA SE-alleles.  
Figure 3 Citrullinated residues in SF proteins from RA patients. (A) Schematic overview of flanking 
amino acids that are over- or underrepresented at each position (–5 to +5 with respect to the citrulline 
residue) in synovial proteins of RA patients. The percentage of each amino acid at each position was 
compared with its natural occurrence. Overrepresented amino acids occur more than 2 times their 
natural occurrence; underrepresented amino acids occur less than 0.5 times their natural occurrence. 
(B) Residues of citrullinated proteins that were identified in the studies described in Chapters 3 and 4, 
corresponding to overrepresented amino acids are marked in green; residues corresponding to 
underrepresented amino acids in red. X: citrulline. The score was derived from the combination of over- 
and underrepresented amino acids. (C) The over- and underrepresented amino acids (green and red, 
respectively) flanking citrullination sites in synovial fluid proteins were compared with preferred amino 
acids of PAD2 and PAD4 in different experimental systems as indicated .  
 
 
 
A 
B 
C 
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Hill and collaborators demonstrated that the conversion of arginine to citrulline at the 
peptide side-chain position interacting with the SE significantly increases peptide-HLA 
affinity and leads to the activation of CD4
+
 T cells in transgenic mice expressing the RA-
associated MHC class II molecule DRB1*0401 (DR4-IE tg mice) 38.  
A few years later these authors showed that citrullinated fibrinogen (citFib) is able to 
induce arthritis in these transgenic mice, in contrast to unmodified fibrinogen or in the 
corresponding wild-type mice 
151
. Recently, James and collaborators confirmed and 
extended these findings 266. In these studies they did not determine which citrullinated 
residues are responsible for the induction of arthritis. Hill and colleagues used 
citrullinated fibrinogen in their study, which most likely contains comparable 
citrullinated residues as those identified in Chapter 4, some of which are highly 
reactive with RA sera. Besides fibrinogen peptides, B-cell responses against several 
peptides derived from other proteins (vimentin, alpha-enolase, collagen type II and 
fibronectin) have been associated with HLA-DRB1 SE-alleles 
154
 (Chapter 6). It can be 
concluded that the SE alleles significantly increase the chance of developing ACPA 
154;267
.  
As already mentioned above, the PAD4 gene has also been associated with RA in some 
(mainly Asian) populations 107. In addition, PAD4 is an autoantigen, because 
autoantibodies against PAD4 have been detected in RA and appeared to be associated 
with disease severity 268. 
Besides genetic factors, environmental factors play a role in the development of RA. A 
proposed risk factor is smoking 
33;182
, which may trigger the ACPA response 
182
. In 
agreement with this, a weak association between anti-citrullinated fibronectin peptide 
antibodies (Chapter 6) and smoking was observed. This finding is consistent with 
observations made by Willemze and co-workers, which recently suggested that 
smoking promotes citrullination of proteins in a relatively non-specific way rather than 
citrullination of specific antigens 190. 
The involvement of other genes (e.g.TRAF1-C5, CTLA4, STAT4, TNFAIP3) and 
environmental factors (e.g. mineral oil, silica exposure) in the pathogenesis of RA has 
been suggested 180;183;269, but requires further investigations.  
Interestingly, all known genetic risk factors are associated with anti-CCP2-positive 
disease with the exception of the HLA-DR3 allele (also part of the HLA-DRB1 family), 
which is associated with CCP2-negative RA 270. This supports the subdivision of RA 
patients in at least two clinically distinct subgroups: anti-CCP2-positive and anti-CCP2-
negative RA. 
 
What is the role of citrullinated autoantigens and ACPA in the RA synovium? 
Although several citrullinated antigens have been described so far (e.g. fibrinogen, 
vimentin, alpha-enolase, fibronectin), until now their role in RA pathogenesis is still not 
fully understood. Citrullinated fibrinogen has been the most extensively studied 
citrullinated protein 30;52;152. Several citrullinated residues of human fibrinogen had 
been identified before we initiated our studies 155;156 and a number of these were 
found to be important for the recognition of fibrinogen by autoantibodies 52;55;123;133.  
In most studies synthetic peptides 
52;155
 or in vitro citrullinated recombinant human 
fibrinogen 
156
 were/was used.  
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Our studies identified several citrullinated residues for the first time in RA SF samples 
(Chapter 3 and 5). In addition, in Chapter 4 we have mapped 26 novel citrullinated 
residues in human fibrinogen after in vitro citrullination with human PAD2 and PAD4.  
Taken together, these data show that fibrinogen can be extensively citrullinated by 
PAD enzymes and that fibrinogen belongs to the most highly citrullinated proteins in 
RA SF. 
The RA associated B-cell response efficiently targets citrullinated fibrinogen 
52;152
 
(Chapter 4), Evidence for the arthritogenic capacity of citrullinated fibrinogen comes 
from experiments in animal models; citrullinated fibrinogen induced arthritis in mice 
55;151
. In RA patients, citrullinated fibrinogen has been detected in immune complexes, 
which are important in maintaining the chronic inflammatory response in RA 
56;133
, 
most likely because they are able to activate macrophages to produce cytokines 
56
. 
Cytokines are the driving force behind RA chronicity by activating immune cells and 
pathways (JAK-STAT) that can ultimately lead to apoptosis. These findings suggest a 
prominent role for fibrinogen in RA pathogenesis. Fibrinogen is a central player of the 
coagulation cascade and it has been suggested that these proteins have 
proinflammatory properties and in this way may contribute to RA pathogenesis as well  
132. During coagulation fibrinogen is converted to fibrin and fibrin deposits form a 
pathological hallmark in RA 30.  
Citrullinated fibronectin (FN) is present in synovial tissue and synovial fluid (SF) of RA 
patients 50;134 (Chapter 3). We have identified its citrullinated residues in RA SF and 
investigated the presence of autoantibodies against these citrullinated FN epitopes in 
RA patients. As described above a fraction of ACPA is directed to citrullinated FN. 
Interestingly, 2% of RA patients appeared to be reactive with only the citrullinated 
fibronectin peptide (FN-Cit1035,1036), whereas they did not recognize citrullinated 
peptides derived from vimentin, fibrinogen and alpha-enolase. Therefore, anti-
citrullinated FN peptides may have additional value for diagnostics and patient 
classification. Like citrullinated fibrinogen, citrullinated FN has been detected in pannus 
tissue and in immune complexes present in sera of RA patients 191. Moreover, FN might 
play a role in articular cartilage destruction, because it has been observed that FN 
fragments can stimulate the production of multiple mediators of matrix destruction, 
such as various cytokines and metalloproteinases 193;194. 
The other well-documented citrullinated antigens in RA are vimentin 28 and alpha-
enolase 49. In case of vimentin, especially the B-cell response towards a specific 
citrullinated region (using peptide VYATCitSSAVCitLCitSSVP, comprising amino acids 59-
74) has been extensively studied. Autoantibodies against this peptide have been 
observed in RA patients (RA SF), were found to be present in immune complexes  and 
are associated with the shared epitope (SE) allele HLA-DRB1*04 42;154. It has also been 
demonstrated that T-lymphocytes play an important role in the immune response to 
citrullinated vimentin in mice as well as in humans 57 . Moreover, the vimentin gene 
has been reported to be mutated in some RA patients (at the codons for amino acid 
residues 16, 59 and 147; in all cases glycine to arginine; arginine 147 can be 
citrullinated), which gives rise to an even more antigenic protein 253. Our studies 
identified citrullinated vimentin for the first time in RA SF.  
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Because our experiments did not detect sequences of the N-terminal 100 amino acids 
of vimentin it is not possible to compare our data with those mentioned above, except 
for position 147, at which indeed a glycine residue was found in RA SF.  
The absence of sequences corresponding to the first 100 amino acids of vimentin was 
also observed in mass spectrometry experiments performed by Tilleman and 
coworkers 
135
, who analyzed extracts from synovial tissue samples and suggested that 
this might be due to cleavage by caspase-3, as indeed has been suggested before 
271
.  
Citrullination of vimentin may result in the disassembly of the vimentin filaments, as 
for example observed in the presence of a calcium-ionophore in cultured cells (mouse 
peritoneal macrophages). This can then lead to shapeless citrullinated vimentin 
clusters around the nucleus of a cell, which may trigger chromatin condensation and 
DNA fragmentation, which can ultimately lead to apoptosis 
272
. These events can lead 
to the citrullination of both intra- and, after leakage from the dying cells, extracellular 
proteins (Figure 1). 
Citrullinated alpha-enolase was first identified by Kinloch and colleagues 
49
. It was 
detected in RA SF 
137
 and RA-specific autoantibodies against citrullinated alpha-enolase 
peptide (CEP-1) have been found as well 203;203;273.  It has been suggested that anti-
citrullinated alpha-enolase antibodies are associated with both smoking as well as HLA-
DRB1 SE alleles 154;273. However, no significant differences in clinical or radiological 
outcomes were observed between the CEP-1-negative/CCP2-positive and CEP-1-
positive/CCP2-positive patients 274.  
Alpha-enolase is a glycolytic enzyme and in RA synovial cells an increase of glycolysis is 
observed. The increased glycolysis activity may trigger, via enzymes and products of 
the glycolysis pathway, autoimmunity (via alpha-enolase) 275, angiogenesis (via pyruvic 
acid) 276, tissue destruction via metalloproteinases (via glucose-6-phosphate isomerase 
or GPI) 277 and apoptosis (possible link between glycolysis and apoptosis) 278, which are 
the main features of RA pathogenesis. Citrullination of alpha-enolase might alter its 
function and may increase its antigenicity 49. Interestingly, we have identified 
citrullinated isoforms of additional glycolytic enzymes in RA SF, glyceraldehyde-3-
phosphate dehydrogenase and pyruvate kinase (Chapter 3). It remains to be 
investigated whether the citrullination of glycolytic enzymes contributes to the 
pathophysiology of RA and whether also the latter enzymes are targeted by ACPA. 
Although alpha-enolase was found to be present in RA SF, evidence for its citrullination 
was not obtained. This does, however, not exclude the possibility that alpha-enolase 
can be citrullinated in RA SF, because material from only 2 patients was analyzed and 
the sequence coverage was only 46%.  
The proteomic analysis of SF from RA patients showed that in addition to the known 
citrullinated proteins mentioned above, many other polypeptides are citrullinated. 
Some of these, apolipoprotein E (ApoE), myeloid nuclear differentiation antigen 
(MNDA), beta actin and cyclophilin A (CypA), were found in material from both of the 
patients that were analyzed (Chapter 3). An indication that ApoE might play a role in 
RA came from a recent study in which collagen-induced arthritis (CIA) was shown to 
lead to an enhanced autoimmune response in ApoE-deficient mice 279.  
It is tempting to speculate that the inflammation-associated citrullination of ApoE 
results in similar effects.  
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However, a role for ApoE in the immune response in RA is not supported by data 
published by Asquith and coworkers, who found that ApoE-/- mice are resistant to CIA 
139
.   
MNDA is a member of the p200 or HIN-200 protein family, which can be induced by 
interferon and interferons are known to play a central role in both the innate and 
adaptive immune responses 
141
. Furthermore, other p200 family members have been 
implicated in autoimmune diseases 
142
. Currently, it is unknown whether (citrullinated) 
beta-actin could play a role in RA. It is likely that beta-actin citrullination affects 
microfilament formation, which may be important for apoptotic events in the inflamed 
joints. 
CypA belongs to the family of peptidyl-prolyl cis-trans isomerases, which are involved 
in protein folding. CypA can upregulate metalloproteinase 9, which contributes to 
cartilage and bone destruction in RA patients 143 and may also act as a cytokine in 
inflammation 
144
. Further research will be required to investigate whether citrullination 
of CypA affects these activities.  
Although up to now only citrullinated fibrinogen, fibronectin and vimentin have been 
found in immune complexes in RA, our data show that most, if not all, citrullinated 
proteins in inflamed joints are targeted by ACPA and thus may contribute to immune 
complex formation, which in turn will keep the chronic inflammatory response going 
(Figure 1). 
The future – What is needed to improve the diagnosis and treatment of RA?  
With the inclusion of ACPA/anti-CCP2 into the new 2010 Rheumatoid Arthritis 
Classification Criteria 18, citrullination and its role in the pathophysiology of RA will 
remain an important topic for further studies, which will be focused on different 
aspects of protein citrullination, ACPA production and autoantibody testing. 
(1) The test. Although the CCP2 test may remain the golden standard of ACPA testing 
for the next few years, new ACPA tests based upon additional citrullinated 
autoantigenic proteins may be developed to differentiate between clinically distinct RA 
patient subgroups 273. Antibodies to citrullinated antigens (e.g. fibrinogen, vimentin 
and alpha-enolase) are almost exclusively found in anti-CCP2-positive RA 123;133;203. We 
have also observed that autoantibodies to FN, ApoE, MNDA and beta-actin are 
predominantly observed in anti-CCP2-positive RA.  
A promising new approach is to analyze ACPA isotype profiles and changes therein 
after treatment. In this respect it is interesting to note that low and intermediate pre-
treatment levels of ACPA appear to be associated with a more favorable response to 
methotrexate treatment in recent onset, anti-CCP-positive arthritis, whereas high 
levels are associated with an insufficient response 280. ACPA profiles could be identified 
by using multiplex assays (e.g iSPR), in which multiple citrullinated antigens are tested 
simultaneously instead of one individual citrullinated antigen per test. 
Another group of modified proteins that could be incorporated in multiplex assays are 
carbamylated proteins. Carbamylation is a post-translational modification, in which 
peptidyllysine is converted into peptidylhomocitrulline and which has recently been 
demonstrated to play a role in the autoimmune response 281. Homocitrulline differs 
from citrulline by an extra methylene group.  
Citrullination: How subtle molecular changes affect loss of self-tolerance in rheumatoid arthritis 
155 
Chapter 8. General discussion 
 
 
Carbamylation occurs spontaneously when the urea concentration rises (e.g. in renal 
dysfunction) or is mediated by the enzyme myeloperoxidase, which is released from 
white blood cells (neutrophils) during inflammation and which produces cyanate that 
can react with lysine resulting in homocitrulline. We have detected myeloperoxidase in 
the SF of both RA patients that were analysed in detail, suggesting that carbamylation 
may be a common phenomenon in inflamed joints. Recently, Shi et co-workers 
observed that antibodies against carbamylated proteins are present in RA sera and 
that these antibodies can predict joint damage 282. It remains to be investigated which 
proteins are carbamylated in the RA synovium and if anti-carbamylated protein 
antibodies (anti-carP) are specific for RA or represent a more general feature of 
inflammation.  
(2) Test standardization. In the context of the new ACR/EULAR criteria it is becoming 
increasingly important to standardize the available ACPA tests. Currently, CCP2 test kits 
are made by several companies. Although they all use the same antigen(s), the CCP2 
kits may differ sometimes in sensitivity, even at stratified specificity (for example the 
INOVA CCP2 test shows significant lower sensitivity at stratified specificity than other 
commercial CCP2 tests) 255, and have different cut-off values. We believe that these 
discrepancies can be solved at least in part by including an internal serum standard 
(available via the Center for Disease Control and Prevention in Atlanta) in the test. That 
may also lead to a more optimal distinction  between low and high ACPA levels, which 
is important for the 2010 Rheumatoid Arthritis Classification Criteria 18. 
(3) Improving treatment and diagnosis.  All the steps involved in the citrulline-
dependent chronic inflammation which we refer to as the RA cycle 283  have now been 
experimentally proven. Therefore we can assume that the successive steps in the RA 
cycle probably describe the major immunological events in RA. Each step of the RA 
cycle (Figure 1), though, has its own characteristics and variations. For example, 
environmental factors and hormones may influence the first three steps, and non-
human PAD enzymes may be involved in the first two steps, as suggested by Venables 
and collaborators 284. Besides environmental factors, genetic factors, such as the SE 
alleles are associated with step 3.  
The RA cycle may give us clues for the development of new therapeutic strategies. 
Most present day treatments (biologicals, methotrexate) are directed to step 5, i.e. to 
achieve a decrease of the inflammation and cytokine production. Other approaches 
intervene with step 3 by lowering antibody production via B-cell depletion therapy 11;12. 
Recently, it was suggested that there could be subtle differences between the 
production of ACPA and the production of antibodies against pathogens. This may 
provide an explanation why the current B-cell depletion therapies are not sufficient 
and a different B-cell targeting approach is needed. 
Ongoing and future research will lead to a better understanding of the role of ACPA in 
RA chronicity and possibly new targets for treatment that are based on protein 
citrullination and the anti-citrullinated protein response. In view of the specificity of 
this response for RA, therapeutic strategies aimed at the citrulline-steps of the RA cycle 
may be more specific and thus arguably less prone to side effects than the currently 
applied therapies which target more general factors of inflammation.  
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An obvious approach would be to block extracellular PAD activity (step 2) by applying a 
PAD2/PAD4 inhibitor. PAD4 inhibitors have been described previously 
285;286
 and were 
shown to reduce collagen induced arthritis (CIA) in a mouse model 
287
. These data 
suggest that interfering with protein citrullination or blocking the formation of 
citrulline-dependent immune complexes may indeed be an effective approach for the 
development of future therapies. Nevertheless, it is important to keep in mind that 
PAD enzymes are widely expressed and interfering with their activity might have 
serious side-effects. The differences in substrate-specificity of the various PAD isoforms 
suggests that isotype-specific inhibitors might be generated and their local 
administration may diminish side-effects to acceptable levels.  
The knowledge that ACPA can differentiate between two subgroups of RA patients 
raises the question whether a specific, non-citrulline dependent immune response is 
associated with the ACPA-negative group. Future research should be aimed at the 
identification of autoantibodies that may be specifically produced by this patient 
group. It is tempting to speculate that in this group also the immune response is 
directed to epitopes that are generated in terminally differentiated or dying cells and 
that also in this case specific HLA alleles are associated with the immune response to 
these epitopes. Padyukov and coworkers have indeed recently observed that ACPA-
positive and ACPA-negative RA display  differences in the association of HLA risk alleles 
. In this regard, the possibility that the ACPA-negative group is not a single, but a 
combination of several distinct groups instead should also be acknowledged.  
In conclusion, although many citrullinated RA autoantigens have been described by us 
and by other researchers, it still remains unclear why these proteins are “selected” for 
modification. It is likely that sequence and charge are important for a candidate 
autoantigen to become citrullinated and presented to the immune system and the 
importance of environmental and genetic factors for the immune response in RA has 
been firmly established. Nevertheless, it is clear that the ACPA response is very 
heterogeneous and differs among individual RA patients. Therefore, identifying ACPA 
profiles and analyzing their association with clinical features, rather than looking at the 
ACPA-positive RA patients as one group, may facilitate the subclassification of patients 
and may aid the development of “patient-tailored” therapies in the future. 
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Rheumatoid arthritis (RA) is a common autoimmune disease, which is characterized by 
chronic inflammation of the synovial joints. Approximately 1% of the human population 
is affected by RA and the incidence in women is higher than in men. Several risk factors 
have been identified so far, of which the so-called shared epitope alleles (genes of the 
HLA-DRB1 family) and smoking are the most well-known. 
The adaptive immune response in RA is characterized by the production of 
autoantibodies to immunoglobulin G, designated rheumatoid factor, and to 
citrullinated proteins. The latter anti-citrullinated protein antibodies (ACPA) are very 
specifically associated with RA. Citrullination is a post-translational modification, in 
which peptidylarginine is converted into peptidylcitrulline, a reaction generally 
catalyzed by a member of the peptidylarginine deiminases (PAD) enzyme family, which 
requires the presence of sufficient amounts of calcium. ACPA are present in 
approximately 70% of RA patients and are already present prior to disease onset 
making them suitable markers for diagnosing RA. Until recently, the diagnosis of RA in 
the clinic was based upon the criteria set by the American College of Rheumatology 
(ACR) in 1987. In 2010, the criteria have been revised in a collaborative effort of the 
ACR and the European League Against Rheumatism (EULAR) and now the presence of 
ACPA, which is generally determined by the so-called CCP2-test, is included as an 
important diagnostic criterion. With the CCP2-test autoantibodies against a synthetic 
citrullinated peptide are measured, in most cases in an ELISA-based format. This test 
allows the detection of the majority of ACPA, which are known to be a collection of 
antibodies targeting distinct citrullinated epitopes. 
It has been suggested that an initial trigger (such as smoking or an infection) leads to an 
influx of immune cells in the synovium or another organ (such as the lung or the 
gingiva). The resulting inflammation is associated with cell death and may, as a result of 
impaired clearance of the dying cells and/or massive cell death, result in the release 
and the activation of PAD enzymes due to the elevated calcium levels. PAD enzymes are 
expressed in many tissues and cells (as described in Chapter 2) and can citrullinate 
multiple target proteins. The mammalian genome contains 5 genes encoding distinct 
PAD isotypes, of which PAD2 and PAD4 are expressed in cells of the immune system. In 
Chapter 2 the expression and activity of PAD enzymes was studied in PAD2 and PAD4 
knock-out mice.  In almost all tissues of the PAD2-/- mice that were analysed, hardly 
any PAD activity and no citrullinated proteins were detected. PAD4 expression in the 
PAD4 knock-out mice turned out to be only partially decreased, which can be explained 
by the removal of the knock-out cassette from primary transcripts by pre-mRNA 
splicing, and therefore these mice were named PAD4-low mice. The PAD activity and 
the presence of citrullinated proteins in tissues from the PAD4-low mice were 
comparable to those of the wild-type mice. In white blood cells of PAD2-/- and PAD4-
low mice subtle differences in PAD activity were observed, particularly in cells from 
mice devoid of PAD2.  
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In both the PAD2-/- and PAD4-low mice the expression of PAD6 protein appeared to be 
up-regulated in all tissues analyzed, with the exception of spleen and testis. These data 
suggest that protein citrullination is solely dependent on PAD2 activity in various mouse 
tissues. The reason why the expression level of PAD6 is elevated upon depletion of 
either PAD2 or PAD4 expression remains enigmatic, especially because PAD6 does not 
seem to possess deiminase activity. 
In susceptible individuals, such as people carrying shared epitope alleles, citrullinated 
proteins may elicit an immune response by acting as an autoantigen. Several 
citrullinated autoantigens have been described before the start of the studies described 
in this thesis. Nevertheless, in most studies synthetic citrullinated peptides not 
corresponding to these citrullinated proteins have been used to detect ACPA. The 
experiments presented in Chapter 3 were aimed at the identification of citrullinated 
proteins identified in synovial fluid (SF) samples of RA patients by a proteomics 
approach. Analysis of RA SF samples by a citrullinated protein-specific detection 
procedure revealed several distinct patterns of citrullinated proteins, indicative of 
heterogeneity of protein citrullination in the inflamed joints of different patients. By 
mass spectrometry (fragments of) 192 proteins were identified in the SF samples 
analyzed (samples from two RA patients), including 53 citrullinated proteins, some of 
which contained multiple citrullinated residues. Several known citrullinated proteins 
were identified, such as vimentin and fibronectin, but the majority had never been 
reported before. Moreover, the results of these analyses also provided insight into the 
amino acid residues of these proteins that can be citrullinated. Previously, 15 
citrullinated proteins occurring in the RA synovium were found and autoantibodies 
against 5 of these (fibrinogen, vimentin, alpha-enolase, collagen and CapZ alpha 1) have 
been described.  In our study (Chapter 3), several citrullinated proteins were detected 
in material from both patients analysed. Only one of these, fibrinogen, was among the 
previously identified citrullinated proteins. The others are histones, apolipoprotein E 
(ApoE), myeloid nuclear differentiation antigen (MNDA), beta-actin and cyclophilin A 
(CypA).  ApoE, MNDA and beta-actin were studied in more detail, the results of which 
are also described in this chapter. The citrullination of fibrinogen and its autoreactivity 
were addressed in detail in the studies described in Chapters 4 and 5. About two-thirds 
of the 81 arginines of human fibrinogen were found to be susceptible to citrullination 
by the human PAD2, the human PAD4 or the rabbit PAD2 enzyme. Furthermore, the 
results in Chapter 5 show that the synovial fluid of RA patients contains peptide 
fragments derived from fibrinogen, which contain significant amounts of citrulline 
residues and in some cases also a phosphorylated serine. In addition, elevated levels of 
citrullinated fibrinogen fragments were found to be present in RA SF samples when 
compared to SF samples of patients with other types of arthritis.  
Citrullinated peptides derived from these autoantigens can by presented by antigen 
presenting cells via human leukocyte antigen molecules class II (HLA class II) to cells of 
the immune system and ultimately lead to the activation of B-lymphocytes. It has been 
proposed that the shared epitope-containing members of the HLA class II family can 
present citrullinated peptides better due to the altered charge of the peptide after 
citrullination (the positively charged arginine is converted into a neutral citrulline). This 
may facilitate the activation of ACPA-specific B-lymphocytes and their differentiation 
into ACPA-producing plasma cells. Indeed, ACPA production has been demonstrated to 
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be strongly associated with shared epitope alleles in RA. In Chapter 6 data are 
presented showing that there is an association between anti-citrullinated fibronectin 
antibodies and shared epitope alleles.  
Several B-cell epitopes of citrullinated antigens are reported in this thesis. 
Autoantibodies directed against citrullinated ApoE, MNDA, and beta-actin epitopes 
were found to represent ACPA subtypes in Chapter 3 and these antibodies appeared to 
target a subset of citrullinated epitopes in each of these proteins. The most frequently 
targeted regions by RA autoantibodies were identified by synthetic peptide ELISAs. A 
multiplexed microarray-based surface plasmon resonance imaging (iSPR) system was 
applied to identify the citrullinated B-cell epitope regions in human citrullinated 
fibrinogen (Chapter 4). Three major citrullinated epitope regions were found. In 
addition, ACPA against citrullinated fibronectin peptides were found to occur in 46% of 
the RA patients (Chapter 6). Taken together these data demonstrate that the ACPA 
response in RA patients is very heterogeneous, because multiple citrullinated proteins 
are recognized.  
ACPA can form immune complexes with the citrullinated proteins/peptides, as has 
been demonstrated for citrullinated fibrinogen and citrullinated vimentin. These 
immune complexes can activate other immune cells, such as macrophages, leading to 
the production of cytokines, which act as the driving force in the chronic inflammation 
typical for RA.  
Unfortunately, there is still no cure for RA; the currently applied medication is aimed at 
diminishing the progression of joint damage as much as possible and at improving the 
quality of life of patients.  In Chapter 7 a number of genes were identified, the 
expression of which is altered in arthritis and which might serve as potential targets for 
future therapies for RA. Amongst these genes are two members of the signaling 
lymphocyte activation molecule family, SLAMF7 and SLAMF8, and a disintegrin and 
metalloprotease domain family member, ADAM28, which were studied in more detail. 
Recombinant single-chain antibody variable fragments (isolated from phage display 
libraries) to these proteins were generated. These antibody fragments confirmed their 
localization at the surface of white blood cells. When white blood cells were incubated 
with recombinant SLAMF7 and SLAMF8, though not with ADAM28, the IL-10 (an anti-
inflammatory cytokine) levels increased. The results described in Chapter 7 show an 
increased expression of SLAMF7, SLAMF8 and ADAM28 in the inflamed synovium of RA 
patients and suggest that signaling through SLAMF7 and SLAMF8 may play a role in the 
pathophysiology of RA by stimulating the production of IL-10. 
In Chapter 8, I discuss why certain citrullinated proteins may trigger an immune 
response, whereas others do not. Furthermore, I speculate about the possible role of 
several citrullinated antigens described in this thesis in the development of RA. 
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Normaliter vallen cellen van het immuunsysteem alleen potentiële ziekteverwekkers 
en niet lichaamseigen producten (zoals eiwitten) aan. In een auto-immuun ziekte kan 
het immuunsysteem zich gaan keren tegen lichaamseigen componenten en zo een 
immuunreactie opwekken. 
Een voorbeeld van een auto-immuunziekte is reumatoïde artritis (RA), ook wel reuma 
in de volksmond genoemd. Bij patiënten met RA vindt een chronische ontsteking van 
het synovium (of synoviale membraan) plaats. Het synovium is een weefsel dat de 
binnenkant van (de meeste) gewrichten in het lichaam bekleedt. Normaal produceren 
cellen in dit weefsel (een minimale hoeveelheid aan) synoviaal vocht (ook wel 
gewrichtssmeer genoemd), dat er voor zorgt dat gewrichten soepel kunnen bewegen. 
Bovendien zorgt het er voor dat kraakbeen in het gewricht van voedingsstoffen wordt 
voorzien en dat de toegang van schadelijke stoffen tot het kraakbeen gehinderd wordt. 
Wanneer het synovium chronisch ontstoken is, zoals in RA, vindt er meer productie van 
synoviaal vocht plaats en hierdoor verliest het zijn positieve functie en dit kan leiden tot 
het binnendringen van ontstekingscellen en schadelijke stoffen. Uiteindelijk kan dit 
leiden tot afbraak van het kraakbeen en, wanneer de situatie onbehandeld blijft, tot 
botafbraak. 
Ongeveer 1% van de mensen wordt getroffen door RA en de ziekte komt vaker bij 
vrouwen voor dan bij mannen. Er zijn verschillende risicofactoren beschreven (zoals 
bepaalde erfelijke factoren en roken), maar op dit moment blijft RA een ongeneeslijke 
ziekte, die voor veel ongemak in het dagelijks leven zorgt en uiteindelijk tot invaliditeit 
kan leiden. Op dit moment zijn er alleen maar geneesmiddelen die de symptomen 
bestrijden. 
Een specifiek fenomeen in RA patiënten is de aanwezigheid van autoantilichamen tegen 
gecitrullineerde eiwitten of tegen delen van eiwitten (peptiden). Ongeveer 70% van de 
RA patiënten hebben deze autoantilichamen in hun bloed. Deze autoantilichamen 
worden anti-gecitrullineerde eiwit of peptide antilichamen genoemd en afgekort met 
ACPA (“anti-citrullinated protein/peptide antibodies”). Bij het stellen van de diagnose 
wordt sinds kort onder andere gebruik gemaakt van de aanwezigheid van deze 
autoantilichamen in het bloed van de patiënt die met behulp van de zogenaamde CCP2 
test (tweede generatie van de “cyclic citrullinated” peptide test) aangetoond kan 
worden. ACPA kunnen namelijk al jaren (zelfs 10 jaar voor diagnose) aanwezig zijn 
voordat de ziekte zich manifesteert.  
Citrullinering is een proces dat kan optreden nadat een eiwit gemaakt is (post-
translationele modificatie) en wordt gekenmerkt door een kleine chemische 
verandering van het eiwit (een arginine residu wordt omgezet in een citrulline residu). 
Deze verandering wordt gekatalyseerd door een bepaalde enzymfamilie, de 
peptidylarginine deiminasen (PAD). Citrullinering is niet specifiek voor RA patiënten, 
maar de reactie van het immuunsysteem (vorming van ACPA) tegen gecitrullineerde 
eiwitten/peptiden is dat wel. 
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De afgelopen jaren is steeds meer duidelijk geworden over de potentiële rol van PAD 
enzymen, gecitrullineerde eiwitten en ACPA in de ontwikkeling van RA.  
De gedachte gaat dat door een (combinatie van) omgevingsfactor(en) (zoals roken of 
een infectie) er een primaire ontsteking ontstaat, waarbij immuuncellen naar de plaats 
van ontsteking gestuurd worden. Dit kan het synovium zijn, maar kunnen ook in andere 
delen van het lichaam zijn, zoals de eerder genoemde longen en gingiva (tandvlees). Als 
gevolg van de met ontstekingsprocessen gepaard gaande celdood zal de 
calciumconcentratie in de cel stijgen en zal het PAD enzym geactiveerd worden, waarna 
bepaalde eiwitten gecitrullineerd kunnen worden. In personen die hiervoor bevattelijk 
zijn, doordat ze een bepaalde genetische achtergrond hebben, zullen delen van dit 
gecitrullineerde eiwit gepresenteerd worden aan cellen van het immuunsysteem. 
Alleen in deze personen zal dit kunnen leiden tot de productie van ACPA. ACPA 
productie kan lokaal in het gewricht optreden of in bijvoorbeeld de longen of de 
gingiva. Via de bloedbaan kunnen de autoantilichamen zich vervolgens verspreiden 
door het lichaam en migreren naar het synovium. Op plaatsen waar gecitrullineerde 
eiwitten voorkomen, bijvoorbeeld als gevolg van een ontstekingsproces, kunnen er 
complexen (immuun-complexen) gevormd worden, die op hun beurt leiden tot 
verschillende processen die de chronische immuunreactie, zoals die voorkomt bij RA 
patiënten, in stand kunnen houden. 
In dit proefschrift zijn verschillende aspecten van bovengenoemde processen 
beschreven. 
Een algemene inleiding op het onderwerp wordt gegeven in Hoofdstuk 1. In Hoofdstuk 
2 worden de verschillende PAD enzymen beschreven. Het humane genoom bevat 5 
genen coderend voor PAD enzymen (isotypes), PAD1, PAD2, PAD3, PAD4 en PAD6. Elk 
isotype wordt gekenmerkt door weefselspecifieke expressiepatronen. In dit hoofdstuk 
wordt een overzicht gegeven waar welke PAD enzymen voorkomen. Daarnaast is in 
muizen bestudeerd wat er gebeurt met de aanwezigheid van deze enzymen en hun 
activiteit als een van de PAD enzymen (PAD2 of PAD4) niet meer of in mindere mate tot 
expressie komt. De data beschreven in dit hoofdstuk laten zien dat wanneer PAD2 of 
PAD4 uitgeschakeld wordt, de expressie (aanwezigheid) van PAD6 in verschillende 
weefsels omhoog gaat. Verder laten de resultaten zien dat wanneer PAD2 wordt 
uitgeschakeld er in diverse weefsels geen activiteit van PAD meer kan worden 
gedetecteerd, wat suggereert dat in de betreffende weefsels alleen PAD2 
verantwoordelijk is voor het citrullineren van eiwitten. Nader onderzoek is nodig om 
een verklaring te vinden voor de verhoogde expressie van PAD6 als gevolg van een 
afname in de PAD2 en PAD4 niveaus. 
In Hoofdstuk 3 is geanalyseerd welke eiwitten er in het synoviaal vocht van RA 
patiënten aanwezig zijn en in het bijzonder welke gecitrullineerde eiwitten daar 
aangetroffen worden. Er zijn in totaal 192 verschillende eiwitten gevonden in synoviaal 
vocht monsters van twee RA patiënten. Van deze eiwitten bleken er minstens 53 
gecitrullineerd te zijn.  Sommige van deze gecitrullineerde eiwitten waren al bekend, 
maar het merendeel is voor het eerst beschreven in Hoofdstuk 3. Drie van deze 
“nieuwe” gecitrullineerde eiwitten, apolipoprotein E (ApoE), myeloid nuclear 
differentiation antigen (MNDA) en beta-actine, zijn in meer detail bestudeerd. 
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Daarvan werden er twee ook in gecitrullineerde vorm gevonden in synoviaal vocht 
monsters van andere RA patiënten. Bovendien werden tegen alle drie de eiwitten 
autoantilichamen (ACPA) gevonden in het bloed van RA patiënten, maar niet in het 
bloed van gezonde personen of van patiënten met een andere ziekte. Dit wekt de 
suggestie dat deze eiwitten mogelijk een rol spelen bij de ontwikkeling van de ziekte 
RA. 
De herkenning van een al eerder beschreven gecitrullineerd autoantigeen 
(lichaamseigen eiwit waartegen het immuunsysteem een reactie vormt), fibrinogeen 
door RA sera en het voorkomen van gecitrullineerd fibrinogeen in synoviaal vocht 
worden beschreven in de Hoofdstukken 4 en 5. Eerst worden de resultaten 
gepresenteerd van experimenten die aantonen welke arginine residuen van fibrinogeen 
door welk PAD enzym (PAD2 en/of PAD4) worden veranderd in citrulline residuen. Met 
een recent ontwikkelde techniek voor parallelle analyses van biomoleculaire interacties 
werd gevonden dat er drie gebieden in het eiwit zijn, die binden met autoantilichamen 
in het bloed van een groot deel van de RA patiënten. De experimenten in Hoofdstuk 5 
tonen voor eerst aan dat delen van het fibrinogeen eiwit (fibrinogeen peptiden) in 
hogere mate voorkomen in het synoviaal vocht van RA patiënten in vergelijking met 
patiënten met andere typen gewrichtsontstekingen. 
Een ander gecitrullineerd autoantigen gevonden in RA synoviaal vocht is fibronectine. 
De eigenschappen van van fibronectine afgeleide peptiden in synoviaal vocht worden 
beschreven in Hoofdstuk 6. Verder laat het in dit hoofdstuk beschreven onderzoek 
zien, dat RA patiënten ook tegen dit gecitrullineerde eiwit ACPA hebben. Deze 
autoantilichamen worden al gevonden in “vroege” RA patiënten (dus vroeg in het 
ziekteproces) en er wordt een associatie tussen deze antilichamen en een genetische 
factor voor RA aangetoond. 
De gecombineerde resultaten laten zien dat de autoantilichaam respons tegen 
gecitrullineerde eiwitten erg divers is, want nagenoeg alle geanalyseerde 
gecitrullineerde eiwitten worden herkend door RA autoantilichamen en in het 
ontstoken gewricht van RA patiënten bevindt zich een grote diversiteit van zulke 
eiwitten. Desalniettemin blijkt deze klasse van autoantilichamen specifiek geassocieerd 
te zijn met RA. 
Hoofdstuk 7 beschrijft potentiële nieuwe aangrijpingsmoleculen voor de ontwikkeling 
van nieuwe geneesmiddelen voor de behandeling van RA. Het betreft onder andere 3 
eiwitten (SLAMF7, SLAMF8 en ADAM28 genaamd) die zich bevinden op het 
plasmamembraan van witte bloedcellen. Zowel de corresponderende recombinante 
eiwitten (delen daarvan) als antilichamen die daartegen gericht zijn werden 
gegenereerd via recombinant DNA technologieën. Deze antilichamen zijn vervolgens 
gebruikt om de eiwitten in weefselmateriaal van patiënten te bestuderen. Er is 
bijvoorbeeld gekeken in welke cellen deze eiwitten gedetecteerd kunnen worden. 
Verder zijn witte bloedcellen in celkweek behandeld met de recombinant eiwitten. De 
aanwezigheid van zowel SLAMF7 als SLAMF8 bleek de concentratie van een bepaald 
signaleringsmolecuul (ook wel cytokine IL-10 genoemd), dat belangrijk is voor de 
regulering van het immuunsysteem, verhoogd te zijn. Mogelijk spelen deze twee 
eiwitten een rol in de regulering van de immuunreactie, die plaatsvindt in RA. 
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De rol van gecitrullineerde eiwitten, PAD enzymen en ACPA in de pathofysiologie van 
RA wordt in Hoofdstuk 8 bediscussieerd. Er wordt daarbij ingegaan op de selectiviteit 
van eiwit citrullinering en de selectiviteit van het immuunsysteem voor gecitrullineerde 
epitopen. 
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Het heeft iets langer geduurd dan ik gepland had en het heeft de nodige bloed (sera), 
zweet en tranen gekost, maar hier is ‘ie dan: Mijn proefschrift!  Maar omdat ik dit 
natuurlijk niet in mijn eentje voor elkaar gekregen heb, wil ik graag een aantal mensen 
persoonlijk bedanken. 
 
Beste Ger, bedankt voor de mogelijkheid dat ik als AIO op jouw afdeling aan de slag kon 
en voor je vertrouwen dat ik het tot een goed einde zou brengen. Bedankt voor al je 
hulp, je goede suggesties, je humor en dat je altijd tijd vrij maakte als ik weer iets te 
vragen had, ook al had (heb) je het veels te druk! Bij deze ook mijn excuses! 
Beste Walther, ook al ben ik nooit AIO onder uw “bewind” geweest. Ik wil u hier toch 
bedanken, omdat ik toch de nodige reviews met u samen mocht schrijven. Daar ben ik 
stiekem toch wel trots op, want in mijn ogen bent en blijft u toch de CCP2-goeroe! 
Beste Els, bedankt dat ik altijd kon binnenlopen als ik weer wat te zeuren, iets kwijt 
wilde of gewoon even gezellig wilde kletsen; dat doet een AIO goed! Bedankt hiervoor! 
Beste Lettie en Wilbert, bedankt voor alle nuttige opmerkingen en suggesties tijdens 
werkbesprekingen maar ook tijdens de pauzes. Lettie, ik kan nooit meer naar een DNA-
molecuul kijken, zonder me af te vragen of nou die rechts –of linksdraaiend is.  
 
Beste paranimfen, Carla (S./West/de W) en Bart, dank jullie wel dat jullie meteen de 
“zware” taak van mentale ondersteuning op jullie wilden nemen. 
Lieve Carla, bedankt voor alle experimenten die je voor me hebt uitgevoerd. Helaas 
heeft niet al je harde werken het boekje gehaald (mini-mini bank). Ik vond het erg fijn 
(2 X eigenwijs = wijs) en gezellig om met je te mogen samenwerken. Je bent een echte 
TOP-analiste! Veel geluk met Mark en je (jullie) nieuwe experimentje!  
Bart, 12 jaar geleden begonnen we tegelijkertijd in Utrecht en toen al hebben we een 
“pact” gesloten dat we elkaars paranimf zouden worden…helaas ben je geen 
promotieonderzoek gaan doen, maar ik vond “mentale ondersteuning” toen je Prins 
was wel een goed tegenvoorstel hoor! Verder ben ik je erg dankbaar dat je me op een 
dag (carnavalsmaandag) meegenomen hebt naar het zonnige zuiden (“Ell, waar ligt 
da?”), want anders had ik Paul nooit ontmoet. Heel veel geluk en succes met je nieuwe 
uitdaging en natuurlijk met Marjon (geen suc6 hiervoor nodig, alleen veel geluk)! 
 
Lieve Sandy, eigenlijk zou je mijn derde paranimf moeten zijn. Bedankt voor je 
gezelligheid en steun op het lab! Wat een feest (letterlijk en figuurlijk qua muziek en 
zang) was het toen je naar “mijn” U verhuisde en wat jammer toen je me weer verliet 
(naar ROCKville of all places….ROCK!)! We hebben het zelfs samen tot IMM covergirls 
geschopt! Wie kan dat nu zeggen? WIJ!!!! 
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Ook de Vierdaagse hebben we samen (met Marleen) overleefd…ook al hadden we 
duidelijk andere opvattingen over de “gezelligheid” tijdens de (barre) tocht. 
Ik heb ook erg genoten van het feit dat ik je kon komen opzoeken vorig jaar in the USA 
en dankzij de Renzo Tour (bedankt Rens; je bent de beste Mister Guide ever!) heb ik 
toen in vogelvlucht kennisgemaakt met the American way of life met goede muziek 
(Foo Fighters live in DC!), mooie monumenten, (veel) lekker eten (“beer-battered 
nachos”…woehoe!) en een biertje op z’n tijd ;). Heel veel geluk verder nog samen met 
je lieve hubby, succes met je experimenten in the USA (of NL???) en stiekem hoop ik 
toch wel dat je er de 7de december bij bent….. 
 
En dan natuurlijk de rest van de (ex-)collega’s, want een aangename sfeer op het lab 
draagt zeker bij aan het (succesvol) voltooien (en het verwerken) van je 
promotieonderzoek…. 
 
Lieve Judith en Annemarie, ook aan jullie heb ik veel te danken! Jullie zijn ook echt een 
geweldige ondersteuning (praktisch maar ook mentaal) geweest! 
Judith, bedankt voor de vele ELISAs wat gepaard gaat met het verdunnen en uitvullen 
van honderden sera! Bedankt! Annemarie, jij hebt me samen Han in het begin op weg 
geholpen, zodat ik het goede PAD zou volgen. Bedankt voor je ondersteuning en niet te 
vergeten de nodige kloneringen! 
 
Lieve Carla (Oost), Wilma en Siebe (& Theo), bedankt dat ik altijd gebruik kon maken 
van jullie enorme kennis! Daar heb ik dan ook de nodige (mis)(ge)bruik van gemaakt!  
Carla en Wilma, bedankt voor jullie altijd goede zorgen! Siebe (en/of Theo), bedankt 
voor resetten van mijn hartslag door me altijd weer te laten schrikken…zegt dat iets 
over mij of toch meer over jou/jullie ;) 
 
Lieve Chantal, ik ben blij dat je snel het gat in de U opvulde nadat Sandy hem gesmeerd 
was. Ook al ligt onze muzieksmaak niet echt op een lijn, we waren wel een goede combi 
in de popquiz! En ok, zelfs ik heb wel eens meegezongen op woensdag hakkuh-
dag….Bedankt voor je gezelligheid en succes met het afronden van je boekje; ff 
doorzetten, dan komt alles goed! 
 
Lieve Sanne & Lonneke, bedankt voor jullie gezelligheid en goede gesprekken over het 
zware leven van een onderzoeker!  
Sanne, heel veel succes met het afronden van je proefschrift! Maar met al dat harde 
werken gaat dat zeker goedkomen! Lonneke, ik hoop dat je snel een uitdaging vindt die 
bij je past; dat heb je zeker wel verdiend! 
 
Beste Sander, ik hoop dat alles nog steeds voortvarend gaat in DEUTSCHLAND! Bedankt 
voor je gezelligheid en altijd gemeende interesse! Heel veel geluk met je toekomstige 
vrouw Julia! 
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Raymond en Remon a.k.a. Rembo & Rembo; wat een geweldige (maar soms 
gevaarlijke) combi zijn jullie! Wat heb ik toch moeten lachen om al jullie 
grappen/streken en aparte “experimentjes”! Succes met het afronden van jullie 
boekjes! 
 
Dear Tamara and Elina, it was really fun having you two in the lab.  
Elina, I will never forget your ice cream made from liquid nitrogen! Good luck with 
finishing your PhD! Tamara, (our minority ;) ) thank you for your always optimistic 
attitude and your wonderful conversations about the finer things in life (which are not 
suitable to describe any further)! Good luck with your new challenge! 
 
Dear Marina, I hope everything works out fine and that you can finally continue what 
you want to do! I really admire your perseverance! Good luck! 
 
Beste Han, Reinout, Helma, Geurt, Angelique, Tim, Jeroen, Danielle, Erwin, Kalok en 
Constance bedankt voor al jullie hulp, jullie goede suggesties, jullie gezelligheid en jullie 
grappige anekdotes! Ik heb veel van jullie geleerd!  
Han, bedankt voor al je hulp tijdens mijn opstartfase en je geweldige woordgrapjes! 
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bedankt voor al je hulp, wat geresulteerd heeft in 3 co-publicaties! Zonder jou was het 
boekje toch heel wat dunner geweest! Helma, was iedereen maar zo geordend als jij! 
Indrukwekkend hoor! Geurt, jij geordende chaoot! Geweldig! Nooit begrepen hoe je 
dat deed zonder labjournaal… Angelique, ik had stiekem nog gehoopt op een duo-
promotie…heel veel succes met de laatste loodjes! Tim, je bent in mijn ogen echt een 
“weird scientist” en dat bedoel ik goede zin! Wat een geweldige ideeën en vreemde 
geluiden kon je toch altijd produceren! Jeroen, bedankt voor je Brabantse gezelligheid! 
Groots gezellig met een zachte G! Danielle, ik ben altijd erg onder de indruk geweest 
van jouw manier van werken; zo georganiseerd en rustig! Erwin, heel veel geluk verder 
in Parijs! Kalok, bedankt voor je gezelligheid! Constance, thanks for your helpful 
discussions on the PAD project! 
 
Beste Mirthe, Els, Remi, Jeroen, Loes, Luc, Jasmijn en Rinske, ik heb het genoegen 
gehad jullie te begeleiden tijdens een van jullie stages. Ook al kon ik met de een beter 
opschieten dan met de ander, ik heb van jullie allemaal wat geleerd! Hopelijk hebben 
jullie ook iets van mij geleerd. Bedankt voor jullie inzet! Heel veel suc6 met het 
afronden van jullie PhD (zet hem op Mirthe!), met het afronden van jullie studie (Luc, 
Jasmijn en Rinske) en met jullie verdere toekomst! 
 
Beste (ex-)collega’s van Modiquest Research; beste Jos (2X), Renato, Linda, en oud-
werknemers Mark en Leon, bedankt voor de samenwerkingen, gezelligheid en de 
introductie op het gebied van faag display! 
 
Beste collega’s van Reumatologie, bedankt voor de gezelligheid en natuurlijk jullie hulp! 
Ex-buurvrouwen Tamara en Lenny en buurman Ben, bij deze ook mijn oprechte excuses 
voor mijn niet altijd zuivere noot tijdens een van mijn vele meezing en fluit acties. 
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Beste Annemiek, Rene, Albert, Jan Wouter en Richard, bedankt voor de 
samenwerkingen en dat ik gebruik mocht maken van jullie kennis! Borut, thank you for 
the synovial fluid samples! Without them there would be no thesis! 
Lieve vriendjes en vriendinnetjes; lieve Odile, Robert (ondertussen familie Veugelers), 
Marjon, Bart, Marleen, Rens, Anouk, Rob, Petra, Chris, Steffie, Sjack (bijna familie van 
de Kruys…..spannend!), Harm en (sjeik) Remco, ontspanning op z’n tijd heeft zeker 
bijgedragen aan het afronden van dit boekje! Bedankt voor de vele gezellige etentjes, 
gezellige avondjes in de donkere kroeg aan de Sebastiaanstraat, de gezellige 
carnavalsactiviteiten, de nodige stapavondjes, de nodige ijscoupes bij Florence, de vele 
wandelingen met als hoogte- (of was het toch een persoonlijk diepte-) punt het 
(uit)lopen van de Nijmeegse 4-daagse en de nodige bezoekjes aan muziekfestivalletjes 
(zowel in Ell als in Landgraaf)! Ik heb er nog steeds geen moment spijt van dat ik als 
Brabo naar het mooie Limburg ben verhuisd, mede dankzij jullie! BEDANKT! 
Lieve (schoon-)familie, bedankt voor al jullie steun! Beste Jan, misschien was het even 
wennen dat Paul thuiskwam met een Brabantse, maar gelukkig heb ik daar zelf niets 
van gemerkt. Bedankt voor je gastvrijheid en dat ik me al snel thuis voelde in Ell! Lieve 
Suzanne en Paul en natuurlijk niet te vergeten lieve Luuk en Anne, bedankt voor het feit 
dat ik me meteen thuis voelde bij jullie…..misschien komt het doordat Paul Brabantse 
genen heeft… ik ben ook supertrots op mijn kleine neefje (ik was namelijk alleen maar 
meisjes gewend) Luuk en natuurlijk petekindje Anne; twee van de liefste kleine 
wezentjes op de aardbol! 
Lieve zusjes, lieve Monique en Mance, we zien elkaar eigenlijk te weinig, maar ja dat 
krijg je als je alle drie in een andere hoek van het land gaat wonen, hè? Ook zijn we niet 
zo bellerig, maar dat is typisch een van Beers’en kwaal.  Ik heb het altijd heel bijzonder 
gevonden dat mijn zusjes “iets” ouder waren dan ik…wie kon namelijk toen ik 8 was 
zeggen dat ze bij een van haar zussen ging logeren.  
Lieve Monique, toen ik op de basisschool zat, had ik nog een spreekbeurt gehouden 
over je beroep (analiste op een Klinisch Chemisch lab), daar stond ik dan met de 
naalden en plas –en poepbekertjes voor de klas. Toen wist ik al dat ik toch ook iets in 
die richting wilde doen. Bedankt voor de ingeving! 
Lieve Mance, was ik maar zo creatief als jij; wat kun je toch mooie creaties tot stand 
brengen zeg! Ik ben altijd onder de indruk van hoe je met bepaalde situaties omgaat! 
Daar kan ik nog wel iets van leren hoor! 
Ik ben altijd supertrots geweest op het feit dat ik jullie “kleine”zusje ben! Bedankt dat 
jullie mijn zusjes zijn! 
Lieve Max, Emmy en Lily, ik ben supertrots op mijn knappe (zowel letterlijk als 
figuurlijk) nichtjes! Max, super dat je voor de HAVO geslaagd bent en heel veel succes in 
Leiden! Zet hem op! Lieve Emmy, heel veel succes op de middelbare school, maar dat 
komt zeker goed! Lieve Lily, blijf vooral zoals je bent, dan schop je het nog heel ver! 
Lieve Tom en Pieter, bedankt dat jullie altijd zo goed op mijn zusjes passen! 
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Lieve pap en mam, bedankt voor alles wat jullie altijd voor me gedaan hebben! 
Lieve pap, helaas kun je dit niet meer meemaken. Bedankt voor je eeuwige optimisme 
en doorzettingsvermogen. Dat heb je gelukkig wel aan mij doorgegeven en dat heb ik 
ook zeker kunnen gebruiken bij het afronden van mijn promotie. Ik denk nog elke dag 
aan je! Dit boekje is voor jou!  
Lieve mam, ik ben supertrots op je! Bedankt voor alles wat je nog steeds voor me doet! 
Als ik later, als ik groot ben, maar half de sterke (letterlijk als figuurlijk) vrouw word als 
jij, ben ik al tevreden. Je bent met recht een supermama! Dit is ook een beetje ons 
boekje, aangezien jij de illustratie op de voorpagina hebt geleverd! Bedankt hiervoor; ik 
ben er erg blij mee! 
Lest best…..lieve Paul, ik kan het “nie” vaak genoeg zeggen, maar ik ben je erg dankbaar 
voor je steun en alles wat je altijd voor me doet! Samenwonen met jou in het mooie 
Limburg is een van de betere beslissingen in mijn leven (als het niet de beste is)! Wat 
kan ik verder nog hieraan toevoegen dan: 
 
    “Ich wil aad waere mit dich, aad waere mit dich 
Zo gaer, wil ich 
Aad waere mit dich 
Ich haop hevig des dich dan onnog 
Aad wils waere mit mich...” 
 
  (Songtekst "Aad waere mit dich" van Ge Reinders ) 
 
Luvjoe! 
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